Trending Visuals
ASCO26 Trending Images
Curated visuals from the ASCO 2026 KOL and finance communities.
Erman Akkus @Erman_Akkus
gilberto lopes @GlopesMd
NEJM @NEJM
Madeleine Armstrong @ByMadeleineA
NEJM @NEJM
Adam Feuerstein ✡️ @adamfeuerstein
Adam Feuerstein ✡️ @adamfeuerstein
Madeleine Armstrong @ByMadeleineA
Dawood Findakly, MD, FACP @CancerExorcist
Dawood Findakly, MD, FACP @CancerExorcist
soria @jsoriamd
Samer Al Hadidi, MD,MS,FACP @HadidiSamer
Elisabetta Bonzano MD, PhD @to_be_elizabeth
Paolo Tarantino @PTarantinoMD
Dawood Findakly, MD, FACP @CancerExorcist
Harold J. Burstein, MD, PhD, FASCO @DrHBurstein
Dawood Findakly, MD, FACP @CancerExorcist
Dawood Findakly, MD, FACP @CancerExorcist
Erika Hamilton, MD, FASCO @ErikaHamilton9
Yüksel Ürün @DrYukselUrunOn-Site & Virtual Events
Events & Networking at ASCO 2026
CME symposia, satellite sessions, medical receptions and networking meetups curated from the ASCO 2026 community. Pick a day, type or KOL below to reveal matching events, add them straight to your calendar, and tap Event details for venue and full faculty.
Pick a day, event type, or KOL above to reveal matching events.
Fri May 29 · 1:00 PM CDT
Networking
IMG Oncologists @IMG_Oncologists
Fri May 29 · 3:30 PM CDT
Symposium
OncoDaily @oncodaily
Fri May 29 · 6:30 PM CDT
SymposiumCMEVirtual option
PeerView @PeerView
Fri May 29 · 6:30 PM CDT
SymposiumCMEVirtual option
Fri May 29 · 6:30 PM CDT
SymposiumCMEVirtual option
Fri May 29 · 6:30 PM CDT
SymposiumCMEVirtual option
Fri May 29 · 6:30 PM CDT
SymposiumCMEVirtual option
Fri May 29 · 6:30 PM CDT
SymposiumCMEVirtual option
Fri May 29 · 6:45 PM CDT
SymposiumCMEVirtual option
AnswersinCME @AnswersinCME
Fri May 29 · 8:20 PM CDT
PanelVirtual option
Fri May 29
Panel
Sat May 30 · 5:00 PM CDT
Symposium
OncoDaily @oncodaily
Sat May 30 · 5:00 PM CDT
Networking
KMittaloncMD @KMittalmd
Sat May 30 · 6:00 PM CDT
Reception
Sat May 30 · 6:30 PM CDT
Reception
Legend Biotech @LegendBiotech
Sat May 30 · 6:30 PM CDT
SymposiumCMEVirtual option
LUNGevity Foundation @LUNGevity
Sat May 30 · 6:30 PM CDT
SymposiumCMEVirtual option
PeerView @PeerView
Sat May 30 · 6:30 PM CDT
Symposium
Oncology Brothers @OncBrothers
Sat May 30 · 6:30 PM CDT
SymposiumCMEVirtual option
Sat May 30 · 6:30 PM CDT
SymposiumCMEVirtual option
Sat May 30 · 6:30 PM CDT
SymposiumCMEVirtual option
Sat May 30 · 6:30 PM CDT
SymposiumCMEVirtual option
Sun May 31 · 11:00 AM CDT
Networking
Abi Siva MD @AbiSivaMD
Sun May 31 · 5:00 PM CDT
Symposium
Lung Cancers Today @Lung_Cancers
Sun May 31 · 6:00 PM CDT
SymposiumCME
Paolo Tarantino @PTarantinoMD
Sun May 31 · 6:00 PM CDT
Reception
Sun May 31 · 7:00 PM CDT
NetworkingVirtual option
eChinaHealth @eChinaHealth
Sun May 31 · 9:00 PM CDT
Reception
Mon Jun 1 · 4:45 PM CDT
Other
Michael Hofman @DrMHofman
See invite for date
Other
IDEOlogy Health @IDEOlogyHealth
×
![]()
Conference Buzz
Top Themes at ASCO 2026
Most-discussed scientific topics across 3,622 curated tweets from 562 researchers and oncologists. Tap any card to see the tweets.
250
Immunotherapy
344.3K impressions
tap to see tweets
130
ADC / Payload
325.8K impressions
tap to see tweets
126
KRAS / RAS Inhibitors
287.5K impressions
tap to see tweets
92
ctDNA & Liquid Biopsy
159.0K impressions
tap to see tweets
41
Cell Therapy
80.8K impressions
tap to see tweets
31
Epigenetics & DNA Repair
45.6K impressions
tap to see tweets
26
AI in Oncology
12.8K impressions
tap to see tweets
21
Protein Degradation
107.4K impressions
tap to see tweets
14
MRD Monitoring
13.5K impressions
tap to see tweets
8
FDA & Regulatory
73.6K impressions
tap to see tweets
4
Early-Onset Cancer
3.9K impressions
tap to see tweets
1
Spatial Omics
156 impressions
tap to see tweets
What's New & Anticipated
Most Anticipated at ASCO 2026
What practicing oncologists are most looking forward to heading into the meeting — ranked by impressions, one pick per physician. Physician voices only.
Only 2 weeks until the 2026 @ASCO Annual Meeting in Chicago!
>275 abstracts on ADCs, including almost 40 oral/rapid oral presentations.
👇Here the list of the 15 ADCs that will be presented for the first time at #ASCO26! https://t.co/WOe3bMqemm
👁 23.4K
❤ 79
🔁 26
May 15
If you don't know @NazliDizman she is a must follow! From @cityofhope > @YaleIMed > @UTMDAnderson > @DanaFarber, she has blazed an incredible trail in #oncology. Can't wait to get her insights on #ASCO26. https://t.co/FPtjou4llw
👁 16.5K
❤ 83
🔁 16
May 21
The most important breast abstract from #ASCO26 is out. 4429 pts with ER+/HER2- BC randomized to SoC vs PAM50-directed adjuvant treatment. 19% had N2 dz (4-9 nodes), premenopausal pts received LHRHa. No benefit from chemo if ROR≤60. Looking forward to the full presentation. https://t.co/qX8HnKyBne https://t.co/rAnA0ULjic
👁 16.0K
❤ 124
🔁 44
May 21
👉👉👉Breaking News 📰 | Proud to share the wonderful news for our patients & families facing #BPDCN of @US_FDA @FDAOncology approval for #Pivekimab #CD123 for our patients with #BPDCN !🙏| led by @doctorpemm & @Daver_Leukemia | @UTMDAnderson #endcancer
https://t.co/XNtstk6Q7V https://t.co/FcPYLzec6t
👁 14.3K
❤ 125
🔁 36
May 27
#ASCO26 is coming up!
With abstracts released I put together a top 10 (ok, top 12) GI abstracts I'm excited for.
Some things might fall off (or be added) pending full abstract text, but these are what I'm watching for and might be practice changing or scientifically https://t.co/RpFKvdnZlJ
👁 12.5K
❤ 197
🔁 75
Apr 25
The are likely multiple different resistance mechanisms when cancer progresses after EV/Pembro treatment.
Looking forward to @MichalSternsch @MSK_DeptOfMed presenting at #ASCO26 some of the first data with paired biopsies to describe what happens to nectin-4, trop-2, and HER2
👁 10.3K
❤ 37
🔁 12
May 21
#ASCO26 has released most abstracts. I will break down GI cancer-related abstracts to five tables:
Important studies
Interesting studies
Important negative studies
Novel agents
Practice re-affirming studies
Abstracts that have not been released but are eagerly anticipated: https://t.co/FVc9Pgdgds
👁 9.7K
❤ 84
🔁 28
May 24
OncoPoll📊
Which lower GI abstract at #ASCO26 are you personally most excited about?
@ASCO @OncoAlert
👁 9.5K
❤ 11
🔁 4
May 27
🧬 My Top 10 DT abstracts at #ASCO2026
3 storylines I'm watching:
→ KRAS G12D: noncovalent DN022150 (Ph I/IIa) + RNK08954 (Ph II) in parallel
→ Macrocyclic EGFR arrives: BH-30643 FIH
→ Radioligand enters SCLC: 177Lu-DOTA-TATE in #SCLC
@OncoAlert @oncodaily @Larvol https://t.co/toMicQYdgs
👁 8.7K
❤ 65
🔁 27
Apr 26
ctDNA is an exciting and important advance but not a replacement for imaging for recurrence post-cystectomy.
IMvigor011 highlights an important biologic shedding pattern of ctDNA with nodal disease being missed. CtDNA should be considered complementary, not a replacement for https://t.co/SvXFuqypf2
👁 8.4K
❤ 38
🔁 12
May 22
Hello, Chicago! Home for the next week. Looking forward to some amazing advancements in cancer care. #asco26 https://t.co/2NWiK19jYw
👁 7.3K
❤ 135
🔁 21
May 28
Excited to be selected as an #ASCO26 Featured Voice, along with esteemed colleagues and friends!!
It's going to be an incredible meeting! From practice-changing lung cancer trials to landmark plenary sessions across oncology, there is SO much to cover. 🫁
Can't wait to share https://t.co/7mMaAwHXs6 https://t.co/MrYZzNxwXk
👁 6.7K
❤ 56
🔁 23
May 21
Abstract Lists to Watch
Curated Staff Picks & Abstract Lists
Per-tumor "abstracts to watch" roundups curated by trusted voices — the @OncoAlert network and physician-curators like Dr. Nieves Martinez Lago (sarcoma/GI) — surfaced by editorial value, not impressions.
★ Featured Thread 🫁 Lung Cancer
@ASCO LUNG ABSTRACTS MEGA-THREAD
⭐️I've said it before; #ASCO26 is like a giant music festival - the @coachella of oncology
🎵You have the headliners [plenaries], acts on the main stages [halls B & D], & indie gems on the side [posters]
🎗️My PERSONAL list of the MOST interesting https://t.co/W3UFSikCTs
👁 5.1K
❤ 65
🔁 15
May 26
📋 Multi-Tumor
Only 2 weeks until the 2026 @ASCO Annual Meeting in Chicago!
>275 abstracts on ADCs, including almost 40 oral/rapid oral presentations.
👇Here the list of the 15 ADCs that will be presented for the first time at #ASCO26! https://t.co/WOe3bMqemm
👁 23.4K
❤ 79
🔁 26
May 15
🫁 Lung Cancer
🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1
🆙 @JCO_ASCO
☑Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC
🎙Dr. Lyudmila Bazhenova @HHorinouchi
#LCSM @OncoAlert @Larvol
https://t.co/k4lOuFfjrl https://t.co/esWC2okMGP
👁 9.5K
❤ 100
🔁 48
May 27
📋 Multi-Tumor
The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer .
A snapshot of what will shape GU https://t.co/MdPqZFFXX1
👁 8.3K
❤ 45
🔁 28
May 25
🫁 Lung Cancer
#ASCO26
One of the coolest abstract I’ve seen so far isn’t GI, and its a rapid oral most people have missed.
ARCHER: Prophylactic peptide targeting ALK resistance mutations in advanced ALK+ NSCLC
Abstract #: 8517
Presentation: Rapid Orals Lung, May 30
The usual cancer playbook
👁 6.6K
❤ 48
🔁 13
May 25
🟣 Multiple Myeloma
With #ASCO26 approaching, here are the potentially practice-changing abstracts in plasma cell disorders that caught my attention. I will update my thoughts as simultaneous publications are released for some of them🧵#MultipleMyeloma #Amyloidosis
👁 4.9K
❤ 42
🔁 13
May 25
🔵 GI Cancers
Abstract Titles #ASCO26
Rapid oral, CRC
◾️Onvansertib + chemo + bev in 1L RAS mut mCRC: Interim results from rPh2 CRDF-004 trial
◾️ctDNA clearance in CodeBreaK 300
◾️Ph3 CR-SEQUENCE trial: FOLFOX + pani ➡️ FOLFIRI + bev vs FOLFOX + bev ➡️ FOLFIRI + pani in RAS wt, left-sided mCRC
👁 2.9K
❤ 25
🔁 8
Apr 25
📋 Multi-Tumor
Looking into this abstract in more details, there are few concerns #ASCO26 #mmsm
1⃣κ Isotype sample sizes are impossible:
➡️Table reports κ anselamimab N=481 and placebo N=24
➡️Total trial enrollment was only 271 + 135 = 406 patients — κ cannot exceed this
➡️λ subgroup alone https://t.co/4vIxdX4kxy
👁 2.6K
❤ 7
🔁 3
May 22
🎗️ Breast Cancer
Only a few days to go until #ASCO26 @ASCO!
Here’s the list of the top Breast Cancer abstracts selected by the @OncoAlert faculty! 👇👇👇 https://t.co/C8rL4wO6N4
👁 2.2K
❤ 15
🔁 7
May 25
🌑 Melanoma
COWBOY at #ASCO26 (Abstr 9513, rapid oral): in BRAF V600E/K melanoma with elevated LDH, does a short BRAF/MEK induction (vem/cob ×6 wks) to debulk and normalize LDH before dual ICI improve outcomes vs upfront ipi/nivo?
Randomized open-label phase 2, treatment-naïve, n=71
👁 1.7K
❤ 20
🔁 7
May 23
🫁 Lung Cancer
🔥🔥off the press @ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1
Via @JCO_ASCO
☑Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC
➡️Updates on : retifanlimab
Ivonescimab, plus BAP BRAIN (avastin+pemetrexed for
👁 1.7K
❤ 25
🔁 7
May 29
📋 Multi-Tumor
Very excited for next week’s #ASCO2026 meeting! Had a great time being part of this year’s breast local-regional tract planning committee and excited to moderate the local-regional rapid oral session with superstar @Omene_CO !!! @ASCO #breastcancer
👁 1.7K
❤ 30
🔁 3
May 23
📋 Multi-Tumor
🚨 OncoAlert GU Faculty TOP 🔟 abstracts in GU Oncology for #ASCO26
Truly honored and proud to be among the Leads 🗺
Selected by our leads and finalized through a Delphi voting process with senior GU experts across 🌎🌏🌍
#ProstateCancer #KidneyCancer #BladderCancer.
💛 A https://t.co/f2AiyszqLg
👁 1.6K
❤ 24
🔁 8
May 25
🫁 Lung Cancer
🫁 As you build your schedule for #ASCO26, don’t miss (or 🔖 bookmark to watch later) several interesting #LungCancer abstracts being presented outside the lung cancer tracks. Some highlights include ⬇️
1️⃣ ctDNA Clinical Science Symposium:
FLAME: osimertinib ± chemotherapy in https://t.co/BYnCrWn5up
👁 1.6K
❤ 32
🔁 16
May 24
📋 Multi-Tumor
We bring to you the Community of Practice on Health Policy…
Don’t miss this exciting and stimulating discussion at the #ASCO26 - Saturday morning, 8:00-9:30 AM CST.
We have come long ways in 2 years!
@healthpolicycop @ASCO @ASCOTECAG @ASCOPost
@WadeSwenson @yuan_ruiling https://t.co/vKNJPY5Xk7
👁 1.6K
❤ 17
🔁 6
May 5
Leaderboard
Top Voices by Impressions
Ranked by total impressions across all ASCO 2026 pre-conference tweets captured. Switch tabs to view physicians, institutions, media, pharma/corporate, and finance/investor voices separately.
Top Tweets & Trials
Top Tweets by Tumor Type
Highest-impact physician tweets by cancer type. Expand the Clinical Trials section under each tumor type to drill into trial-specific discussion.
Lung Cancer692 tweets captured
Introducing my original #ASCO26 thoracic oncology abstract database!
All key lung cancer & thoracic abstracts curated, structured, and searchable in one place.
Built to make this year's data faster to navigate, compare, and revisit 🫁🧬
https://t.co/dDUER3WgQk
@ASCO @OncoAlert https://t.co/OAekcqYKAW https://t.co/r6gxhFSKCi
👁 20.3K
❤ 66
🔁 21
May 22
#ASCO26
7 years later… the median PFS with lorlatinib is STILL not reached in advanced ALK+ NSCLC.
CROWN continues to deliver one of the most durable targeted therapy signals ever seen in solid tumors.
🧬 CROWN Trial
Lorlatinib vs Crizotinib
1L advanced ALK+ NSCLC
📌 Key https://t.co/iYsPuzltFV https://t.co/U0Q3FbSJr6
👁 14.1K
❤ 90
🔁 36
May 25
Impact of 1L amivantamab + lazertinib vs osimertinib on acquired resistance in EGFR mutant NSCLC @JTOonline. Ami/laz reduces MET amp (3.4% vs 13.1%) and acquired EGFR resistance mts (1.4% vs 7.6%). 2L PFS longer in ami/laz arm vs osi (8.4m vs 5.3m).
https://t.co/UYIfOrJEmZ
👁 14.0K
❤ 119
🔁 37
Apr 29
The 7-year CROWN triql update is now published in @Annals_Oncology, concurrently with #ASCO26
Median PFS remains unreached with lorlatinib, with a 7-year PFS rate of 55%‼️
A level of durability rarely seen with targeted therapy👇
https://t.co/gZSP1WHz9Y https://t.co/PC8y4YOIYJ
👁 10.3K
❤ 39
🔁 19
May 29
🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1
🆙 @JCO_ASCO
☑Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC
🎙Dr. Lyudmila Bazhenova @HHorinouchi
#LCSM @OncoAlert @Larvol
https://t.co/k4lOuFfjrl https://t.co/esWC2okMGP
👁 9.5K
❤ 100
🔁 48
May 27
🧬 My Top 10 DT abstracts at #ASCO2026
3 storylines I'm watching:
→ KRAS G12D: noncovalent DN022150 (Ph I/IIa) + RNK08954 (Ph II) in parallel
→ Macrocyclic EGFR arrives: BH-30643 FIH
→ Radioligand enters SCLC: 177Lu-DOTA-TATE in #SCLC
@OncoAlert @oncodaily @Larvol https://t.co/toMicQYdgs
👁 8.7K
❤ 65
🔁 27
Apr 26
Clinical Trials20 trials with discussion
CROWN — Abs 8502
Lorlatinib vs Crizotinib · 7-yr update · 1L ALK+ NSCLC
▼
7yr CROWN update of 1L lorlatinib
55% progression-free at 7 YEARS.
Median PFS STILL not reached.
In metastatic solid tumors, this is essentially unheard of. Let that sink in.
And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26 https://t.co/HulNInGI1e
👁 79.8K
❤ 141
🔁 44
May 29
Remarkable is an understatement!
#ASCO26 7-yr update (Abstract 8502, CROWN): 1L lorlatinib in advanced ALK+ NSCLC — median PFS STILL not reached at 7 years, the longest ever in advanced NSCLC. 7-yr PFS 55% vs 3% for crizotinib. Clear 24 mo and you have a 79% chance of being PFS https://t.co/FdjyMSzkIi
👁 17.6K
❤ 68
🔁 24
May 22
🧵 CROWN 7-Year Update: Lorlatinib in 1L ALK+ NSCLC: the longest PFS ever reported in advanced NSCLC keeps getting longer!!! #ASCO26 🫁 Abstracts! Presenter: @TonyMok9
Key takeaways: 👇 @ALKPositiveinc
1) 1/ 📈 Median PFS STILL not reached at 7 years.
• 7-yr PFS rate: 55% https://t.co/SoInsv7wwc
👁 16.3K
❤ 119
🔁 42
May 21
The precision oncology hype machine just found its new weapon to sell a paradigm. CROWN 7yr lorlatinib. 55% progression-free. Median PFS not reached. Proof the paradigm works. Except it isn’t. Let’s go. 🧵 https://t.co/sFm2JyM7wY
👁 14.7K
❤ 46
🔁 7
May 30
Day 1 #ASCO26 highlights:
1. #CROWN (update): ALK+ NSCLC
2. #OptiTROPLung05: SacTMT/IO NSCLC
3. #WuKONG28: EGFR 20 NSCLC
4. #EV302 (update): EV-Pembro mUC
5. #MajesTEC9: Teclistamab in RRMM
6. #SUCCESSOR2: Mezigdomide in RRMM
#OncTwitter @ASCO
1/7 https://t.co/OglbDzr7Ym
👁 13.1K
❤ 146
🔁 58
May 29
#ASCO26
CROWN 👑
This is what happens when you find the right target… and then build the right drug.
At 7 years of follow-up in CROWN, median PFS with lorlatinib remains not reached. More than half of patients remain progression-free at 7 years (55%), compared with just 3%. https://t.co/MBratwPyjE
👁 6.7K
❤ 94
🔁 17
May 30
Dr. @TonyMok9 at #ASCO26 presents update on CROWN in ALK+ NSCLC. After 7y, median PFS with lorlatinib still not reached. Between years 5 and 7, only 4 progression events occurred. Unusual but fantastic to see such a tail with targeted therapy - this is truly raising the bar. https://t.co/AvwYIdQ1HB
👁 6.3K
❤ 153
🔁 67
May 29
🔥BREAKING‼️ @Annals_Oncology 🆙
🔥CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC
✅mPFS NR (HR 0.19)
✅7-yr PFS 55% vs 3%
✅No new IC progression after 30m
🎙️ @TonyMok9
🔢8502
☑️NCT03052608
🔗 https://t.co/TvjW5Uj5jP
@OncoAlert @Larvol @ASCO @IASLC @ALKPositiveinc https://t.co/yypbkrLJ6m
👁 5.5K
❤ 23
🔁 11
May 29
Alright - day 1 was a great start for #ASCO26. Here’s my #LCSM summary
6 trials that matter, in one thread
1️⃣ CROWN — 7-yr lorlatinib
2️⃣ AcceleRET-Lung — pralsetinib
3️⃣ Lunbotinib P2 — next-gen RET
4️⃣ OptiTROP-Lung05 — sac-TMT + pembro
5️⃣ WU-KONG28 — sunvozertinib
6️⃣ CHRYSALIS-2 https://t.co/ZSY4CSL9Py
👁 5.2K
❤ 61
🔁 18
May 30
🔥🚨@OncoAlert Hot off the press.
Just published @Annals_Oncology in conjunction with presentation @ASCO #ASCO26
⭐️7-Year #Updates from the:
👑 #CROWN phase 3 trial of #1st line #Lorlatinib vs #Crizotinib in Advanced #ALK+ Non–Small Cell #LungCancer
❇️❇️IMPRESSIVE Results https://t.co/seVXk3a2Jn
👁 4.8K
❤ 39
🔁 26
May 29
🆙 #ASCO26 #LCSM Oral
🔥CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC
✅mPFS NR (HR 0.19)
✅7-yr PFS 55% vs 3%
✅44% still on lorlatinib at 7y
✅No new IC progression after 30m
🎙️ @TonyMok9
🔢8502
☑️NCT03052608
🔗 https://t.co/GgYuAT7iil
@OncoAlert @Larvol @ASCO @ALKPositiveinc https://t.co/UhlKhW6F54 https://t.co/D5Oj4bFXZY
👁 3.8K
❤ 36
🔁 13
May 22
#ASCO26 Concomitant publication in Annals of Oncology
The CROWN 7-year update changes the tone in ALK+ NSCLC.
Lorlatinib is no longer just “better than crizotinib.”
It is showing what chronic control may look like.
🫁 1L advanced ALK+ NSCLC
CROWN phase III: lorlatinib vs https://t.co/7AaJYW3Lt9 https://t.co/Ut2gVjT4qy
👁 3.6K
❤ 40
🔁 15
May 29
🆙 @OncoAlert #ASCO26 #LCSM 🔝🔟Abstracts
Leads: @HHorinouchi @UOzkerim @WeOncologists
1 HARMONi-6
2 LIBRETTO-432
3 WU-KONG28
4 OptiTROP-Lung05
5 TRITON
6 CROWN 7yr
7 LORIN
8 AcceleRET-Lung
9 Silevertinib
10 Concurrent CRT + durvalumab in ES-SCLC
@ASCO @Larvol https://t.co/JUNcBp39Vo
👁 3.3K
❤ 50
🔁 20
May 27
🆙 #ASCO26 #LCSM Oral Abstract Session
🔥CROWN: Lorlatinib vs Crizotinib as First-Line Treatment for Advanced ALK+ NSCLC: 7-Year Update
🎙️ @TonyMok9
🔢8502
☑️NCT03052608
🔗 https://t.co/GgYuAT6KsN
@OncoAlert @Larvol @ASCO https://t.co/CVByWraVH8 https://t.co/JcbFKPl6DZ
👁 3.3K
❤ 22
🔁 7
Apr 26
🔁REVIEW #ASCO26 #LCSM Oral
🔥CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC
✅mPFS NR (HR 0.19)
✅7-yr PFS 55% vs 3%
✅No new IC progression after 30m
🎙️ @TonyMok9
🔗 https://t.co/TvjW5Uj5jP
@OncoAlert @Larvol @ASCO @IASLC @ALKPositiveinc https://t.co/6zz1p3LoLV https://t.co/l2Kh9rWlMj
👁 3.1K
❤ 28
🔁 10
May 30
1. CROWN (7yrs Update): PhIII, n= 296, Lorlatinib vs. Crizotinib ALK+ mNSCLC.
- mPFS not reached for lorlatinib vs. 9.1 mos w/ crizotinib (HR:0.19)
- 7yr PFS 55% w/ lorlatinib vs. 3%
- Gr 3/4 AEs: 77% vs. 57% (given such a profound benefit, focus now should be on AEs)
2/6 https://t.co/gKlsHRHyKR https://t.co/EMLOIEMHyD
👁 2.8K
❤ 22
🔁 10
May 29
#CROWN 7 yr data will be a highlight of #ASCO26. Transformative.
But do you know the scientist behind the engineering of such an impressive molecule? Dr. Jean Cui. 👏 Shout out to Dr. Cui + many other med. chemists whose genius is foundational for making advances! @ASCO #LCSM https://t.co/pYZNsHdh7L
👁 2.1K
❤ 63
🔁 13
May 30
Looks like pCR was named after CROWN- the CROWN jewel of ALK TKIs and path responses alike!
But as a real CROWN princess- while lorla is amazing it also requires some extra pampering! https://t.co/MHp0rURjte https://t.co/2hHXXURzX9
👁 1.9K
❤ 22
🔁 3
May 23
🚨 #ASCO26 | CROWN 7-year update
Lorlatinib vs crizotinib in 1L advanced ALK+ NSCLC
📚Simultaneously published in Ann Oncol
https://t.co/KDHODGKCvG
📈 7-year outcomes:
・PFS: 55% vs 3%
・Median PFS: NR vs 9.1 mo
・HR 0.19
🧠 Intracranial control:
・7-year IC progression-free https://t.co/bwZ45t0rlv
👁 1.8K
❤ 27
🔁 6
May 29
Day 1 of #ASCO26 is the one everyone underestimates.
CROWN (7-yr), EV-302 (3.5-yr), CHRYSALIS-2, AcceleRET-Lung, SUCCESSOR-2, LINKER-AL2. And the LBAs to come: RASolute 302, HARMONi-6, LIBRETTO-432, PROTEUS, SERENA-6, NHS-Galleri.
Full breakdown in the article.
#LCSM #blcsm https://t.co/OKlj3Nf4yf
👁 1.7K
❤ 6
🔁 4
May 29
#ASCO26
We often talk about years of follow-up.
CROWN is now talking about 7 years.🔥
More than half of patients treated with first-line lorlatinib remain progression-free, with median PFS still not reached.
A remarkable achievement in ALK+ NSCLC.
@OncoAlert @StephenVLiu https://t.co/mGuu6Lerwg
👁 1.5K
❤ 13
🔁 8
May 29
Day 1 of #ASCO2026
EGFR EXON20: New frontline EGFR exon 20 insertion data with encouraging efficacy signals in this historically difficult-to-treat population.
CROWN: The 7-year update confirmed the durability of lorlatinib in ALK+ NSCLC, with mPFS still not reached & sustained https://t.co/IPlRVWMdjL
👁 1.4K
❤ 18
🔁 6
May 30
The sexiest survival curve at #ASCO26 by far: updated 7-year PFS from the ITT population of #lorlatinib in the #CROWN trial for ALK+ #lungcancer, presented by @TonyMok9.
Longest duration of response yet seen with targeted therapy in #lungcancer: median PFS still not reached at 7 https://t.co/P4E35yuD9Z
👁 1.4K
❤ 37
🔁 11
May 29
CROWN 7yr fu. 50% PFS rate produced to be reached at year 9 translating to a projected mPFS of 108 months (9x12). The 7 yr PFS rate of lorlatinib has surpassed the 7yr OS rate of alectinib from ALEX. We have been the early believers.. @ASCO @ALKPositiveinc @ALKpositiveINT https://t.co/xjTxoARUeJ
👁 1.2K
❤ 8
🔁 2
May 28
🫁 Amazing CROWN 7-year update at #ASCO26
Dr. @TonyMok9: In 1L advanced ALK+ NSCLC, median PFS with lorlatinib is STILL not reached at 7 yrs!
📊 7-yr PFS 55% vs 3% (crizotinib), HR 0.19
🧠 No new intracranial progression after 30 mo
Longest PFS ever reported in advanced NSCLC! https://t.co/80b6SI2b7a
👁 1.1K
❤ 19
🔁 7
May 29
Top Trials to Follow on Day 1 @ASCO 2026
WU-KONG28 | CHRYSALIS-2 | CROWN | ALKOVE-1 | AcceleRET Lung | OptiTROP-Lung05 | RADICAL | KEYNOTE-564 | KEYNOTE-A39 | NEXUS-01 | KEYNOTE-868 | MajesTEC-9
#ASCO #ASCO26 #ASCO2026 #Cancer #Oncology #Hematology #BloodCancer #OncologyEvents https://t.co/M20sU5fXox
👁 1.0K
❤ 1
🔁 1
May 29
🆙 #ASCO26 #LCSM Oral
🔥CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC
✅mPFS NR (HR 0.19)
✅7-yr PFS 55% vs 3%
✅44% still on lorlatinib at 7y
✅No new IC progression after 30m
🎙️ @TonyMok9
🔢8502
☑️NCT03052608
🔗 https://t.co/TvjW5Uj5jP
@OncoAlert @Larvol @ASCO @IASLC https://t.co/7fBd6q7JI9
👁 742
❤ 16
🔁 11
May 29
CROWN TRIAL: Lorlatinib vs crizotinib in ALK+ NSCLC 7-years Updated.
The longest PFS reported in metastatic solid tumors. Very proud to participate in this trial.
#ASCO26 @Pos_CAO #POSTCAO26
@Hospital_FJD
@UAM_Madrid
@quironsalud
@AEACAP
#IIS-FJD
#LCSM
@OncoAlert https://t.co/a0675CtRgc
👁 684
❤ 8
🔁 6
May 29
📸 #ASCO26 Meet 🆙
🌟 @bensolomon1
👑 CROWN prince of ALK+ NSCLC
#LCSM @Oncoalert @ASCO @IASLC https://t.co/yYkwDMEsLT
👁 659
❤ 16
🔁 3
May 31
#ASCO26 In CROWN, those who required dose reduction of lorlatinib also did extremely well (PFS and intracranial PFS). Interesting observations in correlatives: early progressives had higher TMB and more TP53 mt compared to long-term responders. https://t.co/0nePVy4r5X
👁 630
❤ 13
🔁 1
May 29
#ASCO26
🫁 Lung Cancer Oral Track 💥
👑 CROWN: Lorlatinib vs Crizotinib #ALK NSCLC 7-yr FUP
🗣️ @TonyMok9
✅ PFS NR vs 9.1m, HR 0.19!
✅ Intra🧠 PD 92 vs 16% at 7yrs
☣️ HyperDLP and TG, edema, peripheral neuropathy, 21% mood change
🤔 Early progressives: higher #TP53 and higher https://t.co/q0W9q3K6eu
👁 596
❤ 6
🔁 3
May 29
Seven-year follow-up of CROWN confirms the durability of first-line #lorlatinib in ALK+ NSCLC: 55% remain progression-free at 7 years, median PFS unreached, and intracranial control is unprecedented (HR for IC progression 0.06). A new benchmark in targeted therapy. #ASCO26 https://t.co/X1Vl4mTP53
👁 592
❤ 7
🔁 6
May 29
CROWN Trial — 7-Year Update
First-line lorlatinib continues to deliver unprecedented long-term disease control in advanced ALK+ NSCLC.
• 55% progression-free at 7 years
• Median PFS still not reached
• HR 0.19 vs crizotinib
• Remarkably durable intracranial control
• No https://t.co/L2zmxeO3wj
👁 565
❤ 7
🔁 5
May 27
One Core Takeaway — CROWN Trial 7-Year Update
55% of patients remained progression-free at 7 years with frontline lorlatinib in advanced ALK+ NSCLC — with no new intracranial progression observed after 30 months.
A landmark durability signal in metastatic NSCLC.
#ASCO2026 #ALK https://t.co/goqrjNwNtZ
👁 533
❤ 3
🔁 3
May 27
Still thinking about the landmark CROWN 7-year lorlatinib update.
Beyond the stats, this represents real, meaningful time for our patients & families living life while managing scans, visits, & AEs. CROWN is setting a phenomenal new benchmark for all TKIs to strive for! #ASCO26 https://t.co/jvVJ8n4FHS
👁 495
❤ 11
🔁 5
May 30
Block 2 - ALK and RET
8502 — Lorlatinib vs crizotinib, first-line ALK+, 7-year CROWN update. Mok, CUHK. The longest follow-up in oncogene-driven NSCLC; the durability question for frontline lorlatinib.
•8503 — ALKOVE-1: neladalkib (NVL-655) in advanced ALK+. Lin, Mass General
👁 486
❤ 4
🔁 3
May 29
I will keep it brief on this one
With median PFS for lorla arm not reached at 7 years- the CROWN study deserves the Tony award! https://t.co/6daKiOWEtV
👁 422
❤ 27
🔁 10
May 29
#ASCO26
#️⃣8502 | CROWN (Ph3, 7-yr update)
✨ Ph3 1:1 of 1L lorlatinib vs crizotinib in advanced ALK+ NSCLC.
🔍 With PFS still NR at 5 yrs, this 7-yr update characterizes long-term outcomes (n=296, median PFS f/u 83 mo)
📊 Median PFS NR vs 9.1 mo (HR 0.19); 7-yr PFS 55% vs 3%
👁 413
❤ 3
🔁 1
May 28
Oncologist Perspectives on the CROWN Study – Lorlatinib in Stage III ALK-Positive NSCLC
@BalazsHalmosMD @GlopesMd @DrRiyazShah @OncBrothers @Tony_Calles @LauraAlderMD @HHorinouchi @TonyMok9 @SuyogCancer
https://t.co/DQaCdLJ6Tz https://t.co/ARdFSWjp2e
👁 386
❤ 8
🔁 3
May 23
In 2024 I have used the word unprecedented to describe the 5-year PFS of Lorlatinib in the CROWN trial. The 7-year PFS, without reaching median PFS? Just mind blowing. #ASCO26 https://t.co/MCwByMfVff
👁 386
❤ 6
🔁 2
May 29
The 7 year-follow up data on the CROWN study “cements lorlatinib as the wearer of the crown.”
And raises many questions: are there other members of royalty in the works? and what is the physical cost patients pay for this crown?
Dr. Angel Qin @umichmedicine discusses RET+ and https://t.co/t2l1maLaWt
👁 243
❤ 2
🔁 2
May 29
Lorlatinib reigns as frontline standard
CROWN (Abs 8502): 7-yr lorlatinib vs crizotinib, 1L ALK+ NSCLC. Median PFS still not reached vs 9.1 mo; HR 0.19  — 55% vs 3% progression-free at 7 years , the longest PFS ever reported in advanced NSCLC. No new CNS progression after 30 https://t.co/FKmGlr2WPG
👁 226
❤ 5
🔁 1
May 30
#ASCO26 | CROWN 7-Year Update
Practice-changing long-term data continue to reinforce lorlatinib as the benchmark first-line therapy for advanced ALK-positive NSCLC.
✅ Median PFS: Not reached vs 9.1 months with crizotinib
✅ HR 0.19 (95% CI 0.13–0.26)
✅ 55% of patients remain https://t.co/iPDQMRCp3b
👁 167
❤ 3
🔁 3
May 29
My favourite survival curve from the CROWN trial is the transformative impact in CNS control with lorlatinib
Patients with ALK tumors used to have >60% of brain metastasis along their disease. A devastating condition with huge personal, social and economic consequences. Now the https://t.co/bQ36B4ROPJ
👁 148
❤ 2
🔁 1
May 29
For CROWN 7-year Lorlatinib PFS, I have one take. Are we reaching a plateau in ALK+ NSCLC? Crossing the 2 year barrier is a surrogate for going the (very) long way? 30% of events in 24 months. 15% of events in the subsequent 60 months. Boom. #ASCO26
👁 114
❤ 0
🔁 1
May 29
7yr CROWN update of 1L lorlatinib
55% progression-free at 7 YEARS. https://t.co/LI2EFD2aPs
👁 105
❤ 0
🔁 0
May 29
ASCO26 in #NSCLC ALK+ 🧬 7-year follow-up of phase 3 CROWN trial confirms impressive long-term benefit with lorlatinib.
Not much to be said:
mPFS not Reached at 7 years!
7-year intracranial time to progression: 92% (sustained plateau after 30 months)
🔹: PFS benefit is https://t.co/1kPN9WZuJa
👁 59
❤ 0
🔁 2
May 29
🚨 Latest #Oncology Update!
🔷 Updated 7-year results from the Phase III CROWN trial showed Lorlatinib (LORBRENA) achieved the longest progression-free survival (PFS) reported to date in ALK-positive advanced NSCLC, with 55% of patients remaining progression-free at seven years https://t.co/dND8LWxhRb
👁 55
❤ 0
🔁 0
May 30
At #ASCO2026, Prof. Tony Mok @TonyMok9 presented 7-year follow-up of the phase 3 CROWN study. Lorlatinib continued to show unprecedented efficacy in treatment-naïve ALK-positive NSCLC, with median PFS not reached (83 months follow-up) and 7-year PFS rate of 55% (HR 0.19 vs https://t.co/gyIDCXARM2
👁 37
❤ 1
🔁 1
May 30
WU-KONG28 — LBA8500
Sunvozertinib mono vs Chemo · 1L EGFR exon20ins NSCLC (Phase 3)
▼
Results from phase III WU-KONG28 @NEJM: first line sunvozertinib vs carbo/pem for EGFR exon 20 insertion NSCLC (n=324). Sunvozertinib clear winner here: RR 59% vs 31%, DOR 11.2 vs 7.1m PFS 10.3m vs 7.5m, HR 0.65, 12m PFS 46% vs 27%. Note toxicity: diarrhea 87% (G3+ 14%). #ASCO26 https://t.co/18VnCm0kiA
👁 10.8K
❤ 85
🔁 34
May 29
‼️ Phase 3 WU-KONG28: 1L Sunvozertinib v Chemotherapy in EGFR exon20 NSCLC
▫️mPFS 10.3 v 7.5 mos (HR 0.65)
▫️ORR ~60% v 30%
Keep in mind, 1L PAPILLON (Amivantamab + chemo) is currently our SOC (mPFS 11.4 mos, ORR of 73%)
#ASCO26 @ASCO https://t.co/oCkiYgrSuH
👁 7.3K
❤ 45
🔁 26
May 29
How meaningful is “practice-changing” data if patients still cannot access the drug?
Sunvozertinib has shown promising activity in EGFR exon20ins NSCLC, yet access remains the real endpoint that matters. A drug approval means little if, patients still cannot receive it. https://t.co/TS79rCb01u
👁 4.4K
❤ 65
🔁 23
May 29
Concomitant NEJM publication 🚨
WU-KONG28 puts oral sunvozertinib firmly into the 1L EGFR exon20ins NSCLC conversation.
Phase III | 324 pts
Sunvozertinib vs carbo-pemetrexed
📌 PFS: 10.3 vs 7.5 mo
HR 0.65 | P<0.001
📌 ORR: 58.9% vs 31.1%
📌 DoR: 11.2 vs 7.1 mo
📌 OS immature, https://t.co/IOnLurWGWt https://t.co/mEOKGNKgf7
👁 3.9K
❤ 12
🔁 5
May 29
#ASCO26 Presentation on WU-KONG28 by John Heymach looks at first line sunvozertinib vs chemotherapy for EGFR exon 20 insertion NSCLC. PFS favors targeted therapy: 10.3m vs 7.5m, HR 0.65 with RR 59% vs 31%. Note high crossover rate from chemo to sunvozertinib. https://t.co/trM0Res77Z
👁 3.4K
❤ 35
🔁 13
May 29
🆙 #ASCO26 #LCSM Oral Abstract Session
🔥WU-KONG28: Sunvozertinib Monotherapy vs Platinum-Based Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR Exon20ins
🎙️Dr. John V. Heymach
🔢LBA8500
☑️NCT05668988
🔗 https://t.co/xakJ6JI2Nk
@OncoAlert @Larvol @ASCO @IASLC https://t.co/Xx6rJtGaT6
👁 3.4K
❤ 22
🔁 15
May 29
🫁 #ASCO26 prep ❶
#️⃣LBA8500 | WU-KONG28 (Ph3, multinational)
✨ First multinational Ph3 RCT of sunvozertinib (oral EGFR exon20 ins–selective TKI) vs platinum-based chemotherapy as 1L in advanced NSCLC with EGFR exon 20 ins mutations
📊 Primary analysis to be presented as LBA https://t.co/fuOYAPBW4q
👁 3.4K
❤ 11
🔁 5
May 28
Our Dr. John Heymach @UTMDAnderson presents WU-KONG28 at #ASCO26:
✅ mPFS: 10.3 vs 7.5 mos (HR 0.65)
✅ ORR: 58.9% vs 31.1%
✅ DoR: 11.2 vs 7.1 mos
🔄 ~90% on chemo crossed over to sunvozertinib on study
⚠️ G3+ TRAEs: 61% (diarrhea any grade 84%, G3 13.5%)
@ASCO https://t.co/EvnOplboEG https://t.co/c0LTVpGTeX
👁 3.1K
❤ 12
🔁 6
May 29
90% crossover in WU-Kong28 looks like a record for a clinical trial (cf 85% in Splash, 84% in PSMAfore, 76% in Bruin CLL-321) #ASCO26 via John Heymach https://t.co/K3czsqLqmE
👁 3.1K
❤ 2
🔁 2
May 30
LBA8500: WU-KONG28 delivers a positive phase 3 result in EGFR exon20ins NSCLC.
Sunvozertinib monotherapy improved PFS vs platinum/pemetrexed: •
mPFS 10.3 vs 7.5 months
• HR 0.65 (p=0.0008)
• ORR 58.9% vs 31.1%
• DoR 11.2 vs 7.1 months
• 90% crossover to sunvozertinib after https://t.co/n45lBiaIsz
👁 2.9K
❤ 21
🔁 11
May 29
Dizal: crossover ate my OS benefit. #ASCO26 data from WU-Kong28 in 1st-line exon20 NSCLC, via @ApexOnco -> https://t.co/8fzt66W6eo $JNJ $CGEM
👁 2.7K
❤ 8
🔁 3
May 29
And the concomitant #ASCO26 publications are out:
#WU-KONG28 Ph3 trial of 1L #Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
➡️ mPFS 10.3 vs 7.5 mos
⬆️ ORR 58.9% vs 31.1%
⚠️ AEs renal, GI, anemia
👎 FDA approved in July 2025 but not yet available in the US for https://t.co/gLoBx6Fpz6
👁 2.5K
❤ 22
🔁 10
May 29
🔥🚨@OncoAlert Hot off the press.
Just published @NEJM in conjunction with presentation @ASCO #ASCO26
⭐️Results of #WUKONG28 trial of:
✅#Sunvozertinib Vs #Chemotherapy
For #1st line Tx of advanced #NSCLC with #EGFR #Exon20 insertion mutations.
👇🏻
https://t.co/2MSWJNq3DM https://t.co/7DbXMT4WMz
👁 2.4K
❤ 25
🔁 12
May 29
Three ASCO 2026 Day 1 LBAs to watch closely: ( only 3 of them in adult solid tumors -too low for Day 1 ? ) @dr_yakupergun
1 - WU-KONG28: Sunvozertinib vs platinum chemotherapy in frontline EGFR exon20ins NSCLC.
Sunvozertinib is a next-generation oral EGFR TKI designed https://t.co/0MbCtbsg6G
👁 1.9K
❤ 23
🔁 5
May 28
WU-KONG28 was published in @NEJM simultaneously with #ASCO26
In 1L EGFR exon20ins NSCLC, oral sunvozertinib showed:
PFS 10.3 vs 7.5 mos
HR 0.65
12-month PFS: 46.1% vs 26.7%
ORR 58.9% vs 31.1%
In PAPILLON, 12-month PFS with ami-chemo was approximately 48%.
Sunvozertinib seems https://t.co/G5YegzzCqV
👁 1.6K
❤ 29
🔁 11
May 29
#ASCO26 🫁
Sunvozertinib may finally redefine frontline therapy for EGFR exon20ins NSCLC.
In the phase 3 WU-KONG28 trial:
🧬 Sunvozertinib vs platinum-pemetrexed chemo
👥 Untreated advanced EGFR exon20ins NSCLC
📊 n=324
Key results:
✅ mPFS: 10.3 vs 7.5 mo
✅ HR 0.65 https://t.co/722jYHaFdZ https://t.co/pPVLzYt8Eo
👁 1.6K
❤ 12
🔁 7
May 30
🔁REVIEW #ASCO26 #LCSM Oral
🔥WU-KONG28: 1L Sunvozertinib vs Platinum-CT in EGFR Exon20ins NSCLC
✅mPFS 10.3 vs 7.5m (HR 0.65; 95%CI 0.50-0.85)
✅ORR 58.9 vs 31.1%
🎙️Dr. John V. Heymach
🔗 https://t.co/xakJ6JI2Nk
@OncoAlert @Larvol @ASCO @IASLC @Exon20Group @EGFRResisters https://t.co/hQ0a6zT6OY https://t.co/OcVYyRyPBC
👁 1.6K
❤ 11
🔁 8
May 30
WUKONG28: 1st line sunvozertinib (300 mg) improved PFS vs CT in mNSCLC & EGFRex20ins. First positive trial. Qx🧐
-dose:200 or 300? FDA approved 200 in 2L. Toxicity!
-TKI alone or TKI+CT specially for EGFR20ins far-loop?
-Other trials ongoing, crowded space
-Best sequence? #ASCO26 https://t.co/ai0i00vj5y
👁 1.5K
❤ 35
🔁 14
May 29
With @ASCO 2026 around the corner, we asked leading AI models to identify the most anticipated lung cancer trials, here’s their combined ranking.
There was strong consensus around trials like WU-KONG28, CROWN, LIBRETTO-432, and HARMONi-6 highlighting continued momentum in https://t.co/525R66H0vI
👁 1.5K
❤ 17
🔁 8
May 27
🆙 Abstract #ASCO26 #LCSM Oral
🔥WU-KONG28: 1L Sunvozertinib vs Platinum-CT in EGFR Exon20ins NSCLC
✅mPFS 10.3 vs 7.5m (HR 0.65; 95%CI 0.50-0.85)
✅ORR 58.9 vs 31.1%
🎙️Dr. John V. Heymach
🔗 https://t.co/xakJ6JI2Nk
@OncoAlert @Larvol @ASCO @IASLC @Exon20Group @EGFRResisters https://t.co/X5snIRA3ag
👁 1.1K
❤ 20
🔁 12
May 29
🧬✨ASCO26 starts tomorrow and the lung cancer🫁 program really looks packed this year📢
From HARMONi-6 and LIBRETTO-432 to WU-KONG28, perioperative ALK strategies and KRAS/STK11-focused IO approaches, there’s a lot of potentially impactful thoracic oncology data ahead. https://t.co/dVOYd3vctx
👁 1.1K
❤ 18
🔁 9
May 28
🔥BREAKING‼️ @NEJM 🆙
✅WU-KONG28: Sunvozertinib vs Platinum-CT as 1st-Line Tx for Advanced NSCLC with EGFR Exon20ins
🎯PFS HR 0.65 (95%CI 0.50-0.85)
🎯1-y PFS rate 46.1 vs. 26.7%
🎙️ Dr. Caicun Zhou
🔜 #ASCO26 #LCMS, ORAL
@OncoAlert @Larvol @ASCO @IASLC @Exon20Group https://t.co/BZGW31cF4q
👁 981
❤ 22
🔁 9
May 29
🚨 #ASCO26 | WU-KONG28
Sunvozertinib vs platinum-based chemotherapy
1L advanced NSCLC with EGFR exon20ins
#️⃣Abstr 8500
🔥Simultaneously published in NEJM
https://t.co/CWBmjrbQWh
✅ Primary endpoint met:
・mPFS 10.3 vs 7.5 mo
・HR 0.65, P=0.0008
🎯 Tumor response:
・cORR https://t.co/nHZzwkPR0T
👁 956
❤ 9
🔁 2
May 29
Sunvozertinib (WU-KONG28 trial): a new major player on front line to replace chemoT - Amivantamab: very likely and while awaiting the next ones, including firmonertinib for EGFR Ex20ins pts. World of EGFR definitely never stops its scientific revolution and progress…@NEJM #EGFR https://t.co/JwpQKsAP8l
👁 800
❤ 13
🔁 6
May 29
Dizal Zegfrovy data from WU-Kong28, in NEJM https://t.co/qx2TwwHq7g #ASCO26 $CGEM $JNJ
👁 794
❤ 2
🔁 0
May 29
WU-KONG28 in @NEJM and #ASCO26:
First-line sunvozertinib beat chemo in advanced NSCLC with EGFR exon 20 insertions.
PFS 10.3 vs 7.5 months (HR 0.65)
Response rate 59% vs 31% (meaningful tumor shrinkage)
Duration of response 11.2 vs 7.1 months
An oral, chemo-free option for a https://t.co/qw0dWUAx1s
👁 725
❤ 6
🔁 2
May 29
#ASCO26
🫁 Lung Cancer Oral Track 💥
WU-KONG28 Phase III Trial:
🗣️ Dr. Hey mach @UTMDAnderson
🎯 Sunvozertinib versus platinum-based chemotherapy as 1L NSCLC with EGFR exon20ins
✅ PFS 10.3 vs 7.5m
✅ PFS2 21.7m vs 15.5m
✅ ORR 59 vs 31%
✅ DOR 11.2 vs 7.1m
☣️ Toxicity: https://t.co/NFillJP5aF
👁 680
❤ 10
🔁 4
May 29
#ASCO26 No survival difference noted in WU-KONG28 between sunvozertinib vs chemo: 29.8 vs 28.8 - immature and high crossover but no real signal in early part of the curve. https://t.co/Kc5jpC44sO
👁 602
❤ 7
🔁 2
May 29
Phase 3 data presented by Dr. John Heymach at #ASCO26 show sunvozertinib significantly improved progression-free survival and response rates compared with chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins mutations.
The findings support sunvozertinib https://t.co/pgYqAukvkj
👁 584
❤ 6
🔁 2
May 29
Two phase III trials.
Two very different frontline strategies for EGFR Exon20 NSCLC.
🔹 PAPILLON set the efficacy benchmark with amivantamab + chemotherapy.
🔹 WU-KONG28 delivered the first phase III chemo-free option with sunvozertinib.
The next unanswered question may not https://t.co/NkUpYaaFYO
👁 509
❤ 6
🔁 2
May 29
🫁 #ASCO26 #LungCancer
WU-KONG28: 1L Sunvozertinib in EGFR exon20ins NSCLC
Compared to carbo/pemetrexed, sunvozertinib improved:
🔹mPFS 10.3 vs 7.5 mo (HR 0.65; 95% CI, 0.50 to 0.85)
🔹12mo PFS: 46.1% vs 26.7%
🔹ORR: 58.9% vs 31.1%
🔹mDOR 11.2 vs 7.1 mo
⬆️G3 or higher https://t.co/bPSBDsFeQ9
👁 496
❤ 8
🔁 2
May 29
💊 Sunvozertinib is the first single oral agent to improve PFS over chemotherapy in 1L Exon 20 EGFRmut NSCLC although there were differences by subgroups that needs to be acknowledged. Simultaneous publication @NEJM Already approved by FDA for 2nd line. #ASCO26 #LCSM @Exon20Group https://t.co/HVOaI3wGAK
👁 492
❤ 13
🔁 6
May 29
@SuyogCancer Agree. WU-KONG28 is important because it finally gives a positive oral, chemo-free phase 3 option in 1L EGFR exon20ins NSCLC.
For high tumor burden, symptomatic disease, or need for deep early response, PAPILLON still looks stronger: ORR 73%, HR 0.40.
For selected lower-burden
👁 471
❤ 6
🔁 2
May 29
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations | New England Journal of Medicine https://t.co/WnT5nRihr9
👁 409
❤ 4
🔁 1
May 29
#ASCO26
🫁 Lung Cancer Oral Track 💥
WU-KONG28 Phase III Trial:
🗣️ Dr. Ramakant
⚡🧠 Wait or treat? Managing asymptomatic brain metastases in #EGFR #ALK NSCLC
RT upfront vs delayed RT:
✅ Intracranial 🧠PD 21.7 vs 50% (HR 0.35!)
❌ Intracranial PFS 18.2 vs 14.8m
❌ Overall https://t.co/MmqvIa9YSZ
👁 404
❤ 4
🔁 4
May 29
#ASCO26
WU-KONG28 delivers a positive phase III result in frontline EGFR exon20ins NSCLC.
✅ Higher ORR
✅ Longer DoR
✅ Improved PFS
✅ Fully oral treatment option
The next big question may no longer be whether EGFR exon20ins TKIs work in the first-line setting—but how best https://t.co/lndQnEPOvu
👁 365
❤ 9
🔁 5
May 29
Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28) oral session ASCO26# @Hospital_FJD @UAM_Madrid @quironsalud #LCSM @OncoAlert https://t.co/Wp7gBl6HzS
👁 351
❤ 8
🔁 9
May 29
Block 1 - EGFR.
•LBA8500 — Sunvozertinib monotherapy vs platinum chemo, first-line EGFR exon20ins NSCLC (WU-KONG28), multinational phase 3. Heymach, MD Anderson. The headline of the block: an oral exon20ins TKI challenging chemo in the first-line setting, where exon20ins has
👁 344
❤ 5
🔁 2
May 29
My unscientific rankings(Clinical Significance): 1. CROWN 2. CHRYSALIS Interesting but not there yet 1. OptiTROP-Lung 05 ( Chinese only study. Need better global or US studies.) 2. WU-Kong28( not just horsepower. Pay attention to Toxicity profile). https://t.co/xMh5rPoRge
👁 319
❤ 2
🔁 2
May 30
First-Line Sunvozertinib Demonstrates Superior Efficacy Over Chemo in Advanced NSCLC With EGFR Exon 20 Insertions https://t.co/EEWLIRVeSO
#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti
👁 318
❤ 4
🔁 4
May 30
First-Line Sunvozertinib Demonstrates Superior Efficacy Over Chemo in Advanced NSCLC With EGFR Exon 20 Insertions https://t.co/BnYEdO6EUX
#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti
👁 318
❤ 6
🔁 5
May 29
@NEJM - Just looking at numbers #sunvozertinib not a clear winner in 1L EGFR20ins mPFS 10.3 lower than PAPILLON #amivantamab + chemo mPFS 11.4 mos-
Although #sunvozertinib may be easier to administer for some (but currently not available in US) and we have gotten better at managing
👁 298
❤ 2
🔁 0
May 29
Another important step forward for EGFR exon20ins NSCLC.
WU-KONG28 demonstrates significant improvements in ORR, DoR and PFS with first-line sunvozertinib versus platinum-based chemotherapy, bringing a new oral option into the frontline setting.
The key question now may be how https://t.co/IPFn294syH
👁 285
❤ 9
🔁 5
May 29
ASCO 2026 | LBA8500
In this Phase 3 trial, sunvozertinib demonstrated a meaningful PFS improvement over platinum-pemetrexed chemotherapy in the first-line treatment of advanced NSCLC with EGFR exon 20 insertion (HR 0.65).
While these findings establish sunvozertinib as the https://t.co/FeCcqY6Gwy
👁 270
❤ 4
🔁 3
May 30
Excellent way to start off the conference – LUNGevity SAB member, Dr. John Heymach @UTMDAnderson presents important data for pts w/ EGFR exon 20 ins lung cancer.
First-line sunvozertinib outperformed platinum chemotherapy in phase 3 WU-KONG28 study, extending median https://t.co/hhi85gWg9p
👁 263
❤ 5
🔁 2
May 29
The CNS question remains unanswered.
While WU-KONG28 firmly established the systemic efficacy of first-line sunvozertinib in EGFR Exon 20 insertion–mutated NSCLC, its impact on brain metastases is still unclear.
Only 13% of enrolled patients had CNS disease, all required to be https://t.co/s2vSL6puxN
👁 230
❤ 2
🔁 1
May 29
Pre @ASCO 2026: Top #LungCancer Abstracts
LIBRETTO-432 | HARMONi-6 | WU-KONG28 | TRITON | CROWN | Krascendo170 | REVOL858R | SOLARA | OptiTROP-Lung05 | ALKOVE-1 | AcceleRET Lung | CHRYSALIS-2 | TSN1611-2023-101 | TIAN-SHAN2 | HLX43-FIH101 | HLX43-NSCLC201 | ROSETTA Lung-02 | https://t.co/sb5Uxhtbmm
👁 220
❤ 1
🔁 0
May 27
EGFR Exon 20 insertion NSCLC has long waited for an effective TKI.
WU-KONG28 suggests that wait may be over.
Sunvozertinib improved response, tumor shrinkage, duration of response, and PFS versus platinum–pemetrexed in the frontline setting.
With >90% crossover to https://t.co/py7FXC3ViW
👁 217
❤ 1
🔁 2
May 29
WU-KONG28 (1L sunvozertunib vs chemo) showed improved PFS2 of 21.7 vs 15m (OS immature) with prolonged DoR (11.2 v 7mo). CPK elevation seen in 20%. @ASCO #lcsm #lcsm #ASCO26 https://t.co/EKLoTPPntj
👁 193
❤ 6
🔁 4
May 29
🔵 New in @NEJM & at #ASCO26:
Sunvozertinib vs chemo, 1L EGFR exon 20 NSCLC (WU-KONG28)
mPFS 10.3 vs 7.5 mo | HR 0.65 (0.50-0.85)
ORR 58.9% vs 31.1% | mDOR 11.2 vs 7.1 mo
First oral TKI to beat chemo 1L in exon 20. OS still immature.
#LCSM #NSCLC https://t.co/b3lHLheDx2
👁 188
❤ 2
🔁 1
May 29
EGFR exon20ins NSCLC is finally entering the targeted-therapy era.
In the phase III WU-KONG28 trial, first-line sunvozertinib outperformed platinum/pemetrexed:
• mPFS: 10.3 vs 7.5 mo (HR 0.65)
• ORR: 58.9% vs 31.1%
• DoR: 11.2 vs 7.1 mo
• 12-mo PFS: 46.1% vs 26.7%
An https://t.co/HUj58RIptp
👁 171
❤ 1
🔁 1
May 30
WU-KONG28: EGFR Ex20ins 1st line sunvo vs chemo; Meets PFR ORR DOR; Xover was allowed and 90% did in chemo arm; dose reductions in 40%, discontinuation 7%: #ASCO26 https://t.co/xs0ZDdL6up
👁 148
❤ 0
🔁 1
May 29
🫁 SUNVOZERTINIB vs PBC in treatment-naïve EGFR exon20ins advanced NSCLC (WU-KONG28) at @ASCO
Significant PFS improvement:
10.3 vs 7.5 months, HR 0.65 (p=0.0008)
Higher ORR: 58.9% vs 31.1%
Median DoR: 11.2 vs 7.1 months
Manageable safety profile with no treatment-related fatal https://t.co/AUW2kTFlTT
👁 119
❤ 3
🔁 2
May 29
Updates from #ASCO26: Phase 3 #WUKONG28 results show #sunvozertinib significantly improved #PFS in previously untreated patients with #EGFR-mutated advanced #NSCLC, supporting a new frontline targeted therapy option. Learn more: https://t.co/8KSkJDUpUs
#medtwitter #onctwitter https://t.co/QR5yHW6ulX
👁 92
❤ 0
🔁 0
May 29
Just out: First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations #ASCO26 https://t.co/zmJ2XFhiTO
👁 87
❤ 4
🔁 3
May 29
#ASCO26
🫁 Lung Cancer Oral Track 💥
WU-KONG28 Phase III Trial:
🗣️ Dr. Ramakant
⚡🧠 Wait or treat? Managing asymptomatic brain metastases in #EGFR #ALK NSCLC
RT upfront vs delayed RT:
✅ Intracranial 🧠PD 21.7 vs 50% (HR 0.35!)
✅ Delayed arm had more change to receive https://t.co/JXB6mhIOkh
👁 73
❤ 4
🔁 3
May 29
Jury is still out if sunvozertinib can be approved by the FDA as first-line treatment in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations. Not too impressed with phase 3 Wu-Kong28 trial https://t.co/k8lVnseN4H
👁 67
❤ 0
🔁 0
May 29
🔥BREAKING‼️ @NEJM 🆙
✅WU-KONG28: Sunvozertinib vs Platinum-CT as 1st-Line Tx for Advanced NSCLC with EGFR Exon20ins
🎯PFS HR 0.65 (95%CI 0.50-0.85)
🎯1-y PFS rate 46.1 vs. 26.7%
🎙️ Dr. Caicun Zhou
🔜 #ASCO26 #LCMS, ORAL
@OncoAlert @Larvol @ASCO @IASLC @Exon20Group
👁 54
❤ 2
🔁 1
May 29
#Sunvozertinib en #NSCL with EGFR exon20ins: Improves PFS but not yet OS (inmature data)
#ASCO26 https://t.co/GZzACP3zay
👁 51
❤ 0
🔁 1
May 29
And the concomitant #ASCO26 publications are out:
#WU-KONG28 Ph3 trial of 1L #Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
➡️ mPFS 10.3 vs 7.5 mos
⬆️ ORR 58.9% vs 31.1%
⚠️ AEs renal, GI, anemia
👎 FDA approved in July 2025 but not yet available in the US for https://t.co/gLoBx6Fpz6
👁 37
❤ 2
🔁 0
May 29
🚨 Latest #Phase 3 Update!
🔷 In the Phase III WU-KONG28 trial, Sunvozertinib demonstrated improved efficacy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations.
🔷 Sunvozertinib achieved median progression-free https://t.co/XyCCxwuhAr
👁 24
❤ 0
🔁 0
May 31
From PAPILLON to WU-KONG 28, outcomes for EGFR exon20 NSCLC continue to improve. The challenge now is not only efficacy, but defining the right drug, dose, and patient. CNS penetration, resistance (e.g., C797X), and biomarker-driven development remain key unmet needs. #ASCO26 https://t.co/L0yL6el6B3
👁 15
❤ 1
🔁 1
May 29
LIBRETTO-432 — LBA3
Adjuvant Selpercatinib · Stage IB-IIIA RET-fusion+ NSCLC (EFS)
▼
🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26
May 29 - June 2 | Chicago
Which trial are you watching most closely?
🌟 PLENARY GAME-CHANGERS
1️⃣ PROTEUS
Perioperative apalutamide + ADT in high-risk localized prostate cancer
2️⃣ LIBRETTO-432
Adjuvant selpercatinib in RET+ NSCLC https://t.co/vABvne9Yft
👁 34.7K
❤ 278
🔁 123
May 15
🫁 THE 10 MOST IMPORTANT LUNG CANCER TRIALS OF #ASCO26
🎯 TARGETED THERAPY MOVES EARLIER
1️⃣ LIBRETTO-432 (LBA3)
Adjuvant selpercatinib in resected RET+ NSCLC
Precision medicine officially enters curative-intent RET disease.
2️⃣ NeoADAURA
Neoadjuvant osimertinib ± https://t.co/EE74GQQjzG https://t.co/wsAdevStyx
👁 24.3K
❤ 135
🔁 53
May 21
🆙 #ASCO26 #LCSM Plenary Session
🔥LIBRETTO-432: Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC
🎙️Dr. Jonathan W. Goldman
🔢LBA3
☑️NCT04819100
🔗 https://t.co/GSrrTlVitL
@OncoAlert @Larvol @ASCO https://t.co/ePA1n6FNLw https://t.co/BU8415bIlm
👁 3.0K
❤ 14
🔁 5
Apr 26
@ASCO #ASCO26 Plenary Session Abstracts were just released and like a parent only seeing their kid at the stage- I’m only seeing the 2 thoracic 🫁abstracts and the RAS (ON) for pancreatic cancer drug that we need for lung cancer. #lcsm
▶️ #LIBRETTO432 Adj #selpercatinib 🫁
▶️ https://t.co/qZsVqmAmla
👁 1.4K
❤ 33
🔁 9
Apr 21
📢🔥ASCO26 begins tomorrow — and LIBRETTO-432 may be one of the key thoracic studies to watch.
Adjuvant selpercatinib in RET fusion-positive NSCLC has the potential to further expand the role of precision oncology in early-stage disease.
The adjuvant targeted therapy era in https://t.co/JhOTtPJbPv
👁 998
❤ 10
🔁 5
May 27
@SuyogCancer LIBRETTO-432 and RASolute 302 may bring some energy to the room, but overall this ASCO does not feel like it will generate major excitement🤔
👁 942
❤ 6
🔁 2
May 29
The results are in! From oncogene-driven NSCLC to new data in SCLC, here is what your colleagues will be watching at the #ASCO26 Annual Meeting:
🔥 Top Focus Areas:
• Oncogene-driven NSCLC
• 1L Squamous NSCLC
🚀 Key Abstracts to Watch:
• LBA3: LIBRETTO-432 results for
👁 344
❤ 2
🔁 0
May 8
At ASCO this Friday, LIBRETTO-432 will report EFS data for adjuvant selpercatinib in resected stage IB–IIIA RET fusion+ NSCLC. If details confirm the top-line result, RET may join EGFR and ALK in precision adjuvant therapy—making surgical tissue + molecular testing central.
👁 227
❤ 1
🔁 1
May 28
🧬 2/ LIBRETTO-432 (Plenary, LBA3) — adjuvant selpercatinib in resected RET+ NSCLC
Phase 3, n=151, stage IB–IIIA.
What we know from press release:
▶️Met primary endpoint: significant and clinically meaningful EFS benefit with selpercatinib vs placebo. ▶️OS immature but trending
👁 89
❤ 0
🔁 0
May 26
Adjuvant selpercatinib in resected Stage IB–IIIA RET fusion+ NSCLC — primary EFS results from Phase 3 LIBRETTO-432.
Plenary · Abstract LBA 3
📍 Hall B1, Chicago
🗓 May 31 · 19:13 CT
Embargoed until presentation. If positive: no RET+ resected patient reaches Stage IV without a
👁 58
❤ 1
🔁 0
May 28
Watching LIBRETTO-432 and HARMONi-6 closely. Good trials, but calling them practice-changing for UK patients is fantasy while procurement and staffing are broken. https://t.co/6UeA8VhlZp
👁 58
❤ 0
🔁 0
May 21
4. Selpercatinib (LIBRETTO-432) — adjuvant RET inhibition in resected stage IB–IIIA NSCLC. Catching RET fusions before stage IV.
Buzz Score: 92% (5/9)
#ASCO26 #NSCLC
👁 27
❤ 0
🔁 0
May 27
📢🔥ASCO26 begins tomorrow — and LIBRETTO-432 may be one of the key thoracic studies to watch.
Adjuvant selpercatinib in RET fusion-positive NSCLC has the potential to further expand the role of precision oncology in early-stage disease.
The adjuvant targeted therapy era in https://t.co/7uGoaZ1lIa
👁 2
❤ 1
🔁 0
May 27
Beamion LUNG-1
Zongertinib · HER2-mut NSCLC
▼
Original Article: First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer (Beamion LUNG-1 trial) https://t.co/VgM9kRUNTa
Editorial: 𝘌𝘎𝘍𝘙’s Poor Sibling https://t.co/Nei4F2FRu9
#Oncology https://t.co/LGfmF9KWUO
👁 20.5K
❤ 92
🔁 23
May 3
This is the treatment algorithm we have used to drive our 🗣️ with @lungoncdoc on targeted options in 1L for metastatic NSCLC!
✅ Zongertinib recently added
✅ Data around front line when you have multiple options
✅ Role of Re-testing
#lcsm #OncTwitter @OncoAlert @OncUpdates https://t.co/k3Bf3SXVgp https://t.co/c2q1e8HvyI
👁 9.7K
❤ 74
🔁 28
May 12
Beamion LUNG-1 trial: Until recently, no first-line targeted treatment options were available for HER2-mutant non–small-cell lung cancer. Research evaluating zongertinib is summarized in a new Quick Take video. https://t.co/LAVElpvitp https://t.co/a4IwfEOIum
👁 7.3K
❤ 25
🔁 7
Apr 30
New in the April 30, 2026, issue of NEJM:
First-Line Zongertinib in Advanced HER2-Mutant NSCLC (Beamion LUNG-1 trial) https://t.co/VgM9kRUNTa
An Intervention to Improve Maternal Infection Outcomes (APT-Sepsis trial) https://t.co/2Rt6qT01bR
Mim8 in Hemophilia A with or without https://t.co/v5DQBkyWHp
👁 6.3K
❤ 31
🔁 7
Apr 30
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer
https://t.co/hek4yk2UUN https://t.co/3xRfrxhAzI
👁 2.1K
❤ 34
🔁 8
Apr 29
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer
https://t.co/wCTYPWUA4L https://t.co/IUqXTT55Jl
👁 994
❤ 14
🔁 6
Apr 30
🫁 First-line results for HER2-mutant #NSCLC:
Zongertinib:
• 76% ORR
• Durable responses (~15 months)
• Activity in brain mets
➡️ Selective HER2 inhibition may help balance efficacy + toxicity.
🔸 John Heymach, MD, PhD of @UTMDAnderson | @NEJM
https://t.co/it91AmzBGr https://t.co/DsOMI6zf9t
👁 903
❤ 6
🔁 5
Apr 25
The #FDA granted accelerated approval to zongertinib, a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous #NSCLC whose tumors have HER2 TKD activating mutations. https://t.co/RsIUYI6vQ3 https://t.co/bVDaG6Ckif
👁 893
❤ 7
🔁 6
May 11
🇨🇳 Boehringer Ingelheim’s Hernexeos (zongertinib) wins approval in China for a new indication: 1L monotherapy for adults with unresectable locally advanced or metastatic NSCLC harboring HER2 (ERBB2) activating kinase‑domain mutations — previously granted priority review.
👁 752
❤ 5
🔁 0
May 22
THEME 1: What is the optimal sequencing strategy for patients with #HER2 mutations? We have 1L zongertinib approval, but should we intensify with HER2 TKI + platinum / pem, HER2 TKI + HER2 ADC, or something else (like a modified BRIGHTSTAR) approach? What about non-TKD HER2? https://t.co/sjujUcmEp0
👁 603
❤ 9
🔁 5
Apr 26
At #ASCO26, Dr. Xiuning Le highlighted emerging data on zongertinib and sevabertinib for patients with nonsquamous non–small cell lung cancer, underscoring ongoing progress in precision oncology and biomarker-driven treatment strategies. @LeXiuning #EndCancer https://t.co/0tC1wZHr0H
👁 575
❤ 7
🔁 2
May 29
The NMPA Grants Conditional Approval to @BoehringerTR's Hernexeos for 1L HER2-Mutant NSCLC
#boehringeringelheim #hernexeos #zongertinib #bi1810631 #nsclc #beamionlung1 #regulatory #nmpa #conditionalapproval #beamionlung2 #beamionlung3
https://t.co/onePRsrQFC
👁 52
❤ 0
🔁 0
May 22
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer in @NEJM
https://t.co/wCTYPWUA4L https://t.co/1JVD8qHOWj
👁 4
❤ 1
🔁 0
Apr 30
OptiTROP-Lung05 — Abs 8506
sac-TMT + Pembro vs Pembro · 1L PD-L1+ NSCLC (Merck/Kelun)
▼
First pivotal sacituzumab-TMT win for $MRK https://t.co/PnTm6idjlE https://t.co/zjAamEPcPo
👁 10.4K
❤ 7
🔁 2
May 18
Presented at #ASCO26—OptiTROP-Lung05 phase 3 interim analysis.
The findings suggest first-line treatment with sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly prolonged PFS vs pembrolizumab alone in patients with PD-L1-positive advanced NSCLC without https://t.co/MM3qtctXPB
👁 5.2K
❤ 13
🔁 5
May 29
🔁REVIEW #ASCO26 #LCSM Oral
🔥OptiTROP-Lung05: 1L Sac-TMT + Pembro vs Pembro in PD-L1+ NSCLC
✅mPFS NR vs 5.7m (HR 0.35)
✅ORR 70.2% vs 42.0%
✅OS HR 0.55 (95%CI 0.36-0.85, immature)
🎙️Dr. Caicun Zhou
🔗 https://t.co/DcbK1dGrhO
@OncoAlert @Larvol @ASCO @IASLC https://t.co/Vdo86N50h9 https://t.co/512k6dZviW
👁 4.1K
❤ 12
🔁 7
May 30
🆙 #ASCO26 #LCSM Oral
🔥OptiTROP-Lung05: 1L Sac-TMT + Pembro vs Pembro in PD-L1+ NSCLC
✅mPFS NR vs 5.7m (HR 0.35)
✅ORR 70.2% vs 42.0%
✅OS HR 0.55 (95%CI 0.36-0.85, immature)
🎙️Dr. Caicun Zhou
🔢8506
☑️NCT06448312
🔗 https://t.co/DcbK1dGrhO
@OncoAlert @Larvol @ASCO @IASLC https://t.co/B0iJupMU1G
👁 3.6K
❤ 16
🔁 8
May 29
ASCO starts Friday. Forget the 5,000 abstracts — three readouts will reprice more market cap than all of them combined:
• daraxonrasib (RASolute 302): first pan-RAS drug to double OS in pancreatic — the tumor that broke every RAS program before it.
• sac-TMT + pembro (#8506):
👁 2.9K
❤ 20
🔁 5
May 24
🆙 #ASCO26 #LCSM Oral
🔥OptiTROP-Lung05: 1L Sac-TMT + Pembro vs Pembro in PD-L1+ NSCLC
✅mPFS NR vs 5.7m (HR 0.35)
✅ORR 70.2% vs 42.0%
✅OS HR 0.55 (95%CI 0.36-0.85, immature)
🎙️Dr. Caicun Zhou
🔢8506
☑️NCT06448312
🔗 https://t.co/t76ae3dVDU
@OncoAlert @Larvol @ASCO https://t.co/eMpVRm2UrU https://t.co/dSbMUQojWS
👁 2.0K
❤ 17
🔁 9
May 22
Dr. Caicun Zhou at #ASCO26 with results from phase III OptiTROP-Lung05: first-line sacituzumab govitecan (sac-TMT, TROP2 ADC) + pembro vs pembro for PD-L1+ NSCLC (n=413). Sac-TMT superior with PFS NR vs 6.6m (HR 0.38) with benefit across subgroups. https://t.co/LXubHLPXnD
👁 2.0K
❤ 35
🔁 20
May 29
This one needs a thread because there are a lot of caveats:
First-in-class at #ASCO26 (Abstract 8506, OptiTROP-Lung05): the first phase 3 to show an ADC + pembro beats pembro in 1L PD-L1+ NSCLC. Sac-TMT (TROP2 ADC) + pembro vs pembro: PFS not reached vs 5.7 mo, HR 0.35, ORR 70% https://t.co/ThkTczAllD
👁 1.9K
❤ 11
🔁 6
May 22
💣 This is the next major boom in 1L PD-L1+ NSCLC? #ASCO26
OptiTROP-Lung05: Sac-TMT + pembro significantly outperformed pembro alone in 1L advanced PD-L1+ NSCLC.
📈 PFS:
• NR vs 5.7 mo
• HR 0.35, p<0.0001
• 12-mo PFS: 62.4% vs 29.0%
🎯 Responses were deeper and more https://t.co/5ZQfPgyT3d
👁 1.8K
❤ 6
🔁 5
May 29
#ASCO26
TROP2 ADCs continue to make their case as a partner for immunotherapy in the frontline setting.
OptiTROP-Lung05 evaluated sacituzumab tirumotecan (sac-TMT) + pembrolizumab versus pembrolizumab alone in treatment-naïve advanced NSCLC with PD-L1 TPS ≥1%, EGFR/ALK https://t.co/Itf7BeBxG4
👁 1.7K
❤ 17
🔁 14
May 30
Merck's ADC sac-TMT posts its first global Phase 3 win — earlier than expected.
https://t.co/Dla0xwqHVj
👁 1.2K
❤ 7
🔁 1
May 18
🚨 #ASCO26 | OptiTROP-Lung05
Sac-TMT + pembro vs pembro monotherapy
1L PD-L1+ advanced NSCLC
#️⃣Abstr 8506
📚Simultaneously published in The Lancet 🔥
https://t.co/NEyvZYHbjm
📈 Primary endpoint met:
・mPFS: NR vs 5.7 mo
・HR 0.35, p<0.0001
📊 12-mo PFS:
て62.4% vs 29.0% https://t.co/KIE6hEjE9p
👁 819
❤ 6
🔁 3
May 29
ASCO 2026 abstracts go live at 5pm ET today.
The story the market is underpricing: Chinese biotech has moved from pipeline storytelling to head-to-head data. Kelun-Biotech alone landed 3 oral presentations — including the Phase 3 OptiTROP-Lung05 (sac-TMT + pembrolizumab, 1L
👁 812
❤ 0
🔁 0
May 21
#ASCO26 Sac-TMT + pembro improves PFS with PD-L1 low (HR 0.28) but standard here is pembro + chemo. In PD-L1 high, adding sac-TMT improves PFS HR 0.28 - and benefit seen in non-squamous and squamous. OS trend (HR 0.55) with RR 70% vs 42%. Would be good to compare to INSIGNA. https://t.co/a3K0io2V5m
👁 795
❤ 15
🔁 8
May 29
#ASCO26 Adding sac-TMT to pembro does increase toxicity but did not lead to more discontinuation of pembrolizumab (5% both arms). Of note, stomatitis in 40% vs 2% and pneumonitis 12.5% vs 7.4%. https://t.co/rlM7sSwHG5
👁 674
❤ 12
🔁 2
May 29
OptiTROP-Lung05- should we be Optimists about the use of Trop2 ADCs frontline for advanced PD-L1+ NSCLC?
Well- in light of much improved RR and impressive PFS (better for tps 1-49 and. NonSQ) + clear trends for OS benefit with an expected AE profile w/o worrisome signals:
I’d https://t.co/nxQWifOiU0
👁 629
❤ 17
🔁 7
May 29
ASCO 2026 | Abstract 8506
This Phase 3 trial showed that adding the TROP2-directed ADC sacituzumab tirumotecan to pembrolizumab significantly improved PFS in first-line PD-L1–positive advanced NSCLC (HR 0.35). Response rates and depth of response were also higher with the https://t.co/IVnLsydREu
👁 505
❤ 9
🔁 5
May 30
#ASCO26
🫁 Lung Cancer Oral Track 💥
📌 OptiTROP-lung05: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced NSCLC
✅ ORR 70.2 vs 42%
✅ mPFS by investigator NR vs 6.6m, HR 0.38
✅ Benefit in https://t.co/Tf3uVSAg6j
👁 502
❤ 8
🔁 4
May 29
#ASCO26 Abstract 8506 - OptiTROP-Lung05: Sacituzumab tirumotecan + pembrolizumab vs pembrolizumab in PD-L1+ advanced NSCLC. https://t.co/3uiaEYdVdI
👁 490
❤ 4
🔁 1
May 27
Phase 3 OptiTROP-Lung05: sac-TMT + pembrolizumab is the first ADC combo to show significant PFS benefit as first-line treatment for PD-L1+ advanced NSCLC vs pembrolizumab alone. Median PFS not reached vs 5.7 mo (HR 0.35, p<0.0001), with a manageable safety profile. #ASCO26 https://t.co/Rp0BH95F1S
👁 409
❤ 3
🔁 2
May 29
🚨 #ASCO26 | OptiTROP-Lung05
Sacituzumab Tirumotecan (sac-TMT) + pembrolizumab delivered one of the most impressive first-line NSCLC results presented at ASCO 2026.
🫁 Advanced/metastatic NSCLC
✅ PD-L1 TPS ≥1%
✅ No EGFR or ALK alterations
Key findings:
🔹 PFS: Not reached https://t.co/pYjyLT2uOH
👁 382
❤ 8
🔁 4
May 29
🔥🚨@OncoAlert Hot off the press.
Just published @TheLancet in conjunction with presentation @ASCO #ASCO26
⭐️Interim Analysis of phase 3 trial;
#OptiTROP-#Lung05 of:
❇️#Sacituzumab Tirumotecan (Sac-TMT)+ #Pembrolizumab Vs #Pembrolizumab in #PDL1+ advanced non-small-cell https://t.co/dwl1oGnvfP
👁 377
❤ 10
🔁 6
May 30
#ASCO26
✨OptiTROP-Lung05✨
We expected ADCs to move earlier.
We probably didn’t expect a PFS HR of 0.35.
Sacituzumab tirumotecan + pembrolizumab delivered one of the most striking first-line efficacy signals seen in advanced NSCLC this year.
The ADC era keeps moving https://t.co/R7pZ3k86zg
👁 368
❤ 13
🔁 8
May 29
OptiTROP-Lung05 results from #ASCO26 @TheLancet. Phase III of 1L sacituzumab tirumotecan (TROP2 ADC, sac-TMT) + pembro vs pembro mono for PD-L1+ NSCLC. Adding sac-TMT improves PFS (HR 0.35) in both PD-L1 low (HR 0.28) & high (HR 0.47) but also adds tox.
https://t.co/Pj8tGMc303
👁 360
❤ 4
🔁 1
May 29
#OptiTROP-Lung05 met its primary endpoint: sac-TMT + pembrolizumab improved PFS vs pembrolizumab alone in 1L PD-L1+ advanced NSCLC (HR 0.35). Benefit was seen across PD-L1 subgroups (more pronounced in PD-L1 1-49% vs. >=50%), with an early OS signal (HR 0.55). #ASCO26 https://t.co/0TrKnO2eoW
👁 343
❤ 9
🔁 2
May 29
OptiTROP-Lung05 #ASCO2026
ADC + IO may be entering frontline NSCLC.
Sac-TMT + pembrolizumab delivered a striking PFS benefit vs pembrolizumab alone:
• HR 0.35
• ORR 70.2% vs 42.0%
• mPFS NR vs 5.7 mo
Potential chemo-free intensification strategy in PD-L1+ NSCLC.
#NSCLC https://t.co/zc8zp3mfPm
👁 299
❤ 4
🔁 2
May 27
Sac-TMT + Pembro Demonstrates Significant PFS Benefit in PD-L1–Positive Advanced NSCLC https://t.co/HMbJwDnWNc
#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq
👁 287
❤ 5
🔁 4
May 30
OptiTROP-Lung05; sac-TMT + Pembro beats Pembro alone (6w) in PDL1 +ve NSCLC #ASCO26 https://t.co/kKstiNNFWr
👁 218
❤ 3
🔁 1
May 29
OptiTrop-Lung 05: Sac-TMT + Pembro vs Pembro alone in 1L NSCLC in China.
Positive trial for PFS across PDL1 expression and histology subtypes.
Special attention to specific toxicities: mucositis, ocular, IRR.
Unfortunately, pembro alone is not an appropriate control arm as is https://t.co/w7SsFhSAvX
👁 188
❤ 3
🔁 2
May 29
Sac-TMT + pembro beats pembro as a 1st line treatment for advanced NSCLC. The big caveat here is that 60% of the patients in this study had a PD-L1 of 1-49%, so pembro alone wouldn’t have been the recommended treatment for them in many countries, including the US. #ASCO2026 https://t.co/VKghirm3x2
👁 102
❤ 4
🔁 2
May 29
At #ASCO2026, Prof. Caicun Zhou reported the phase 3 OptiTROP-Lung05 trial (N=413). First-line sacituzumab trimetocan (TROP2 ADC) + pembrolizumab significantly improved PFS over pembrolizumab alone in PD-L1-positive advanced NSCLC (HR 0.35; median PFS NR vs 5.7 months). ORR was https://t.co/5uD4O5QarY
👁 39
❤ 1
🔁 1
May 30
CHRYSALIS-2 — Abs 8501
Amivantamab + Lazertinib · 1L atypical EGFR+ NSCLC · OS 41 mo
▼
Significant #ASCO26 update (Abstract 8501, CHRYSALIS-2): 1L amivantamab + lazertinib in atypical EGFR+ NSCLC delivers median OS of 41 months — nearly double afatinib's ~19.4 mo in this hard-to-treat subgroup. 46% alive at 4 yrs, 20% still on 1L therapy. Atypical EGFR finally https://t.co/dTfWspXfmp
👁 5.2K
❤ 38
🔁 13
May 22
#ASCO26 🫁
Could atypical EGFR-mutated NSCLC finally be seeing durable long-term survival?
Updated CHRYSALIS-2 data with frontline amivantamab + lazertinib suggests the answer may be yes.
📌 Study population
Previously untreated atypical EGFR-mutated advanced NSCLC
(Ex20ins https://t.co/sYdX8I7LjX https://t.co/mEOKGNKgf7
👁 3.3K
❤ 16
🔁 6
May 26
🆙 #ASCO26 #LCSM Oral Abstract Session
🔥CHRYSALIS-2: Overall Survival of First-Line Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC
🎙️Dr. Joel W. Neal
🔢8501
☑️NCT04077463
🔗 https://t.co/Yj4jbQrhIo
@OncoAlert @Larvol @ASCO https://t.co/3wPzAWxWmd https://t.co/1zIIUdhlv1
👁 2.5K
❤ 22
🔁 8
Apr 26
🆙 #ASCO26 #LCSM Oral
🔥CHRYSALIS-2: 1L Ami-Laz in Atypical EGFR-Mutated Advanced NSCLC
✅mOS 41.0m
✅3-yr OS 55%, 4-yr OS 46%
✅20% still on 1L tx (up to 4.4yr)
🎙️ @JoelNealMD
🔢8501
☑️NCT04077463
🔗 https://t.co/lH8feekwBu
@OncoAlert @Larvol @ASCO @IASLC @EGFRResisters https://t.co/kqrs4IOIlC
👁 2.4K
❤ 18
🔁 16
May 29
The real exciting update from #ASCO26!
1L Amivantamab + Lazertinib shows strong and durable efficacy in patients with atypical EGFR-mutated advanced NSCLC (CHRYSALIS-2, Cohort C):
ORR: 57%, Median PFS: 19.5 months, Median OS: 41.0 months
A powerful new frontline option for this https://t.co/V3MgR5RGoW
👁 2.4K
❤ 12
🔁 6
May 29
#ASCO26 update in atypical EGFR+ NSCLC from CHRYSALIS-2:
1L amivantamab + lazertinib (n=49)
✅ mOS: 41 mos
✅ 55% alive at 3 yrs
✅ 46% alive at 4 yrs
📌 20% remain on tx
📌 7 pts stayed on amivantamab >3 yrs
For context, historical afatinib mOS: ~19 mos
@JoelNealMD @ASCO https://t.co/pts3cTzWyO
👁 2.0K
❤ 35
🔁 18
May 29
🆙 #ASCO26 #LCSM Oral
🔥CHRYSALIS-2: 1L Ami-Laz in Atypical EGFR-Mutated Advanced NSCLC
✅mOS 41.0m
✅3-yr OS 55%, 4-yr OS 46%
✅20% still on 1L tx (up to 4.4yr)
🎙️ @JoelNealMD
🔢8501
☑️NCT04077463
🔗 https://t.co/Yj4jbQrPxW
@OncoAlert @Larvol @ASCO @EGFRResisters @Exon20Group https://t.co/d9E1DwQrmA https://t.co/Xm2RdZmeRx
👁 1.7K
❤ 18
🔁 9
May 22
🔁REVIEW #ASCO26 #LCSM Oral
🔥CHRYSALIS-2: 1L Ami-Laz in Atypical EGFR-Mutated Advanced NSCLC
✅mOS 41.0m
✅3-yr OS 55%, 4-yr OS 46%
✅20% still on 1L tx (up to 4.4yr)
🎙️ @JoelNealMD
🔗 https://t.co/lH8feekwBu
@OncoAlert @Larvol @ASCO @IASLC @EGFRResisters @Exon20Group https://t.co/2tNATlsFPC https://t.co/dmBLKaPrbr
👁 1.3K
❤ 10
🔁 7
May 30
Update on the eye opening data of CHRYSALIS-2 formots w uncommon EGFR mutation + disease- very impressive PFS and now OS (41 months!) data clearly surpassing other available choices
And now w sq ami and better supportive care delivery is more convenient and safer.
It just https://t.co/R4GD2LIEcw https://t.co/DBdXKEftLF
👁 1.1K
❤ 16
🔁 4
May 29
#ASCO26
Atypical EGFR mutations have long been a therapeutic gray zone in NSCLC.
Now CHRYSALIS-2 Cohort C shows durable activity with 1L amivantamab + lazertinib in treatment-naive atypical EGFR-mutated NSCLC. 👀
📌 Phase 1b
👥 n=49
🧬 Most common mutations:
• G719X: 55%
• https://t.co/uEE1OYbd0o https://t.co/EzEyRy5Y4L
👁 1.0K
❤ 9
🔁 7
May 29
#ASCO26
#️⃣8501 | CHRYSALIS-2 Cohort C (Ph1/1b, OS update)
✨ Cohort C of CHRYSALIS-2 evaluates 1L amivantamab + lazertinib in this subset.
📈 OS update in treatment-naïve pts (n=49, median f/u 31.3 mo)
📊 Median OS 41.0 mo; 3-yr OS 55%, 4-yr OS 46%
⏱ 20% still on 1L
👁 986
❤ 1
🔁 1
May 28
#ASCO26
🫁 Lung Cancer Oral Track 💥
🤔 How to optimize targeting uncommon #EGFR mutations in #NSCLC Trial?
👏🏽 Great discussion by
🗣️ @danieltanmd
✅ Suvozertonib another 💊🎯 for #EGFR20ins in 1L
✅ Amivantamab-lazertinib mOS 41m ok atypical #EGFR #CHRYSALIS-2
⚠️ Differ RT https://t.co/jURu1ugmek
👁 733
❤ 7
🔁 5
May 29
#ASCO26 #Chrysalis-2 updated analysis #Amivantamab plus #lazertinib for Atypical EGFR+ #lungcancer
N=49
mOS 41 mos ‼️‼️
(Alternative oral TKIs have mOS 9-10 mos) https://t.co/IXTKfdaT36
👁 727
❤ 13
🔁 12
May 29
• Historically, atypical EGFR NSCLC had poor long-term outcomes
• Global afatinib data showed median OS of only ~19 months
• In CHRYSALIS-2, 1L amivantamab + lazertinib achieved:
— Median OS: 41 months
— 55% alive at 3 years
— 46% alive at 4 years
• 20% of patients remained https://t.co/dqSrr9tx2y
👁 549
❤ 8
🔁 2
May 27
#ASCO26 Abstract 8501
CHRYSALIS-2: Updated OS with frontline amivantamab + lazertinib in atypical EGFR-mutated advanced NSCLC 🫁 https://t.co/hA7AmAeFB7
👁 451
❤ 3
🔁 2
May 26
CHRYSALIS-2 cohort C: Ami Laz in atypical EGFR first line ; N49; ; 57% ORR; DoR 20.7m PFS 19.5m; mOS 41m👍🏽; Mutational subtype and compound status didn’t predict benefit in subgroups. The mOS probably defines the new gold standard #ASCO26 https://t.co/qpXBtOxief
👁 450
❤ 9
🔁 4
May 29
ASCO 2026 | Abstract 8501
In this Phase 1/1b cohort, amivantamab plus lazertinib demonstrated encouraging activity in the first-line treatment of advanced NSCLC with atypical EGFR mutations, with a median overall survival of 41.0 months and a 3-year OS rate of 55%.
While these https://t.co/dWBZgPcWQQ
👁 430
❤ 8
🔁 6
May 30
CHRYSALIS-2 OS update | #ASCO26
Cohort C 1L amivantamab + lazertinib in ATYPICAL EGFR-mutated NSCLC (n=49):
📊 Median OS 41.0 mo (~3.5 yrs)
• 55% alive at 3y, 46% at 4y
• 20% still on 1L tx at cutoff
~2x the historical ~19.4 mo with afatinib.
#LCSM #LungCancer https://t.co/377qVW73tq
👁 380
❤ 6
🔁 1
May 29
CHRYSALIS-2 (ASCO 2026)
Joel Neal et al.
Core Takeaway
• Historically difficult atypical EGFR biology
• Afatinib-era median OS: ~19 months
• Dual EGFR blockade with amivantamab + lazertinib achieved a median OS of 41 months (~3.5 years)
• Suggests a potential new survival https://t.co/qXEX3Fh48D
👁 286
❤ 3
🔁 2
May 27
CHRYSALIS-2 Cohort C (Abs 8501): 1L amivantamab+lazertinib in atypical EGFR (G719X/L861Q/S768I), n=49. Median OS 41.0 mo; 55% alive at 3y, 46% at 4y . In a population where afatinib is the only approved TKI and outcomes are historically poor , that’s a meaningful bar. New https://t.co/1CwfmMmv8m
👁 250
❤ 8
🔁 5
May 30
Atypical EGFR mutations have been harder to treat than the more common EGFR forms in lung cancer.
@JoelNealMD @Stanford Cancer shares new CHRYSALIS-2 data showing first-line amivantamab + lazertinib may meaningfully extend survival, with median overall survival reaching 41 https://t.co/qG0ZluTlHe
👁 162
❤ 1
🔁 2
May 29
Update on the eye opening data of CHRYSALIS-2 formots w uncommon EGFR mutation + disease- very impressive PFS and now OS data clearly surpassing other available choices
And now w sq ami and better supportive care delivery is more convenient and safer.
It just feels w this our https://t.co/O0IHZmOGTV https://t.co/DBdXKEftLF
👁 119
❤ 1
🔁 1
May 29
We need answers for patients with EGFR PACC mutations. Ami + Lazer seems to find a place in the sun. In this population where Osi does not grant a major benefit, toxicity can be worthwhile. CHRYSALIS-2 cohort C shows 57% for ORR, mPFS 19.5 months and OS of 41.0 mon5hw. #ASCO26
👁 88
❤ 0
🔁 1
May 29
Therapy for Stage IV NSCLC with Driver Alternations:ASCO Living Guidelines Update 2026.3.1 Part 2 @ASCO podcast: https://t.co/pn3fohleGM MARIPOSA and CHRYSALIS-2 https://t.co/e83uMfE0ZF
👁 74
❤ 1
🔁 0
May 26
#Amivantamab+ #lazertinib as first-line treatment for #NSCLC with atypical EGFR mutations
#chrysalis-2 study
#ASCO26 https://t.co/45UjfFT9zx
👁 42
❤ 0
🔁 1
May 29
HARMONi-6
Ivonescimab · NSCLC
▼
$SMMT, Akeso, HARMONI 6
I’m going to guess that we see a 4.5 month Overall Survival differential this weekend.
👁 9.3K
❤ 10
🔁 0
May 29
$SMMT $AKESF $XBI ASCO
I’m guessing that ivonescimab in HARMONI-6 shows a +4.5 mo differential in OS, with an HR of around 0.72.
> HARMONi-6 PFS showed mPFS 11.14 as compared to 6.90 months, HR 0.60, +4.24 months PFS, with higher ORR and DoR, and powered assuming OS HR https://t.co/YlAk0J4ESZ
👁 5.7K
❤ 14
🔁 1
May 30
Very helpful overview of ivonescimab at #RomeLung26 from @GautschiOliver - eagerly awaiting OS results from HARMONi-6 at #ASCO26. https://t.co/dGrAb4cD53
👁 2.3K
❤ 27
🔁 9
May 10
Here we, go #ASCO26. Ivonescimab HARMONi-6 for $SMMT Akeso and all those interested in PD1/VEGFs
STAT's @matthewherper story in the next post.
OS HR 0.66
mOS ivo+chemo 28 months v tis+chemo 24 months
The KM curve https://t.co/0N7GYi1VwR
👁 1.3K
❤ 7
🔁 3
May 31
🆙 #ASCO26 #LCSM Plenary Session
🔥HARMONi-6: Ivonescimab Plus Chemotherapy vs Tislelizumab Plus Chemotherapy in Previously Untreated Advanced Squamous NSCLC: OS Results
🎙️Dr. Shun Lu
🔢LBA4
☑️NCT05840016
🔗 https://t.co/GKbAmcZHEw
@OncoAlert @Larvol @ASCO https://t.co/SRA8Lob4V6 https://t.co/X3tEmRrJQE
👁 1.2K
❤ 7
🔁 0
Apr 26
Impressive results from the phase 3 Harmoni 6 trial of chemotherapy plus ivonescimab or anti-PD1 for advanced squamous lung cancer. HR for overall survival 0.66. May lead to approval in EU, results of Harmoni 3 awaited! #lcsm https://t.co/LaPyP0GWEX
👁 266
❤ 4
🔁 4
May 31
#ASCO26 LBA4 - Zhiwei - Ivonescimab + chemo vs tislelizumab + chemo 1L sq NSCLC - Ph3 HARMONi-6 [May 31, 2026] Zhiwei et al. https://t.co/oWEeVo2oyq #NCT05840016 #lcsm #ImmunoOnc
👁 201
❤ 1
🔁 0
May 26
$SMMT $AKESF $XBI ASCO
I’m guessing that ivonescimab in HARMONI-6 shows a +4.5 mo differential in OS, with an HR of around 0.72.
> HARMONi-6 PFS showed mPFS 11.14 as compared to 6.90 months, HR 0.60, +4.24 months PFS, with higher ORR and DoR, and powered assuming OS HR https://t.co/YlAk0J4ESZ
👁 199
❤ 0
🔁 0
May 30
💊 3/ HARMONi-6 (Plenary LBA4) — ivonescimab + chemo vs tislelizumab + chemo, 1L squamous NSCLC
Phase 3, n=532 (China).
▶️Prior PFS readout: HR 0.60, +4.2 mo PFS benefit, consistent across PD-L1 strata. ASCO 2026 brings the OS data.
Why it matters: Squamous NSCLC has lagged
👁 179
❤ 0
🔁 0
May 26
Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer? https://t.co/IuGugTWrZz Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally. #Akeso #Ivonescimab #ASCO2026 #HARMONi6 #LungCancer
👁 145
❤ 0
🔁 0
May 26
2. Ivonescimab (HARMONi-6) — OS data vs tislelizumab + chemo in advanced squamous NSCLC. One bispecific hitting PD-1 and VEGF at once.
Buzz Score: 98% (3/9)
#ASCO26 #LungCancer
👁 130
❤ 0
🔁 0
May 27
TRITON — Abs 8515
Treme + Durva + Chemo vs Pembro+Chemo · 1L STK11/KEAP1/KRAS NSCLC (Phase 2b)
▼
Alright. Abstracts are out. This is one of the studies I really wanted to see… and I’m disappointed. TRITON IA (T+D+CT vs P+CT, STK11/KEAP1/KRAS NSQ mNSCLC): only ORR + DoR reported, PFS still blinded. ORR within noise (39% vs 35%) but durability intriguing (100% vs 58% in https://t.co/zo6RDG5BuI
👁 5.6K
❤ 58
🔁 24
May 21
🆙 #ASCO26 #LCSM Rapid Oral
🔥TRITON: Tremelimumab + durvalumab + CT vs pembro + CT in 1L NSQ NSCLC with STK11, KEAP1, and/or KRAS mut
✅ORR 39% vs 34.9%
✅KRAS: ORR 48% vs 33.3%
🎙️ @FSkoulidis
🔢8515
☑️NCT06008093
🔗 https://t.co/XCafTEYOfG
@OncoAlert @Larvol @ASCO @KRASKickers https://t.co/VAoqftcLMu https://t.co/YEPV29QHNM
👁 2.2K
❤ 10
🔁 6
May 24
🆙 #ASCO26 #LCSM Rapid Oral
🔥TRITON: Tremelimumab + durvalumab + CT vs pembro + CT in 1L NSQ NSCLC with STK11, KEAP1, and/or KRAS mut
✅ORR 39% vs 34.9%
✅KRAS: ORR 48% vs 33.3%
🎙️ @FSkoulidis
🔢8515
☑️NCT06008093
🔗 https://t.co/WAybTNZiEx
@OncoAlert @Larvol @ASCO @IASLC https://t.co/ZNJMg7b5ts
👁 2.1K
❤ 9
🔁 8
May 30
Dr. @FSkoulidis presents randomized phase 2b TRITON study at #ASCO26: chemo + durvalumab + tremelimumab vs chemo + pembro in non-squamous NSCLC with STK11, KEAP1, and/or KRAS mutations. RR numerically favors dual checkpoint in the challenging STK11 and KRAS subsets. PFS pending. https://t.co/hqlTk38NlF
👁 1.8K
❤ 18
🔁 10
May 30
🚨 #ASCO26 | TRITON interim analysis
Tremelimumab + durvalumab + chemo vs pembrolizumab + chemo
1L NSQ mNSCLC with STK11/KEAP1/KRAS mutations
#️⃣Abstr 8515
🧬 Phase 2b randomized US study
T+D+CT n=41 vs P+CT n=43
IA focused on ORR, DoR, and safety
🎯 Response:
・cORR 39.0% vs https://t.co/UKHNj3ZQ9u
👁 1.3K
❤ 13
🔁 4
May 30
🫁 #ASCO26 TRITON asks the uncomfortable question in 1L NSCLC:
Can CTLA-4 rescue the “cold” STK11/KEAP1/KRAS-mutant subgroup? 👀
📌 Phase 2b, n=84
📌 1L non-squamous mNSCLC
📌 STK11 and/or KEAP1 and/or KRAS mutated
⚔️ T+D+chemo vs pembro+chemo
📊 Key signal:
✅ ORR: 39.0% vs https://t.co/G32TvUO8mT https://t.co/mEOKGNKgf7
👁 1.2K
❤ 6
🔁 3
May 31
🔁REVIEW #ASCO26 #LCSM Rapid Oral
🔥TRITON: Tremelimumab + durvalumab + CT vs pembro + CT in 1L NSQ NSCLC with STK11, KEAP1, and/or KRAS mut
✅ORR 39 vs 34.9%
✅KRAS: ORR 48 vs 33.3%
🎙️ @FSkoulidis
🔢8515
☑️NCT06008093
🔗 https://t.co/WAybTNZiEx
@OncoAlert @Larvol @ASCO @IASLC https://t.co/pOJvQQqL9J https://t.co/2TleY4zy7x
👁 1.0K
❤ 8
🔁 7
May 31
✅ Some NSCLC subgroups continue to challenge our current immunotherapy strategies more than others.
At #ASCO26, the TRITON study explores whether adding anti-CTLA-4 can improve outcomes in STK11-, KEAP1-, and KRAS-mutated nonsquamous mNSCLC — a population often associated https://t.co/emNFAoyNG9
👁 973
❤ 22
🔁 8
May 27
New data from the phase 2b TRITON study suggest that adding tremelimumab to durvalumab + chemotherapy may improve response outcomes in patients with STK11-, KEAP1-, and/or KRAS-mutated metastatic non-squamous NSCLC.
Presented by Dr. Ferdinandos Skoulidis at #ASCO26, interim https://t.co/4OmmHAfEG8
👁 898
❤ 9
🔁 3
May 30
TRITON IA: in 1L NSQ mNSCLC with STK11/KEAP1/KRAS alterations, Tremelimumab+Durvalumab+CT showed generally numerically higher ORRs vs Pembro+CT.
Eagerly awaiting further data including PFS/OS.
#ASCO26 https://t.co/oi38QjJXnJ
👁 708
❤ 10
🔁 5
May 30
And this is the #LCSM trial I wanted to see the most. TRITON at #ASCO26 (Skoulidis et al, Abstract 8515): chemo + tremelimumab + durvalumab vs chemo + pembrolizumab in 1L STK11/KEAP1/KRAS-mutated nonsquamous NSCLC. The science is right, the execution is honest, and the read is https://t.co/QiumFColA2
👁 592
❤ 16
🔁 6
May 31
6. TRITON: PhII, Durva + Treme + Chemo vs. Chemo + IO in mNSCLC w/ STK11 +/- KEAP1 mutation:
- ORR: 39% vs. 34.9%
- Who should get intensified dual ICI moving forward?
7/7 https://t.co/adUUDPeWz6 https://t.co/T4AwOyYl1O
👁 577
❤ 5
🔁 3
May 30
#ASCO26
#️⃣8515 | TRITON (Ph2b, randomized, US)
✨ Ph2b comparing POSEIDON regimen （treme + durva + chemo) vs pembro + chemo as 1L in non-sq mNSCLC with STK11/KEAP1/KRAS mutations
(n=84, planned interim analysis; primary endpoint PFS)
📊 ORR 39.0% vs 34.9%; median DoR NR vs
👁 484
❤ 2
🔁 0
May 28
ASCO26 in #NSCLC TRITON phase IIb interim analysis suggests adding tremelimumab to durvalumab + chemotherapy may improve outcomes in genomically defined, hard-to-treat advanced nsq-#NSCLC. #ASCO2026
🔹 ORR: 39% vs 35% | Unconfirmed ORR: 49% vs 42% (Treme + Durva + CT vs Pembro https://t.co/lWQhKZYmVY
👁 104
❤ 1
🔁 0
May 30
LORIN — Abs 8002
Neoadjuvant Lorlatinib · Stage III ALK-fusion NSCLC (Phase 2)
▼
Pleasant Surprise from #ASCO26 Abstract 8002 (LORIN): neoadjuvant lorlatinib in stage III ALK+ NSCLC hits a pCR of 46.9% and MPR of 81.3% — pathologic responses we rarely see with neoadjuvant TKIs. 75% of initially unresectable pts converted to surgery. Targeted neoadj earning https://t.co/sO30ZxYAZ7
👁 12.8K
❤ 64
🔁 25
May 21
🆙 #ASCO26 #LCSM Oral
🔥LORIN: Neoadj Lorlatinib in Stage III ALK+ NSCLC
✅ORR 83.7%, pCR 46.9%, MPR 81.3%
✅75% unresectable → conversion surgery
✅1y EFS 97.1%
🎙️Dr. Chao Zhang
🔢8002
☑️NCT05740943
🔗 https://t.co/2OWLWDewMH
@OncoAlert @Larvol @ASCO @ALKPositiveinc https://t.co/3EXHCB4IFx https://t.co/4s53cT4Ch5
👁 2.9K
❤ 21
🔁 10
May 23
📝 #ASCO26
Abstr 8002 | LORIN
The prospective phase 2 study evaluating neoadjuvant lorlatinib for stage III ALK+ NSCLC.
All patients had stage III disease, yet the results were striking:
✅ pCR: 47%
✅ MPR: 81.3%
pCR nearly 50% in stage III… seriously? 🤯
🤔 What makes ALK
👁 1.4K
❤ 9
🔁 0
May 22
LUNBOTINIB — Abs 8505
Brain-penetrant RET inhibitor · Pretreated RET+ NSCLC (ORR 87%)
▼
And, as we are talking RET, The new kid on the block: LUNBOTINIB.
We have the trial open @SylvesterCancer in Miami.
Impressive #ASCO26 data (Abstract 8505): lunbotinib, a next-gen brain-penetrant RET inhibitor, posts ORR 87% in PRE-TREATED RET+ NSCLC (mPFS 27.5 mo) & 81% https://t.co/QVyKwgC5ao
👁 5.9K
❤ 40
🔁 17
May 22
🆙 #ASCO26 #LCSM Oral
🔥Lunbotinib: Phase 2 in RET Fusion+ NSCLC
✅Pre-tx: ORR 87.1%, mPFS 27.5m
✅TKI-naïve: ORR 81.3%, mPFS NR
✅IC-ORR 82.6%/75.0% (pre-tx/naïve)
🎙️Dr. Qing Zhou
🔢8505
☑️NCT05265091
🔗 https://t.co/M79VnLrtJb
@OncoAlert @Larvol @ASCO @RetRenegades https://t.co/nsgwccJUji https://t.co/PWLWfzaGp8
👁 2.9K
❤ 19
🔁 10
May 22
🆙 #ASCO26 #LCSM Oral
🔥Lunbotinib: Phase 2 in RET Fusion+ NSCLC
✅Pre-tx: ORR 87.1%, mPFS 27.5m
✅TKI-naïve: ORR 81.3%, mPFS NR
✅IC-ORR 82.6%/75.0% (pre-tx/naïve)
🎙️Dr. Qing Zhou
🔢8505
☑️NCT05265091
🔗 https://t.co/KxqMd9Eli4
@OncoAlert @Larvol @ASCO @IASLC @RetRenegades https://t.co/Vj5s3KNs9s
👁 2.4K
❤ 10
🔁 9
May 29
🔁REVIEW #ASCO26 #LCSM Oral
🔥Lunbotinib: Phase 2 in RET Fusion+ NSCLC
✅Pre-tx: ORR 87.1%, mPFS 27.5m
✅TKI-naïve: ORR 81.3%, mPFS NR
✅IC-ORR 82.6%/75.0% (pre-tx/naïve)
🎙️Dr. Qing Zhou
🔗 https://t.co/KxqMd9Eli4
@OncoAlert @Larvol @ASCO @IASLC @RetRenegades https://t.co/o0qdb9MorP https://t.co/TEZDz47Xom
👁 1.3K
❤ 11
🔁 4
May 30
🇨🇳The registrational study of lunbotinib fumarate (A400/EP0031)—Kelun‑Biotech’s next‑gen selective RET inhibitor—was selected for an oral presentation in the Lung Cancer – Metastatic NSCLC session of #ASCO2026.
Key data from the pivotal Phase 2 study:
- Pre‑treated NSCLC:
👁 646
❤ 1
🔁 0
May 25
Dr. Qing Zhou updates phase II study of lunbotinib (EP0031): next-gen RET inhibitor in NSCLC at #ASCO26. As first-line, RR 87%, PFS NR. With prior therapy, RR 81%, PFS 27.5m. Intracranial RR 18%. 81% ctDNA clearance. TRAEs led to d/c in only 1.2%. Most common AEs: LFTs, anemia. https://t.co/3xX0dKtwPV
👁 540
❤ 15
🔁 6
May 29
ASCO 2026 | Abstract 8505
Lunbotinib showed strong activity in RET fusion-positive NSCLC, with ORR >80% in both previously treated and treatment-naïve patients, alongside robust intracranial responses. Early ctDNA clearance was associated with markedly longer PFS.
#ASCO26 https://t.co/10MMsF5tDL
👁 514
❤ 7
🔁 4
May 30
#ASCO26
#️⃣8505 | Lunbotinib / A400/EP0031 (Pivotal Ph2, China)
✨ Ph2 of lunbotinib (90 mg QD), a next-gen brain-penetrant selective RET inhibitor in advanced RET fusion+ NSCLC.
👥Two cohorts: pre-treated (n=71, post platinum + IO) and TKI-naïve (n=92); primary endpoint ORR by
👁 113
❤ 0
🔁 0
May 28
DeLLphi-304 — Abs 8006
Tarlatamab vs Chemo · Intracranial efficacy · 2L SCLC (Amgen)
▼
🧵🧠 A BiTE that crosses the blood-brain barrier? Tarlatamab just showed intracranial responses in SCLC brain mets — one of the hardest-to-treat populations in oncology!!! @ASCO26: DeLLphi-304: Intracranial efficacy, Presented by @g_mountzios
#SCLC @SclcSMASHERS https://t.co/VFcax1LKbS
👁 4.6K
❤ 73
🔁 26
May 21
With #ASCO26 just around the corner, it is my great pleasure to present in the oral abstract session, alongside prominent colleagues and chairs, the intracranial efficacy data of #tarlatamab from #DeLLphi-304 trial, the first data on CNS efficacy of a T-cell engager in #SCLC. https://t.co/tBoQcy4JaT
👁 2.9K
❤ 30
🔁 10
May 18
Great to see prospective intracranial activity with tarlatamab in SCLC brain mets. I’ve been using it in selected patients with asymptomatic CNS disease and, at times, deferring upfront radiation. Encouraging to finally see supporting data from DeLLphi-304. #SCLC #ASCO26 https://t.co/V3015i24k6
👁 1.8K
❤ 6
🔁 5
May 22
🆙 #ASCO26 #LCSM Oral
🔥DeLLphi-304: Tarlatamab vs CT in 2L SCLC with BM
✅CNS PFS 6.5 vs 4.2mo (HR 0.40)
✅CNS CR 15% vs 5%; CNS shrinkage ≥30%: 56% vs 38%
✅mOS in BM pts: 13.9 vs 6.8mo
🎙️ @g_mountzios
🔢8006
☑️NCT05740566
🔗 https://t.co/8iTfUt34sd
@OncoAlert @Larvol @ASCO https://t.co/XKHMTOP3wN https://t.co/Mgw3Fl7DKx
👁 1.2K
❤ 9
🔁 4
May 23
🆙 #ASCO26 #LCSM Oral Abstract Session
🔥DeLLphi-304: Intracranial Efficacy of Tarlatamab vs Chemotherapy as 2L Treatment for SCLC
🎙️ @g_mountzios
🔢8006
☑️NCT05740566
🔗 https://t.co/8iTfUt2wCF
@OncoAlert @Larvol @ASCO https://t.co/8SvE3wkT71 https://t.co/LGlDkEhy4w
👁 850
❤ 4
🔁 1
Apr 27
#ASCO26
#️⃣8006 | DeLLphi-304 (Ph3, post hoc intracranial analysis)
🧠 Post hoc CNS analysis of the Ph3 trial of tarlatamab vs chemo as 2L for SCLC, in pts with baseline BM (n=197, mRANO-BM)
📉 CNS PFS 6.5 vs 4.2 mo (HR 0.40)
🎯 CNS CR 15% vs 5%; ≥30% CNS shrinkage 56% vs
👁 760
❤ 3
🔁 0
May 28
⭐️ABSTRACT 8006: Intracranial efficacy of tarlatamab (post-hoc DeLLphi 304 analysis)
How well does tarlatamab hit brain metastases? This post-hoc analysis raises some intriguing findings.
1⃣Key findings in pts with baseline BM:
- CNS PFS: 6.5 vs 4.2 mo (HR 0.40)
- CNS CR: 15% vs
👁 535
❤ 6
🔁 3
May 26
ALKOVE-1 — Abs 8503
Neladalkib · Advanced ALK+ NSCLC
▼
🆙 #ASCO26 #LCSM Oral
🔥ALKOVE-1: Neladalkib in ALK+ NSCLC
✅preTKI (91% prior lorlatinib): ORR 31%
✅TKI-naïve: ORR 86%, 12mo DOR rate 91%
✅IC-ORR 78%, no CNS progression
🎙️ @JessicaJLinMD
🔢8503
☑️NCT05384626
🔗 https://t.co/mEe8ZerwcU
@OncoAlert @Larvol @ASCO @ALKPositiveinc https://t.co/PguNa1x9gt https://t.co/lyjIlbGv99
👁 2.1K
❤ 21
🔁 10
May 22
🆙 #ASCO26 #LCSM Oral
🔥ALKOVE-1: Neladalkib in ALK+ NSCLC
✅preTKI (91% prior lorlatinib): ORR 31%
✅TKI-naïve: ORR 86%, 12mo DOR rate 91%
✅IC-ORR 78%, no CNS progression
🎙️ @JessicaJLinMD
🔢8503
☑️NCT05384626
🔗 https://t.co/57bBeYqVsv
@OncoAlert @Larvol @ASCO @IASLC https://t.co/AJaOkP9GmX
👁 1.7K
❤ 8
🔁 10
May 29
🔁REVIEW #ASCO26 #LCSM Oral
🔥ALKOVE-1: Neladalkib in ALK+ NSCLC
✅preTKI (91% prior lorlatinib): ORR 31%
✅TKI-naïve: ORR 86%, 12mo DOR rate 91%
✅IC-ORR 78%, no CNS progression
🎙️ @JessicaJLinMD
🔗 https://t.co/57bBeYqVsv
@OncoAlert @Larvol @ASCO @IASLC @ALKPositiveinc https://t.co/L51F2fHssn https://t.co/2YWhUJjNQi
👁 1.1K
❤ 9
🔁 6
May 30
ALKOVE-1: 🫁 #ASCO26
Neladalkib shows high activity in ALK+ NSCLC, including post-lorlatinib resistance and CNS disease, with deep frontline responses (ORR 86%) and durable disease control supporting phase 3 advancement in precision ALK inhibition.
@ASCO @OncoAlert #Lcsm https://t.co/ZptQZHAB6h
👁 913
❤ 23
🔁 10
May 29
Notable #ASCO26 data (Abstract 8503, ALKOVE-1): neladalkib, a next-gen ALK TKI built to beat resistance, shows real activity AFTER lorlatinib — ORR 26% post-lorla, 48% after a single 2nd-gen TKI, with CNS responses & activity vs G1202R. TKI-naïve ORR 86%. A genuine https://t.co/tR5pWAY0zE
👁 789
❤ 14
🔁 10
May 22
🔥🚨 @OncoAlert Hot off the press.
Just presented @ASCO #ASCO26 by @JessicaJLinMD
⭐️ Results of #ALKOVE1 phase 1/2 trial of:
❇️ #Neladalkib in #ALK+ #NSCLC
✅ Excellent efficacy in pre-treated patients (75% received prior #Lorlatinib) & treatment-naive.
🎯Drug was just https://t.co/wNJjZIP5V0
👁 742
❤ 19
🔁 12
May 29
ALKOVE1 - promising early phase
ALKAZAR is recruiting
#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq https://t.co/DPMBZdDBkt
👁 580
❤ 3
🔁 4
May 29
ASCO 2026 | Abstract 8503
Neladalkib demonstrated meaningful activity in heavily pretreated ALK-positive NSCLC, including post-lorlatinib patients and those with brain metastases. Both systemic and intracranial responses were observed, with signals in G1202R mutations.
These https://t.co/8mvxjaBecr
👁 366
❤ 6
🔁 3
May 30
ALKOVE-1 #ASCO26 update: next-gen ALK inhibitor neladalkib in pretreated ALK+ NSCLC
▫️CNS activity post-lorlatinib
▫️ORR 46% in lorlatinib-naive pts; 26% post-lorlatinib
▫️Activity in ALKG1202R resistance mutations
▫️Tx discontinuation 5%
Phase 3 ALKAZAR 1L neladalkib ongoing. https://t.co/elEOjcz4qX
👁 324
❤ 8
🔁 6
May 29
ALKOVE-1 suggests the ALK story may not end after lorlatinib.
• G1202R ORR: 68%
• CNS activity preserved
• Post-lorlatinib ORR: 26%
Resistance biology may still be targetable.
#ASCO2026 #ALK #NSCLC #ThoracicOncology #MVOnco https://t.co/cUC3oVqCGF
👁 295
❤ 2
🔁 2
May 28
ALKOVE-1 #ASCO2026
Post-lorlatinib ALK inhibition may still be biologically actionable.
Neladalkib demonstrated meaningful activity in heavily pretreated ALK+ NSCLC — with particularly striking signals in:
• G1202R resistance mutations
• CNS disease
• post-lorlatinib https://t.co/NQsQENrjgA
👁 259
❤ 2
🔁 0
May 28
🚨 #ASCO26 | ALKOVE-1
Neladalkib in advanced ALK+ NSCLC
Abstr 8503
🧬 ALK TKI-pretreated pts (N=253):
ORR 31%, mPFS 5.7 mo
✨ Lorlatinib-naïve pts (N=63):
・ORR 46%, mPFS 14.5 mo
・DOR ≥12 mo: 80%
🧠 CNS activity:
・IC-ORR 32% overall
・63% in lorlatinib-naïve pts
🧬 https://t.co/vOTXygabTg
👁 254
❤ 2
🔁 2
May 29
ALKOVE-1 (Neladalkib in mALK+ #NSCLC) presented by @JessicaJLinMD -study showed ORR=46%; mDOR NR, DOR ≥12m for 80% (lorlatinib-naive) and ORR = 20%; median DOR of 17.6m (prior lorlatinib) Efficacy seen in 🧠 regardless of prior TKI tx.
#ASCO26 @ASCO #lcsm @ALKPositiveinc https://t.co/WIdRqjcvn6
👁 182
❤ 2
🔁 1
May 29
One of the key challenges in ALK-positive NSCLC remains treatment after progression on sequential ALK inhibitors.
At #ASCO26, the phase 1/2 ALKOVE-1 study reported encouraging activity with neladalkib:
🔹 ORR 31% in heavily pretreated ALK+ NSCLC
🔹 ORR 46% in lorlatinib-naïve https://t.co/QMWcGJrN5O
👁 178
❤ 1
🔁 0
May 30
As impressive as lorlatinib is in the treatment of ALK+ NSCLC, there’s still room for improvement. Neladalkib can still produce a fair number of responses, including in the brain, post-lorlatinib. Attention patients, this drug can be accessed via an EAP! @ALKPositiveinc #ASCO2026 https://t.co/MVA5f5VUb1
👁 165
❤ 2
🔁 2
May 29
#ASCO26
#️⃣8503 | ALKOVE-1 (Ph1/2, global, single-arm)
✨ Global Ph1/2 of neladalkib, a next-gen ALK TKI designed for compound resistance mutations, brain penetrance, and TRK-sparing.
👥Includes both heavily TKI pre-treated (91% post-lorlatinib) and TKI-naïve pts (n=656)
📊
👁 119
❤ 0
🔁 0
May 28
A question regarding ALKOVE-1. Neladalkib can only be interesting in 1L, since compound mutations are not common mechanisms of resistance after Lorlatinib? Are we going to wait for how long until practice changes? ALK+ NSCLC just became early-stage luminal breast cancer? #ASCO26
👁 91
❤ 0
🔁 1
May 29
#ASCO26
🫁 Lung Cancer Oral Track 💥
👑 ALVOKE-1: phase I/II Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC.
🗣️ Dr. Jessica J Lin
📌 Total of 781pts, efficacy from 253pts
📌 100% had received 2G ALKi
✅ ORR 31%; 46% Lorlatinib naive and 26% in prior https://t.co/tXzCuBEyCn
👁 41
❤ 2
🔁 2
May 29
ALKOVE-1: Safety and activity of neladalkib, a 4th generation, CNS-penetrant, TRK-sparing, ALK inhibitor.
#ASCO26 #LCSM @alk_fusion https://t.co/ifJkVGYzWf
👁 34
❤ 0
🔁 0
May 29
#ASCO26 First-line neladalkib RR 86%, 91% DOR ≥ 12m, intracranial RR 78%. And safety profile very reassuring: dose reduction 17%, discontinuation 5%, most common TEAEs were asymptomatic LFT elevations and profile showing avoidance of TRK related toxicities. Fantastic data. https://t.co/8NL9rBoUo9
👁 34
❤ 1
🔁 0
May 29
Dr. @JessicaJLinMD at #ASCO26 with an important update from ALKOVE-1: phase 1/2 study of neladalkib (NVL-655) in ALK+ NSCLC. Included 253 patients previously treated - median 3 prior lines, 95% had prior 2G TKI, 75% with prior lorlatinib. https://t.co/tD3EYRtJbY
👁 19
❤ 1
🔁 0
May 29
ALKOVE-1: phase 1/2; Neladalkib in ALK NSCKC; n781; good activity in treatment naïve; #ASCO26 https://t.co/fFZPPx69bb
👁 15
❤ 2
🔁 0
May 29
AcceleRET-Lung — Abs 8504
Pralsetinib · 1L RET-fusion+ NSCLC (Phase 3)
▼
🆙 #ASCO26 #LCSM Oral
🔥AcceleRET-Lung: 1L Pralsetinib vs SOC in RET Fusion+ NSCLC
✅mPFS 18.7 vs 9.0m
✅ORR 65.5% vs 41.6%
✅mDOR 20.6 vs 9.7m
🎙️ @DrSanjayPopat
🔢8504
☑️NCT04222972
🔗 https://t.co/gTg2nPXgqk
@OncoAlert @Larvol @ASCO @RetRenegades https://t.co/jPgAz8M0qr https://t.co/jpgd7fBJWR
👁 2.1K
❤ 14
🔁 2
May 22
This is one is personal as I presented the five-year follow-up of ARROS last year: Phase 3 confirmation at #ASCO26 (Abstract 8504, AcceleRET-Lung): 1L pralsetinib doubles PFS vs chemo in RET+ NSCLC (18.7 vs 9.0 mo, p=0.003), ORR 66% vs 42%, DOR 20.6 vs 9.7 mo. RET-directed 1L https://t.co/B3nYlKSYte
👁 1.3K
❤ 21
🔁 9
May 22
🆙 #ASCO26 #LCSM Oral
🔥AcceleRET-Lung: 1L Pralsetinib vs SOC in RET Fusion+ NSCLC
✅mPFS 18.7 vs 9.0m
✅ORR 65.5% vs 41.6%
✅mDOR 20.6 vs 9.7m
🎙️ @DrSanjayPopat
🔢8504
☑️NCT04222972
🔗 https://t.co/JG9GrBMl8y
@OncoAlert @Larvol @ASCO @RetRenegades https://t.co/eujh51qpcM
👁 1.2K
❤ 11
🔁 8
May 29
AcceleRET-Lung (Phase III):🫁
Pralsetinib in 1L RET+ mNSCLC delivers superior PFS vs SOC (18.7 vs 9.0 mo; HR 0.59), but with a clinically significant signal of severe and fatal infections,
⬇️⬇️
@ASCO @OncoAlert #LCSM #ASCO26 https://t.co/WIyXkBafwr
👁 665
❤ 17
🔁 6
May 29
Phase III #AcceleRETLung presented at #ASCO26 by @DrSanjayPopat. Upfront pralsetinib in RET+ adds further evidence supporting precision therapy upfront in lung cancer (mPFS 18.7 vs 9.0 months; HR 0.59). Infection-related AEs deserve careful attention. #NSCLC #RETfusion https://t.co/2mMkJpysZU
👁 651
❤ 9
🔁 8
May 29
#ASCO26 @DrSanjayPopat presents AcceleRET-Lung: first line pralsetinib vs chemo +/- IO in RET+ NSCLC with optional crossover. Study terminated by sponsor at 90% accrual. PFS favors pralsetinib 18.7m vs 9m (HR 0.59) with RR 66% vs 42%, DOR 20.6m vs 9.7m https://t.co/W73zzzT0wk
👁 404
❤ 7
🔁 4
May 29
#ASCO26
Abstract #8504
AcceleRET-Lung: Pralsetinib vs SOC in 1L RET+ NSCLC 🫁🎯 https://t.co/SItL8hAskH
👁 338
❤ 3
🔁 1
May 29
#ASCO26
🫁 Lung Cancer Oral Track 💥
🎯 Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
🗣️ @DrSanjayPopat
📌 Total of 223pts
🔀 Crossover 38pts
✅ https://t.co/7UKJigwLrM
👁 172
❤ 2
🔁 3
May 29
#ASCO26
RET fusion-positive NSCLC finally gets phase 3 confirmation for a selective RET inhibitor. 🎯
In AcceleRET-Lung, first-line pralsetinib significantly improved PFS, ORR, and DOR vs platinum-based SOC in advanced/metastatic RET+ NSCLC.
🧪 AcceleRET-Lung | Phase 3
👥 https://t.co/qh0LgwZPk2 https://t.co/mEOKGNKgf7
👁 140
❤ 1
🔁 0
May 29
CheckMate 77T
Nivolumab · periop NSCLC
▼
ALCHEMIST / EA5142 — Abs 8000
Adjuvant Nivolumab post-surgery + chemo · NSCLC (Phase 3)
▼
🆙 #ASCO26 #LCSM Oral
🔥ALCHEMIST (A081105): Adj Erlotinib vs Obs in Resected EGFRm NSCLC
✅OS HR 0.89 (95%CI 0.59-1.34)
✅DFS HR 0.74 (95%CI 0.55-1.01)
🎙️Dr. Ramaswamy Govindan
🔢8001
☑️NCT02193282
🔗 https://t.co/4KZutaZBj0
@OncoAlert @Larvol @ASCO @EGFRResisters https://t.co/zmfSqsusgx https://t.co/2Ztp4pPqSu
👁 1.7K
❤ 13
🔁 7
May 23
🆙 #ASCO26 #LCSM Oral
🔥ALCHEMIST (EA5142): Adj Nivo after Surgery + Chemo in Resected NSCLC
✅DFS HR 0.97 (95%CI 0.81-1.17)
✅PD-L1 ≥50%: DFS HR 0.86 (95%CI 0.59-1.25)
🎙️ @ChaftJamie
🔢8000
☑️NCT02595944
🔗 https://t.co/0YSU8XAmyJ
@OncoAlert @Larvol @ASCO https://t.co/j0uGrieGSw https://t.co/JYqBoUQEGS
👁 1.5K
❤ 11
🔁 3
May 23
EA5142/ALCHEMIST may end up being one of the most important “negative” thoracic oncology studies at #ASCO26.
In resected EGFR/ALK-negative NSCLC, 1 year of adjuvant nivolumab after surgery +/- chemotherapy did not improve DFS:
• median DFS: 71.3 vs 68.8 months; HR 0.97
• No https://t.co/arH2tMGFQN
👁 318
❤ 3
🔁 1
May 29
Our research at #ASCO26:
-Late-breaking update in Merkel cell carcinoma (STAMP/EA6174)
-Trial results in glioblastoma (EAF151) & lung cancer (EA5142 ALCHEMIST)
-Emerging approaches in precision oncology
- AI-driven insights (TAILORx)
-ctDNA (NCI-MATCH)
https://t.co/EnOS90XlMQ
👁 164
❤ 0
🔁 0
May 21
ECOG-ACRIN at #ASCO26:
- Late-breaking Merkel cell data | STAMP/EA6174
- Glioblastoma trial results | EAF151
- Lung cancer trial results | ALCHEMIST/EA5142
- AI for breast cancer recurrence risk assessment | TAILORx
- ctDNA profiling | NCI-MATCH
- More...
https://t.co/8EHtdAZjYu https://t.co/eHvQH5IBnN
👁 103
❤ 0
🔁 0
May 26
My #ASCO26 #NSCLC guide 🫁 - personal view:
5 abstracts, the prodigal son, and several unresolved questions.
The most underrated for me: EA5142 (ALCHEMIST-ANVIL). It has direct impact on how we should read adjuvant IO.
Full take 👇
👁 30
❤ 1
🔁 0
May 27
IMforte — Abs 8014
Lurbinectedin + Atezolizumab maintenance · ES-SCLC (Phase 3)
▼
Dr. Andrea Ardizzoni discusses maintenance therapy for SCLC at #RomeLung26. Very logical approach but many historic failures for continuous and switch maintenance. Phase III IMforte with maintenance lurbinectedin was the first to improve PFS and OS and a new standard. https://t.co/FMAEPnG4Xf
👁 2.3K
❤ 33
🔁 10
May 9
🆙 #ASCO26 #LCSM Rapid Oral
🔥IMforte: Transcriptomic Analysis of SCLC Subtypes with Lurbi + Atezo
✅Benefit in all 4 sub
✅High TAM sub: lurbi better (OS HR 0.56)
✅SLFN11: not predictive
🎙️ @LuisPaz_Ares
🔢8014
☑️NCT05091567
🔗 https://t.co/xajDS726Vc
@OncoAlert @Larvol @ASCO https://t.co/J9kMmRV7cS
👁 850
❤ 10
🔁 3
May 25
#ASCO26
#️⃣8014 | IMforte translational analysis (Ph3, exploratory biomarker)
✨ Exploratory transcriptomic analysis from the Ph3 IMforte trial.
🔬RNA-seq on 303/483 pre-induction tumor samples to classify SCLC subtypes (SCLC-A/N/I-NE/I-non-NE) and TAM/T-eff signatures
📊
👁 379
❤ 1
🔁 0
May 28
@OncUpdates @sands_jacob @OncBrothers SCLC treatment has quietly had more movement in the last 2 years than in the prior two decades. The ADRIATIC consolidation data was practice changing and now with tarlatamab in 2L+ we finally have something beyond topotecan. Would be great to see how lurbinectedin maintenance
👁 60
❤ 1
🔁 0
May 7
SUNRAY-01
Olomorasib + Pembro ± Chemo · 1L KRAS G12C NSCLC
▼
NOW ENROLLING👉 SUNRAY-01, a Ph3 trial investigating a dual approach to treat advanced, high (≥50%) PD-L1 #KRAS G12C-mutant NSCLC.
Find patient requirements & detailed trial info here: https://t.co/wWLj8Tv2FL
#LCSM #NSCLC #ClinicalTrials https://t.co/BqfTUO1N4c
👁 940
❤ 4
🔁 0
May 15
🆙 #ASCO26 #LCSM Poster Session
🔥SUNRAY-01/LOXO-RAS-20001: 1L Olomorasib + Pembrolizumab in KRAS G12C–Mutant Advanced NSCLC with PD-L1 0-49%
🎙️Dr. Bryan Chan
🔢8628
☑️NCT04956640, NCT06119581
🔗 https://t.co/Gl53r04g8d
@OncoAlert @Larvol @ASCO @KRASKickers https://t.co/LYzDqT0YED
👁 727
❤ 7
🔁 3
May 9
🆙 #ASCO26 #LCSM Poster Session
🔥SUNRAY-01/LOXO-RAS-20001: 1L Olomorasib + Pembrolizumab +/- Chemotherapy in KRAS G12C–Mutant NSCLC
🎙️Dr. Timothy F. Burns
🔢8570
☑️NCT04956640
🔗 https://t.co/UdmQfHlJCv
@OncoAlert @Larvol @ASCO @KRASKickers https://t.co/BlpTbL6xNI
👁 534
❤ 5
🔁 0
May 10
🩺SUNRAY 01 Part A | KRAS NSCLC Phase 3 Trial | Now Enrolling
A phase 3 trial evaluating a targeted, PD 1 inhibitor–based approach in treatment naïve KRAS G12C mutant NSCLC.
🔗 Trial details & enrollment info: https://t.co/DzfMCLDaa2
#NSCLC #ClinicalTrials #LCSM #KRASG12C https://t.co/We5WCsOkdB
👁 460
❤ 4
🔁 0
Apr 28
#ASCO26 attendees, stop by our poster on first-line KRAS G12C inhibitor plus pembrolizumab ± chemotherapy in KRAS G12C-mutant NSCLC from LOXO-RAS 20001 and SUNRAY-01.
May 31, 9:00–12:00 PM CDT, Hall A, Board 360.
Program details here: https://t.co/2qdCGMYpfZ
#NSCLC #LCSM https://t.co/Qe7anpKsE3
👁 119
❤ 1
🔁 0
May 29
Durvalumab + cTRT — LBA8005
Concurrent TRT + Platinum/Etoposide + Durvalumab · ES-SCLC (Phase 3)
▼
Perioperative Toripalimab — Abs 8010
Perioperative Toripalimab · NSCLC (real-world study)
▼
ADAURA
Osimertinib · Adjuvant NSCLC
▼
GU Cancers316 tweets captured
Perioperative durvalumab (12 months) with neoadjuvant EV (3 cycles) shows ‘statistically significant and clinically meaningful’ improved EFS and OS vs cystectomy alone in MIBC (like KN905 (EVP cs cystectomy)). The shorter period of EV is the major difference in trial designs. https://t.co/bwODnn9JDK
👁 80.1K
❤ 168
🔁 75
May 14
Finalizing my PROTEUS Discussant talk for #ASCO26 Plenary. Biggest trial of surgery for prostate cancer, so much data, so many fascinating angles to consider. Will be big moment for Rx of high-risk prostate cancer. Look forward to Dr Taplin reading it out @DanaFarber_GU @gu_onc https://t.co/CM7wZGTeVD
👁 20.8K
❤ 115
🔁 8
May 21
A really thought-provoking study at #ASCO26 (Abstr 4512, Clinical Science Symposium): decision regret after adjuvant pembrolizumab in RCC.
🔹 The question
Do patients regret receiving adjuvant pembro — and if so, is it driven by long-term toxicity that CTCAE grading doesn't https://t.co/Ldr6cXVO5W
👁 14.2K
❤ 72
🔁 21
May 28
As #ASCO26 is approaching, here are my top 10 GU abstracts to be presented (based on the titles).
1-Abstract LBA1: PROTEUS
In high-risk localized prostate cancer, intensifying perioperative therapy may improve long-term outcomes, #DrMaryEllenTaplin from @DanaFarber_GU will https://t.co/5NjVPXJ50L
👁 12.6K
❤ 127
🔁 45
Apr 27
VOLGA Phase III results dropped today. 🔵
Perioperative durvalumab + neoadjuvant EV improved both EFS and OS vs the control arm in cisplatin-ineligible MIBC. The triplet (durvalumab + tremelimumab + EV) also met EFS with a favorable OS trend, though OS did not reach statistical https://t.co/yNQtboyxqg https://t.co/KP6Quti7b0
👁 5.5K
❤ 37
🔁 11
May 14
Important considerations for Proteus as #ASCO26 approaches 👇🏼
MFS is a challenging endpoint when we have PSMA PET available (whether it counts as an event or not) https://t.co/kFJm3Zlw5R
👁 5.1K
❤ 10
🔁 4
May 2
Clinical Trials21 trials with discussion
TALAPRO-3
Talazoparib + Enza · 1L mCRPC HRR+
▼
Day 2 #ASCO26 highlights:
Breast Cancer:
1. #KN522 (update): IO + Chemo TNBC
2. #OPTIMA: Adj Chemo HR+
3. #lidERA: Adj SERD HR+
4. #SENOMAC: ALND omission
Prostate Ca
5. #TALAPRO3: PARPi
NSCLC:
6. #TRITON: Dual ICI mNSCLC
#OncTwitter @ASCO @OncoAlert
1/7 https://t.co/Vl5adT0dNm
──
1. KEYNOTE-522 (final OS Update): current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk early TNBC.
- 7yr EFS: 78.3% vs. 69.8%
- 7yr OS: 85.1% vs. 77.2%
- OS benefit seen regardless of pCR status
- Reaffirms our current SoC
2/7 https://t.co/i0JKHADsTf https://t.co/lMgceXaDf7
──
2. OPTIMA: PhIII, use of PAM50 score to dictate benefit of adj chemo in early HR+ breast cancer
- In low score, chemo omission was NON-INFERIOR even in N+ premenopausal woman (≥ 40yrs)
- Can we extrapolate this to OnctypeDx score? Or should PAM50 be used moving forward?
3/7 https://t.co/nSM8LM7Dim https://t.co/D3lsDzeWKm
──
3. lidERA: PhIII, Adj giredestrant (SERD) vs. AI/Tamox in ER+, HER2– early breast cancer:
- 3yr IDFS (premenopausal): 94% vs. 91.5% (0.65)
- 3yr IDFS (postmenopausal): 91.3% vs. 88.3% (HR: 0.74)
- Less discontinuation rate with Girdestrant
- Awaiting approval
4/7 https://t.co/UsihAVIgiJ https://t.co/pibTsN6cti
──
4. SENOMAC: Omission of ALND, non inferiority trial (Majority HR+, Gr1/2 disease)
- Survival after omission of ALND was NON-INFERIOR
- Improved QoL and physical function with omission
- Omission should be SoC for 1-2LN spread.
5/7 https://t.co/sqknfjWjDz https://t.co/eXJORfTdPk
──
5. TALAPRO-3: PhIII, Enzalutamide + Talazoparib vs. Enza alone in HRR mutated mCSPC:
- At 3yrs, rPFS: 76.6% vs. 56.2% (HR: 0.48)
- rPFS in BRCAm: 77.2% vs. 48.8% (HR: 0.37)
- rPFS in non-BRCA: 76.2% vs. 60.2% (HR: 0.57)
- Germline and somatic testing is critical upfront!
6/7 https://t.co/pbFjPfK0nd https://t.co/QGKdmzJxNy
──
6. TRITON: PhII, Durva + Treme + Chemo vs. Chemo + IO in mNSCLC w/ STK11 +/- KEAP1 mutation:
- ORR: 39% vs. 34.9%
- Who should get intensified dual ICI moving forward?
7/7 https://t.co/adUUDPeWz6 https://t.co/T4AwOyYl1O
👁 13.8K
❤ 71
🔁 32
May 30
JUST In: TALAPRO-3 published in @NEJM
Adding #talazoparib to enzalutamide/ADT
=>3-year rPFS: 77% vs 56% in HRR-deficient metastatic prostate cancer !
Looking forward to full presentation by @neerajaiims who keeps changing SOC, one trial at a time.
@ASCO #ASCO26 @OncoAlert https://t.co/nXiPk4DIXg
👁 11.9K
❤ 137
🔁 63
May 30
Presented at #ASCO26:
In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. Full phase 3 TALAPRO-3 trial results: https://t.co/ma9kEQ8JSV
👁 6.2K
❤ 36
🔁 18
May 30
Trials in #ProstateCancer and #KidneyCancer featured at #ASCO26. @DrRanaMcKay @UCSanDiego joins @zklaassen_md @GACancerCenter previewing 5 #ASCO2026 #GUOncology trials, including PROTEUS, TALAPRO-3, and RaqdiCaL. From perioperative apalutamide in high-risk prostate cancer to PARP https://t.co/GfzvOnpCJK
👁 4.9K
❤ 18
🔁 5
May 26
#ASCO26 GU Oncology Spotlight 🚨
🔬 LBA5007 | TALAPRO-3
Talazoparib + enzalutamide vs placebo + enzalutamide in HRR-altered mCSPC
Presented by Neeraj Agarwal, MD, FASCO
@neerajaiims
@OncoAlert
@ASCO
TALAPRO-3 addresses a key question in metastatic castration-sensitive prostate https://t.co/cBzrq0crmm
👁 4.7K
❤ 22
🔁 13
May 30
GU schedule by day 📆 for #ASCO26 & (among others) looking forward to 💫
1) Bladder CA:
-Data on novel nectin-4 ADCs: #NEXUS01, #EXCEED + #DURAVELO2, Bulumtatug, SHR-A2102
-Updates for: #EV302, #KN905 QoL
-RAD-IO TMT w/ durva
-GemFLP in bladder adenoCA https://t.co/Y199O2urSC
──
2) Kidney CA:
-NonCC-RCC: cadonilimab (PD1/CTLA4 bispecific),final ph2 cabo/nivo
-Updates: #KN564 ctDNA
-Panitumumab-based EGFR block in SAMRCB1-deficient RMC
──
3) Prostate CA:
-#PROTEUS: perioperative apalutamide (plenary!)
-mCSPC: identifying docetaxel benefit analyses from CHAARTED + ENZAMET, & ADT interruption #ADREAM, PARPi #TALAPRO3, #PSMAddition, ZZ-First
-mCRPC: ADC to PSMA/STEAP1, #PLUDO doce vs Lu-617, AVPC chemo-IO
──
4) Testicular CA:
-SWOG S1823 microRNA in predicting active GCT
-Expert session on Optimizing Tx for Pts with Poor-Risk Testicular Cancer
👁 3.9K
❤ 49
🔁 20
May 1
📢Great achievement today for mCRPC patients. Talazoparib plus enzalutamide ⬆️ OS as well as other well known endpoints rPFS and ORR in all comes and HRR. The focus is now for TALAPRO3 in mCSPC. @neerajaiims @urotoday @OncoAlert @GUOncologyNow @Uromigos https://t.co/AVATd2rNeb
👁 3.7K
❤ 36
🔁 10
Oct 10
Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper https://t.co/HmXyNvbExi 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ https://t.co/86ZjBEh22O
👁 3.1K
❤ 86
🔁 52
May 30
So proud to watch the my dear friend & mentor @neerajaiims present TALAPRO-3 at #ASCO26 with a simultaneous publication in @NEJM today!
Tala + enza rPFS (HR 0.48), with 3-year rPFS of 76.6% vs 56.2% in pts with HRR-deficient mHSPC.
Kudos to Neeraj and entire TALAPRO-3 https://t.co/brnoPmO51h https://t.co/1wJDgT2oqi
👁 2.5K
❤ 35
🔁 15
May 30
2-Abstract LBA5007: TALAPRO-3
Delving deeper into PARP inhibition in HRR altered mCSPC . @neerajaiims from @Huntsmancancer will present the phase 3 TALAPRO-3 trial at #ASCO26, evaluating talazoparib + enzalutamide vs placebo + enzalutamide in in patients with HRR-altered mCSPC. https://t.co/MiomNvUKxw
👁 2.3K
❤ 26
🔁 14
Apr 27
Pre-meeting prep for #ASCO26 looked different this year.
🤖 874-page proceedings PDF through an AI agent, scored by trial design, endpoint maturity, and practice impact
📊 Can't miss: 8 sessions | High interest: 10 | On my radar: 9
🎯 TALAPRO-3, RAMPART, ProstACT Global, https://t.co/3yYuF5VA0r
👁 2.2K
❤ 37
🔁 8
May 22
TALAPRO-3 #ASCO26 talazoparib + enzalutamide in HRR-altered mCSPC prostate looks the most impressive PARPi data to date. Efficacy in the non-BRCA HRR population is impressive IMO. Long term treatment is associated with long term side effects. @neerajaiims @OncoAlert https://t.co/9ESFUQuUek
👁 2.0K
❤ 61
🔁 32
May 30
🚨 TALAPRO-3: PARP inhibition moves earlier in mHSPC
Just out in @NEJM
🧬 599 pts w/ metastatic HRR-altered hormone-sensitive #prostatecancer randomized to talazoparib + enzalutamide vs enzalutamide alone.
📉 52% reduction in risk of radiographic progression or death (HR https://t.co/dHpRLnocTo
👁 1.5K
❤ 25
🔁 10
May 30
Trials in #ProstateCancer and #KidneyCancer featured at #ASCO26. @DrRanaMcKay @UCSanDiego joins @zklaassen_md @GACancerCenter previewing 5 #ASCO2026 #GUOncology trials, including PROTEUS, TALAPRO-3, and RaqdiCaL. From perioperative apalutamide in high-risk prostate cancer to PARP https://t.co/SrtU7o2EST
👁 1.4K
❤ 13
🔁 7
May 28
Trials in #ProstateCancer and #KidneyCancer featured at #ASCO26. @DrRanaMcKay @UCSanDiego joins @zklaassen_md @GACancerCenter previewing 5 #ASCO2026 #GUOncology trials, including PROTEUS, TALAPRO-3, and RaqdiCaL. From perioperative apalutamide in high-risk prostate cancer to PARP https://t.co/1k6cZU9OIs
👁 1.3K
❤ 9
🔁 6
May 21
TALAPRO-3 @NEJM
Adding #talazoparib to enzalutamide + ADT reduced the risk of progression or death by 52% (HR 0.48).
📈 3-year rPFS: 77% vs 56%
🧬 BRCA: HR 0.37 🧬 Non-BRCA: HR 0.57
The caveat: ⚠️ Grade ≥3 anemia: 51% ⚠️ Transfusions: 40% ⚠️ OS still immature (HR 0.77).
Looking https://t.co/OCtl9Hrs1b
👁 1.1K
❤ 15
🔁 8
May 30
Big presentation of Day 2 at #ASCO26 is #TALAPRO3 from @neerajaiims, also published in @NEJM. Phase 3 for ADT/enzalutamide +/- talazoparib for mHSPC with HRR alteration.
Primary endpoint met with rPFS (HR 0.48). OS trending favorably but immature. MDS/AML was seen as part of https://t.co/5JNRvZeuZd
👁 894
❤ 13
🔁 7
May 30
TALAPRO-3 met its primary endpoint: talazoparib + enzalutamide cut the risk of progression or death by 52% vs enzalutamide alone in HRR gene-altered mCSPC (rPFS HR 0.481, 95% CI 0.357 to 0.647, p<0.0001).
Phase 3, 599 pts, first-line HRR-altered mCSPC, randomized 1:1 to TALA + https://t.co/Ac2Ak91m5n
👁 860
❤ 15
🔁 9
May 30
Important NEJM update for TALAPRO-3: Talazoparib + enzalutamide + ADT improved rPFS in mHSPC.
The key question remains patient-centered:
Who benefits enough from upfront PARP intensification to justify the added toxicity?
#ASCO26 https://t.co/Y1DjC0jcJz
👁 808
❤ 9
🔁 2
May 30
TALAPRO-3 adds another important layer to mHSPC treatment. @neerajaiims
Happy to be one of the investigators in this global effort. @AnkaraUni 🇹🇷
🧬Talazoparib + enzalutamide + ADT improved rPFS vs enzalutamide + ADT.
⚠️But benefit must be weighed against toxicity and immature https://t.co/AvivfTUbwN
👁 803
❤ 29
🔁 15
May 30
Just presented at #ASCO26: TALAPRO-3 results show that combining talazoparib with enzalutamide improves outcomes over enzalutamide alone for men with HRR-altered mCSPC. #ASCODailyNews has more: https://t.co/h7ENwSb88n
@neerajaiims @huntsmancancer @Dolmos77 https://t.co/5r2lPyaf37
👁 762
❤ 10
🔁 3
May 30
@neerajaiims presents impressive phase III TALAPRO-3 data with concomitant publication in @NEJM: talazoparib + enzalutamide significantly prolonged rPFS in HRR-altered mCSPC (HR 0.48), with particularly striking benefit in BRCA-mutated disease and consistent activity beyond BRCA https://t.co/O2lhsYrFPl
👁 754
❤ 16
🔁 15
May 30
#ASCO26 TALAPRO-3 in HRR-altered mCSPC by @neerajaiims
TALA + ENZA significantly prolonged rPFS vs ENZA alone (HR 0.48). Strongest benefit in BRCAm (HR 0.37) but remained consistent beyond BRCA (HR 0.57).
Concomitant @NEJM publication 👇
https://t.co/ggUeOBKqRO
@OncoAlert https://t.co/FwLna1NE2j
👁 751
❤ 11
🔁 7
May 30
Join us Saturday at #ASCO26 for the Opening Session beginning at 9:45 AM CDT, featuring the NCI Director’s Address from Dr. Anthony Letai.
Also from 3–6 PM CDT: Oral Abstract Session on TALAPRO-3 in metastatic castration-sensitive prostate cancer. https://t.co/vhv0fPwMrk
👁 713
❤ 4
🔁 1
May 30
ASCO26 First Look Video: Dr. Andrew Armstrong on TALAPRO-3 https://t.co/iIqiASJ6XO
#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq @narjustflorezmd @lungoncdoc
👁 660
❤ 9
🔁 5
May 30
Men with metastatic hormone-sensitive prostate cancer and HRR mutations have worse outcomes on standard therapy. TALAPRO-3 asked whether adding a PARP inhibitor earlier could improve outcomes.
Today @NEJM and #ASCO26:
Talazoparib + enzalutamide reduced the risk of progression https://t.co/Ke1Zgq4QcZ
👁 651
❤ 10
🔁 1
May 30
⭐️ Outstanding presentation by @neerajaiims at @ASCO #ASCO26!
TALAPRO-3 meets its primary endpoint 👉 Talazoparib + enzalutamide significantly prolongs rPFS (HR 0.48)
A major advance for patients with mHSPC and HRR alterations👇
Full paper published today in @NEJM https://t.co/eEU2lKjUQC
👁 641
❤ 16
🔁 9
May 30
#ASCO26 | TALAPRO-3:
Practice-Changing in HRRm mCSPC 🧬
Talazoparib + Enzalutamide delivers a 52% rPFS reduction vs ENZA alone (HR 0.48), with deep benefit in BRCA-altered disease, establishing a new precision-based 1L standard pending OS maturity.
@OncoAlert @ASCO https://t.co/uFqeqQjxae
👁 635
❤ 18
🔁 5
May 30
TALAPRO-3: talazoparib + enzalutamide improved rPFS in HRR-altered mCSPC, with OS still immature and toxicity to weigh.
Congratulations @neerajaiims and team.
Happy to be an investigator in this important trial. @AnkaraUni
#ASCO26 @DrChoueiri @TiansterZhang @CathyEngMD https://t.co/A0mRVTZeYe
👁 593
❤ 20
🔁 14
May 30
Impact of anemia and its management on Quality of Life in #mCRPC patients treated with talazoparib + enzalutamide. Presentation by Neal Shore, MD, FACS @CURCMB. #AUA26 written coverage by @RKSayyid @UAUrology > https://t.co/3eicQoDmCd @AmerUrological @TheSTARTCenter https://t.co/PwerpRrP0P
👁 567
❤ 6
🔁 5
May 18
@neerajaiims @Huntsman_GU with news splashing results of #TALAPRO3, talazoparib-enzalutamide vs enza for metastatic AR pathway sensitive HRR altered #prostatecancer. Practice changing. Concurrent @NEJM pub. Kudos to the team! 👏👏
@asco #ASCO26 @oncoalert @urotoday @oncbrothers https://t.co/N5mjM750Bj
👁 495
❤ 11
🔁 9
May 30
#ASCO26 TALAPRO-3 talazoparib + enzalutamide in HRR-altered disease is moving PARP + ARPI to the earlier stage of #prostatecancer
The question: will benefit > long term toxicity❓
Also check simultaneous @NEJM article!
@neerajaiims @DrYukselUrun @OncoAlert #ProstateCancer https://t.co/gy83eV8Jgc
👁 489
❤ 13
🔁 10
May 30
🧬 TALAPRO-3 is high on my #ASCO26 GU watchlist.
Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR gene alterations.
The topline release reported a positive rPFS result and a strong OS trend, but the full data will matter.
⚠️ Key questions before calling
👁 485
❤ 6
🔁 3
May 26
Just left session hall D1 freezing cold @ASCO - will see @neerajaiims on #TALAPRO-3 results from Hotel or read:
https://t.co/pQx7B6CO6P
#ASCO26 @OncoAlert
👁 395
❤ 8
🔁 5
May 30
A new benchmark for HRR-altered metastatic hormone-sensitive prostate cancer. TALAPRO-3 showed a 52% reduction in the risk of progression or death with talazoparib added to enzalutamide + ADT (HR 0.48).
#ASCO26 #PrecisionOncology @OncoAlert @Larvol https://t.co/8sc1zxcPmj
👁 355
❤ 10
🔁 6
May 30
5. TALAPRO-3: PhIII, Enzalutamide + Talazoparib vs. Enza alone in HRR mutated mCSPC:
- At 3yrs, rPFS: 76.6% vs. 56.2% (HR: 0.48)
- rPFS in BRCAm: 77.2% vs. 48.8% (HR: 0.37)
- rPFS in non-BRCA: 76.2% vs. 60.2% (HR: 0.57)
- Germline and somatic testing is critical upfront!
6/7 https://t.co/pbFjPfK0nd https://t.co/QGKdmzJxNy
👁 337
❤ 2
🔁 0
May 30
👉🏻 Happening now @ASCO #ASCO26 : results of the phase 3 TALAPRO-3 trial meeting its primary endpoint with significant rPFS benefit with TALA + ENZA over ENZA in HRR+ mHSPC. Benefit remains significant in BRCA and non-BRCA. @neerajaiims @Huntsman_GU @huntsmancancer https://t.co/EiA2g4VfdO
👁 303
❤ 5
🔁 4
May 30
Talapro 3 trial @neerajaiims :Tala ➕ enza led to significantly better rPFS among patients with mAPMS #PrCa harboring alterations in HRR genes 🧬
#ASCO26 #precisionmedicine
How about toxicity?? 🤦 MDS! https://t.co/sxaI0wo44w
👁 279
❤ 8
🔁 3
May 30
TALAPRO-3 NEJM
#ASCO26
@neerajaiims
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer | New England Journal of Medicine https://t.co/Xu7LGbWCV4
👁 279
❤ 5
🔁 3
May 30
@neerajaiims PhIII TALAPRO-3 of #ADT + enza +/- talazoparib in #1L HRR-mutant #mCSPC ➡️ improved rPFS in BRCA/non-BRCA-mt pts in tala arm, OS immature, G3-4 TRAEs 79% vs 41% in control, 3 cases MDS & 2 cases AML (tala arm) vs 1 case MDS/AML (control arm)
#ASCO26 @OncoAlert https://t.co/BVeSMGuncy
👁 269
❤ 8
🔁 7
May 30
3) Prostate CA:
-#PROTEUS: perioperative apalutamide (plenary!)
-mCSPC: identifying docetaxel benefit analyses from CHAARTED + ENZAMET, & ADT interruption #ADREAM, PARPi #TALAPRO3, #PSMAddition, ZZ-First
-mCRPC: ADC to PSMA/STEAP1, #PLUDO doce vs Lu-617, AVPC chemo-IO
👁 264
❤ 5
🔁 1
May 1
@quimmateo with report of investigator initiated trial of talazoparib-enzalutamide for metastatic #prostatecancer. Even in non HRR altered dz, trend toward improving PFS. Sample size likely too small to show signif. Careful correlative work. @asco #ASCO26 @oncoalert @urotoday https://t.co/mHXPljxDJQ
👁 248
❤ 5
🔁 5
May 30
My ASCO GU 2026 watchlist 👀
① PROTEUS
② TALAPRO-3
③ NEXUS-01
Perioperative PC, ctDNA in RCC, next-gen ADCs… exciting year for GU oncology. #ASCOGU #ASCO2026 https://t.co/TiZfa54A93
👁 232
❤ 3
🔁 0
May 17
One to watch at #ASCO26: TALAPRO-3, a Late-Breaking Oral Abstract evaluating talazoparib + enzalutamide in HRR-altered metastatic castration-sensitive prostate cancer @neerajaiims @ASCO
https://t.co/ByNa4SiPOU https://t.co/lmDgHsTzCd
👁 208
❤ 4
🔁 2
May 23
📢 #AUA26: TALAPRO-2 post hoc analysis showed consistent positive correlation between rPFs and OS across HRR-deficient, BRCAm patient populations receiving talazoparib + enzalutamide or enzalutamide in the first-line metastatic #CRPC setting.
Read more: https://t.co/6b3nQXhky1
👁 183
❤ 2
🔁 0
May 26
@neerajaiims doing a great job at #ASCO26 presenting practice changing data on Talapro-3 for men with HRR+ mAPMS prostate cancer! https://t.co/lhc12C7URe
👁 172
❤ 4
🔁 1
May 30
ASCO 2026 | Abstract 5000
Talazoparib plus enzalutamide and ADT nearly doubled rPFS (28.1 vs 13.8 months) and improved overall survival (HR 0.70) in first-line mCRPC — including patients without HRR mutations.
This is one of the strongest signals yet for combining PARP https://t.co/zVLfu4V9BT
👁 164
❤ 6
🔁 4
May 31
#ASCO26 @neerajaiims Could #TALAPRO3 establish a new SOC for HRR-mutated #mCSPC Talazoparib + enzalutamide reduced the risk of progression or death by 52% (HR 0.48) ATM 🥇Pending OS @urotoday @SCUColombia @achoHematoYOnco @OncoAlert @Uromigos @oncodaily @ASCO @myESMO @UroOnc https://t.co/8P7Hq5EKna
👁 161
❤ 2
🔁 1
May 30
Pre @ASCO 2026: Top #GUCancer Abstracts
KEYNOTE-A39 | SAKK06/19 | RAMPART | TALAPRO3 | KEYNOTE-564 | NCT06879145 | ARACOG | ENZAMET | PROTEUS | Duravelo-2 | AMBASSADOR | A-DREAM | FUZUPRO | Rad-IO | KEYNOTE-905 | COMPPARE | POTOMAC | MAIN-CAV | 9MW281-2023-CP104 | CA209-9KU | https://t.co/vDB69IG1wf
👁 154
❤ 1
🔁 0
May 27
So proud to watch the my dear friend & mentor @neerajaiims present TALAPRO-3 at #ASCO26 with a simultaneous publication in @NEJM today!
Tala + enza rPFS (HR 0.48), with 3-year rPFS of 76.6% vs 56.2% in pts with HRR-deficient mHSPC.
Kudos to Neeraj and entire TALAPRO-3 https://t.co/nRzxfReIrA https://t.co/1wJDgT2WfQ
👁 153
❤ 2
🔁 1
May 30
TALAPRO-3 | NEJM 2026
Earlier precision therapy may be better precision therapy.
In HRR-altered mHSPC, talazoparib + enzalutamide improved 3-year imaging PFS:
• 77% vs 56% • HR 0.48 • 52% lower risk of progression or death
The PARP inhibitor opportunity may begin before https://t.co/UMBXa09fKe
👁 140
❤ 1
🔁 0
May 30
So proud to watch the my dear friend & mentor @neerajaiims present TALAPRO-3 at #ASCO26 with a simultaneous publication in @NEJM today!
Tala + enza rPFS (HR 0.48), with 3-year rPFS of 76.6% vs 56.2% in pts with HRR-deficient mHSPC.
Kudos to Neeraj and entire TALAPRO-3 https://t.co/7Qjxgrg5eK https://t.co/1wJDgT2WfQ
👁 135
❤ 2
🔁 1
May 30
#ASCO26 TALAPRO-3 establishes a new benchmark for HRR-altered mCSPC. Talazoparib + enza significantly improved 3-year PFS versus enza alone (77% vs 56%; HR 0.48, p<0.001), with an early OS trend (HR 0.77). Importantly, benefit was observed across prespecified subgroups https://t.co/i4IdK3dWth
👁 99
❤ 2
🔁 2
May 30
TALAPRO-3: phase 3 trial of Enza +/- Talazo in mHSPC harboring HRR gene alterations #ASCO26 https://t.co/HgJOZVOdYA
👁 68
❤ 0
🔁 0
May 30
So proud to watch the my dear friend & mentor @neerajaiims present TALAPRO-3 at #ASCO26 with a simultaneous publication in @NEJM today!
Tala + enza rPFS (HR 0.48), with 3-year rPFS of 76.6% vs 56.2% in pts with HRR-deficient mHSPC.
Kudos to Neeraj and entire TALAPRO-3 https://t.co/0IDi42XMYW https://t.co/1wJDgT2WfQ
👁 65
❤ 2
🔁 0
May 30
Updates from #ASCO2026: Results from the phase 3 #TALAPRO3 trial demonstrated that #talazoparib plus #enzalutamide significantly improved #rPFS in HRR-deficient metastatic castration-sensitive #prostate cancer. Learn more: https://t.co/uH46dXIJN9
#medtwitter #onctwitter https://t.co/n6igUc9N0Y
👁 51
❤ 0
🔁 0
May 31
TALAPRO-3 changed the PARP inhibitor conversation in prostate cancer.
For years, PARP inhibition was largely reserved for later stages after resistance emerged.
TALAPRO-3 asked a simple question:
If an HRR defect is already present, why wait?
In HRR-altered mHSPC: • rPFS HR https://t.co/izPVIpMxdc
👁 19
❤ 0
🔁 0
May 31
#ASCO2026 | TALAPRO-3
🔥 Talazoparib + enzalutamide met its primary endpoint, reducing the risk of radiographic progression or death by 52% versus placebo + enzalutamide in patients with HRR-altered mHSPC.
📈 The rPFS benefit was observed across both BRCA and non-BRCA https://t.co/Ao8GCLgspp
👁 10
❤ 1
🔁 0
May 31
ASCO 2026 | Abstract 5000
Talazoparib plus enzalutamide and ADT nearly doubled rPFS (28.1 vs 13.8 months) and improved overall survival (HR 0.70) in first-line mCRPC — including patients without HRR mutations.
This is one of the strongest signals yet for combining PARP https://t.co/ucvQWKBNTH
👁 4
❤ 0
🔁 0
May 31
EV-302
Enfortumab + Pembro · UC
▼
Bladder cancer highlights #ASCO26
1) Data for 3 Nectin4/Topo1 ADCs showing efficacy (LY4052031 , LY4101174, SHR-A2102). Can we sequence these drugs after EV? 2) Data from EV302/303 for EVP showing longer term outcomes and QOL 3) adjuvant QOL data for adjuvant pembro (AMBASSADOR)
👁 6.5K
❤ 87
🔁 30
May 26
Ab#4507 @ASCO #ASCO26 by @tompowles1 @shilpaonc👉https://t.co/fxlybBjl6j👉3.5 yr f/u of Ph3 EV-302 in aUC #bladdercancer👉42-month OS rate, 44% vs 24.6%; HR=0.53👉among pts w/ CR, 66% had initially PR👇 @OncoAlert @urotoday @uromigos @BladderCancerUS https://t.co/PtSntGzMpI
👁 5.6K
❤ 36
🔁 19
May 22
EV-302 at 3.5 yrs: @tompowles1 sophisticated dissection of the data, showing EV+pembro continues to separate from chemo in untreated la/mUC. Median OS 33.6 vs 15.9 mo; HR 0.53.
Cumulative CR shows the highest rates at 9 and 12 weeks.
#ASCO26 #BladderCancer
@OncoAlert @asco https://t.co/WRjL6DTnlZ
👁 2.7K
❤ 27
🔁 15
May 29
The 3.5yr OS from EV302 continues to show transformative benefit (HR 0.53 (0.45-0.63)) #ASCO26 for EV/pembro. The landmark OS for the CR population (30%) is ~90%. Median time to CR is 4.5 months (responses mature over time). Response rates of platinum chemo after EVP is 21% (OS https://t.co/MMJNGvIcs2
👁 1.9K
❤ 42
🔁 21
May 29
7-Abstract 4507: EV-302
#DrThomasPowels will provide us with an update at #ASCO26 after 3.5 years of follow-up on the survival and response durability with enfortumab vedotin + pembrolizumab vs chemotherapy in previously untreated la/mUC.
@QMBCI @ASCO @OncoAlert https://t.co/bievd0jQ52
👁 1.6K
❤ 18
🔁 7
Apr 27
#ASCO26
EV + pembrolizumab is not just holding the line in 1L metastatic urothelial cancer.
It is deepening responses over time.
EV-302 / KEYNOTE-A39
3.5-year update
⚡ Median OS
33.6 vs 15.9 months
HR 0.53
⚡ 42-month OS
44.0% vs 24.6%
⚡ No new safety signals
The most https://t.co/DxESKbmen9 https://t.co/Kvv5cfE4Kh
👁 1.6K
❤ 24
🔁 6
May 26
EV+pembro is now first-line standard after EV-302 (updated at #ASCO26). 6 urothelial trials at ASCO 2026 are already testing what follows, 3 in Phase 3.
📈 Two TROP-2 strategies: Dato-DXd post-EV/pembro (TROPION-Uro03) + SG+pembro in ICI-resistant mUC (EA8231)
Ph1: https://t.co/3VdWxWZNH7
👁 1.3K
❤ 23
🔁 14
May 28
Looking forward to today’s bladder and kidney cancer oral sessions at #ASCO26.
Congratulations to all the presenters!
Especially excited to see @tompowles1 present the 3.5-year FU from EV-302 with subsequent Tx & outcomes that will help inform real-world patient care.
Looking https://t.co/hTaTNQaDBp https://t.co/QV1Kb8RHnv
👁 1.2K
❤ 12
🔁 6
May 29
🟡 #ASCO26 GU — Bladder Cancer / Urothelial Cancer
Abstract 4507 | EV-302 / KEYNOTE-A39
“Enfortumab vedotin plus pembrolizumab vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma: 3.5-year follow-up and response analyses from EV-302” https://t.co/Pzd4BGxF9V
👁 1.0K
❤ 19
🔁 10
May 29
One of the most important messages from the EV-302 update:
Responses continue to deepen over time.
Nearly 30% of patients achieved CR, and ~90% of those complete responders remain alive at 3.5 years.
#ASCO2026 @Larvol @OncoAlert @ozdogan_md https://t.co/G74TaQnshi
👁 981
❤ 11
🔁 7
May 29
4. EV-302 (3.5yrs update): PhIII, Pembro + Enfortumab in 1L metastatic bladder Ca (current SoC given doubling of OS)
- mOS 33.6mos vs. 15.9mos (HR: 0.53)
- Post EV+P, 20.7% had response to platinum chemo at the time of progression
- In responders, CR: 45.1% vs. 32.8%
5/7 https://t.co/gYBCRnQgC6 https://t.co/ZLRkvdEmk1
👁 931
❤ 8
🔁 5
May 29
🚨 EV-302: enfortumab vedotin + pembrolizumab vs platinum chemotherapy in 1L metastatic urothelial carcinoma (phase III, n=886) #ASCO26
🎯 Median OS: 33.6 vs 15.9 months (HR 0.53) || 3.5-year OS: 44.0% vs 24.6%
💥 CR rate doubled: 30.4% vs 14.5%
EV keeps delivering the https://t.co/DfaWdIDD84
👁 736
❤ 15
🔁 11
May 30
🚨 #ASCO26 GU highlight | Urothelial carcinoma
Abstract 4507 | EV-302 / KEYNOTE-A39
EV + pembrolizumab vs chemotherapy in 1L locally advanced/metastatic UC BY @tompowles1
@ASCO @OncoAlert
Clinical question:
With longer follow-up, does EV+pembrolizumab continue to sustain its https://t.co/FFtc033sSp
👁 714
❤ 21
🔁 12
May 30
Day 1 GU at #ASCO26.
🎯 EV-302, 3.5 years: median OS 33.6 vs 15.9 months (HR 0.53), 44% alive at 42 months. Two-thirds of CRs converted from PR with a median of 5 more EV cycles. Dose interruptions in 75.5% of patients on treatment >1 year, reductions in 65.8%. Staying on it
👁 500
❤ 6
🔁 3
May 30
📢 Data update! #ASCO26 abstract release: Phase 3 findings from the EV-302/KEYNOTE-A39 study show the long-term benefit of enfortumab vedotin plus pembrolizumab in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
Check out the newly
👁 474
❤ 4
🔁 0
May 21
Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study. To be Presented at #ASCO26
https://t.co/91lKceivB8
Updated https://t.co/IpYQmnHa8K
👁 465
❤ 12
🔁 7
May 27
🎙️ If you missed Day 1 of #ASCO26, OncoAlert has you covered
👑 CROWN keeps its Crown
⚡ EV-302 keeps delivering
🧬 Sunvozertinib steps into the spotlight
🎯 ctDNA sharpens precision RCC care
The data dropped. We picked up the mic🔥 #ASCO26 @OncoAlert https://t.co/cd9yq3c8p0
👁 392
❤ 9
🔁 1
May 30
Enfortumab vedotin + pembrolizumab vs chemotherapy for previously untreated locally advanced or metastatic #UrothelialCarcinoma: 3.5 year follow-up and response analyses from the phase 3 EV-302 study. Presentation by @tompowles1 @QMBCI. #ASCO26 written coverage by @RKSayyid https://t.co/PaIe4OLi3b
👁 321
❤ 8
🔁 8
May 30
ASCO 2026 | Abstract 4507
With 3.5 years of follow-up, the EV-302 trial confirms that enfortumab vedotin plus pembrolizumab maintains a significant and durable overall survival benefit over platinum-based chemotherapy in first-line advanced urothelial carcinoma (HR 0.53). https://t.co/meehDT7k79
👁 320
❤ 6
🔁 3
May 30
Outstanding discussion by @apolo_andrea of the past, present & future of nectin-4 ADCs in UC #ASCO26
From EV-302 establishing EV+pembro as a transformative 1L therapy in mUC to a growing pipeline of next-generation Nectin-4 ADCs, the field continues to move rapidly.
Key https://t.co/QbI9rTQkkA
👁 281
❤ 4
🔁 5
May 29
Excited for #ASCO26 updates in urothelial cancer!
New long-term EV-302 findings continue to evaluate outcomes w EV + pembrolizumab, w intriguing analyses on patients whose responses evolved from partial to complete response over time @tompowles1 @ASCO
https://t.co/hwX5FnDEAv https://t.co/UId7wPO8Rd
👁 225
❤ 3
🔁 1
May 23
@tompowles1 EV-302 of #1L EV-P vs platinum-chemo in #mUC ➡️ updated OS at 3.5 yrs 44% vs 24.6% alive, median 4.3 mos to #CR w/even pts up to 1 yr converting from #PR to #CR, 10% achieve #CR at first scan w/EV-P, (median duration of EV 7.1 mos & 8.5 mos pembro)
#ASCO26 @OncoAlert https://t.co/5COrRmmxqP
👁 198
❤ 5
🔁 7
May 29
ARACOG
Prostate cancer
▼
🧬 THE 10 MOST IMPORTANT GU CANCER TRIALS OF #ASCO26
🎯 PROSTATE CANCER: INTENSIFICATION vs QUALITY OF LIFE
1️⃣ PROTEUS
Perioperative apalutamide + ADT in high-risk localized prostate cancer
Can aggressive ARPI intensification improve curative outcomes?
2️⃣ ARACOG (5005) https://t.co/JbjH3JcyWJ https://t.co/IZUmU0IF1H
👁 15.9K
❤ 77
🔁 38
May 25
@DanaFarber and @DanaFarber_GU ‘s own #AliciaMorgans presents standout cognition-focused data from ARACOG: darolutamide demonstrated significantly more favorable cognitive outcomes than enzalutamide, adding important patient-centered perspective to ARPI selection.
#ASCO26 https://t.co/0KAObrMpCF
👁 2.4K
❤ 28
🔁 13
May 30
THE 10 MOST IMPORTANT GU CANCER TRIALS OF #ASCO26
🎯 PROSTATE CANCER: INTENSIFICATION vs QUALITY OF LIFE
1️⃣ PROTEUS
Perioperative apalutamide + ADT in high-risk localized prostate cancer
Can aggressive ARPI intensification improve curative outcomes?
2️⃣ ARACOG (5005) https://t.co/Yi9AfnWryH https://t.co/IZUmU0I7c9
👁 2.1K
❤ 19
🔁 8
May 30
Early #ASCO26 news:
🚹 In the phase II ARACOG trial, patients with advanced #prostatecancer treated with darolutamide experienced significantly less cognitive decline over 24 weeks compared with enzalutamide.
🗣️ To be presented by @CaPsurvivorship
🔗 https://t.co/89LLKL0v8P https://t.co/KR7TxSnAkt
👁 1.1K
❤ 7
🔁 4
May 23
#ASCO26 GU Oncology Spotlight 🚨
🔬 Abstract 5005 | ARACOG / AFT-47
Cognitive effects of darolutamide vs enzalutamide
Presented by Alicia K. Morgans, MD, MPH, FASCO
@CaPsurvivorship
@OncoAlert
@ASCO
In prostate cancer, we often discuss AR pathway inhibitors through the lens https://t.co/vpZr1w6kc6
👁 901
❤ 22
🔁 15
May 30
#ASCO26 ARACOG is practical: darolutamide showed less cognitive decline than enzalutamide at 24 weeks.
‼️"This is the clinical trial level proof of less CNS penetration of darolutamide!"‼️
Would this influence your ARPI choice? @CaPsurvivorship
@DrChoueiri @DrYukselUrun https://t.co/OR6mR8mo5b
👁 716
❤ 16
🔁 11
May 30
@CaPsurvivorship @DanaFarber_GU reports her many year #ARACOG trial — important objective measures for cognitive changes on darolutamide vs enzalutamide in #prostatecancer. Daro w improved cog fxn vs enza. Important work for ARPI selection. @asco #ASCO26 @oncoalert @urotoday https://t.co/0Of8OInmTG
👁 545
❤ 9
🔁 10
May 30
@DanaFarber and @LankCenterGU’s own #AliciaMorgans presents standout cognition-focused data from ARACOG: darolutamide demonstrated significantly more favorable cognitive outcomes than enzalutamide, adding important patient-centered perspective to ARPI selection.
#ASCO26 https://t.co/VIIUlULqKQ
👁 514
❤ 10
🔁 2
May 30
In between #AUA26 and #ASCO26, we're looking ahead to our webinar on the new ARASEC & ARACOG clinical trial data.
✔️ Catch up in just 30 minutes
✔️ Focus on what matters for your clinical practice
✔️ Interact live with Dr. Rana McKay & Dr. Alicia Morgans
Register to join us https://t.co/iGAjujH2Ga
👁 332
❤ 5
🔁 3
May 21
ARACOG: does AR-targeted therapy affect memory, attention, executive function, and daily life differently?
@CaPsurvivorship @DanaFarber
At 24 weeks, enzalutamide showed greater cognitive decline than darolutamide.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal https://t.co/uHNipIyHZb
👁 314
❤ 9
🔁 5
May 30
@CaPsurvivorship PhII #ARACOG of darolutamide vs enza in adv #pcsm (50-55% mHSPC) ➡️ greater decline in maximally changed cognitive domain (mainly in working memory and executive function) w/enza than daro over 24 weeks, enza offered by #SOC, daro by sponsor
#ASCO26 @OncoAlert https://t.co/O2RWd5q5Jc
👁 262
❤ 9
🔁 8
May 30
ARACOG (AFT-47): More Cognitive Decline Observed With Enzalutamide Versus Darolutamide in Advanced Prostate Cancer https://t.co/n4YqFAOkSf
#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti
👁 191
❤ 2
🔁 2
May 30
ARACOG: cognitive effects of Darolutamide vs Enzalutamide #ASCO26 https://t.co/wgllWfWOuS
👁 157
❤ 3
🔁 5
May 30
Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data? https://t.co/DZpQGkxFXa Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026. #BayerAG #NUBEQA #Darolutamide #Enzalutamide #ASCO26
👁 28
❤ 0
🔁 1
May 31
KEYNOTE-564 (ctDNA)
Adjuvant Pembrolizumab · RCC — ctDNA analysis
▼
KEYNOTE-564 ctDNA analysis at #ASCO26 (Abstr 4502, oral): can ctDNA detect recurrence and refine risk in adjuvant clear cell RCC?
In ccRCC at increased risk post-nephrectomy (n=994; 736 evaluable at baseline), tumor-informed, WES-based ctDNA (Signatera, 16-plex and 64-plex) was
👁 7.2K
❤ 24
🔁 9
May 22
Ab#4502 @ASCO #ASCO26 by @DrChoueiri👉 https://t.co/SZg3hfw1wU👉ctDNA analysis from KEYNOTE-564 trial #kidneycancer👉ctDNA+ associated w/ worse DFS👉ctDNA clearance was higher in pembro arm👇@tompowles1 @OncoAlert @urotoday @kidneyCAN https://t.co/XBoQSZPpQx
👁 6.7K
❤ 29
🔁 15
May 22
“Is the Best Yet to Come in Kidney Cancer?” Detailed and well framed discussion by @MVossMD on the 3 RCC studies: bone mets, non-clear cell RCC, and ctDNA in adjuvant KEYNOTE-564.
#ASCO26 #RCC
@OncoAlert @ASCO @OncBrothers https://t.co/19D1ECxInl
👁 1.8K
❤ 36
🔁 17
May 29
ctDNA 🧬analysis from #KN564 from @DrChoueiri and colleagues at #ASCO26 showing only 10-15% sensitivity and near perfect specificity using #WES baseline testing. https://t.co/RS8ZOpXSzv
This is expected. RCC recurs much slower than UC, majority events are 1yr+ out. Lead time https://t.co/HsjMhnzjP9
👁 1.2K
❤ 14
🔁 5
May 25
🟠 #ASCO26 GU — Kidney Cancer / RCC
Abstract 4502 | KEYNOTE-564 ctDNA
“ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial”
@ASCO @OncoAlert
@DrChoueiri @tompowles1
ctDNA is one of the most important https://t.co/93RE01SYtF
👁 863
❤ 17
🔁 12
May 29
🟠 #ASCO26 GU biomarker highlight | RCC
Abstract 4502 | KEYNOTE-564 ctDNA analysis
Adjuvant pembrolizumab vs placebo in high-risk clear-cell RCC by @DrChoueiri
@ASCO @OncoAlert
Clinical question:
Can ctDNA help identify recurrence risk or treatment dynamics in patients https://t.co/Ub5dKr7D1p
👁 513
❤ 12
🔁 7
May 30
Excited for #ASCO26 oral presentations! New analyses from KEYNOTE-564 will explore how ctDNA status and ctDNA clearance relate to outcomes in RCC treated w adjuvant pembrolizumab @DrChoueiri @ASCO
https://t.co/V0LOAQJQ41 https://t.co/j8tb0DkuBa
👁 413
❤ 13
🔁 8
May 23
#ASCO26
@DrChoueiri shows KEYNOTE-564 ctDNA analysis and provides further evidence that molecular residual disease matters in RCC.
ctDNA positivity identified patients at substantially higher risk of recurrence, while pembrolizumab improved outcomes regardless of ctDNA status https://t.co/qVNL5ndUxw
👁 379
❤ 6
🔁 4
May 29
RCC may simply be a poor ctDNA-shedding tumor.
In KEYNOTE-564, current ctDNA assays detected <15% of future recurrences before clinical relapse.
So in RCC: ctDNA positivity is prognostic — but ctDNA negativity may be poorly reassuring.
#ASCO2026 #RCC #ctDNA #MRD #Oncology https://t.co/8CQaxeqWkK
👁 348
❤ 2
🔁 3
May 27
@DrChoueiri exploratory @NateraOncology #ctDNA analysis of PhIII KN-564 trial of adj pembro in resected #ccRCC ➡️ baseline #ctDNA+ associated w/worse #DFS but DFS in favor of adj pembro, low sensitivity but high specific of assay in this population
#ASCO26 @OncoAlert https://t.co/PMXmxB2m3J
👁 284
❤ 7
🔁 7
May 29
#ASCO26
ctDNA in KEYNOTE-564（adj Pem for ccRCC) abstract 4502
✅術後ctDNA +veは5.4-8.2%と低頻度
✅ctDNA +veはworse DFSに関連
✅ctDNA +veはhigh specificity (98%)だが、low sensitivity (12-15%)
@DrChoueiri https://t.co/yRRUfJmC17
👁 233
❤ 2
🔁 0
May 29
Outstanding presentation by @DrChoueiri at #ASCO26 on ctDNA in KEYNOTE-564: baseline ctDNA positivity was associated with worse DFS, while adjuvant pembro led to higher rates of ctDNA clearance.
#RCC #KidneyCancer https://t.co/Ew2gqeT3P2
👁 204
❤ 3
🔁 1
May 29
🩸 ctDNA analysis in KEYNOTE-564 (adjuvant pembrolizumab in RCC) #ASCO2026
💥 ctDNA+ predicted poorer DFS
🎯 Positivity rate only 5–8%
▪️ Specificity 96–99%; sensitivity 10–15%
✅ Benefit from pembrolizumab regardless of ctDNA status
Not every KEY note is loud enough to hear 😉 https://t.co/HzT8TQmcJ8
👁 148
❤ 6
🔁 0
May 29
ctDNA in the KeyNote-564 study: highlights the limitations of the low cDNA positivity rate in high-risk resected clear cell RCC and does not support the routine use of current cDNA technology (exome-based) to select patients
@DrChoueiri #ASCO26 https://t.co/HJdA7uh0Rl
👁 68
❤ 1
🔁 2
May 29
🧬 Don't miss this at #ASCO26! Elegant ctDNA analysis from KEYNOTE-564 by @DrChoueiri & team — interrogating liquid biopsy as a tool for recurrence risk in high-risk ccRCC after nephrectomy 🔬🩸
What stood out to me 👇
📊 Baseline ctDNA detectable in only a small subset (5.4% w/ https://t.co/Hsu9Fc17mF
👁 63
❤ 2
🔁 0
May 29
🧬 Don't miss this at #ASCO26! Elegant ctDNA analysis from KEYNOTE-564 by @DrChoueiri & team — interrogating liquid biopsy as a tool for recurrence risk in high-risk ccRCC after nephrectomy 🔬🩸
What stood out to me 👇
📊 Baseline ctDNA detectable in only a small subset (5.4% w/ https://t.co/ig4NCpyMT6
👁 23
❤ 0
🔁 0
May 29
KEYNOTE-905 / EV-303 — Abs 4510
Perioperative Enfortumab Vedotin + Pembro · cisplatin-ineligible MIBC (Phase 3)
▼
⚡️ KEYNOTE-905 published in @NEJM: perioperative enfortumab vedotin + pembrolizumab vs surgery alone in cisplatin-ineligible MIBC (n=344).
2-year EFS: 74.7% vs 39.4% (HR 0.40)
2-year OS: 79.7% vs 63.1% (HR 0.50)
pCR: 57.1% vs 8.6%
The trial that supported FDA approval in https://t.co/BwexNjWfdv
👁 4.2K
❤ 69
🔁 30
May 21
Encouraging HRQoL findings from KEYNOTE-905 presented by #PeterODonnell: neoadj/adjuvant EV+pembro maintained patient-reported outcomes comparable to surgery alone in cis-ineligible MIBC, supporting the overall benefit/risk profile of this perioperative approach.
#ASCO26 https://t.co/520huTQnro
👁 1.1K
❤ 18
🔁 13
May 30
Can we measure QOL completely differently? #ASCO26 This podcast with Peter O’Donnell and @BethN01 covers the KN905 EVP data and IM010 data. https://t.co/de7aFIBS7X
👁 643
❤ 13
🔁 10
May 30
In Episode 40, Dr. Girish Kulkarni (@GSK_UofT) shares why the "surgery-first" approach for MIBC is rapidly changing by diving into EV-303 & EV-304 data. Watch or listen to our newest series now to learn how it's shifting the standard of care: https://t.co/xipk6Ukova https://t.co/CCHFQU8sZD
👁 379
❤ 1
🔁 1
May 19
🔬 Abstract 4510 | KEYNOTE-905 / EV-303
HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC
Presented by Peter H. O’Donnell, MD
University of Chicago
@OncoAlert
@ASCO
In muscle-invasive bladder cancer, perioperative treatment decisions are https://t.co/MvjxHdzuXx
👁 374
❤ 13
🔁 7
May 30
🇪🇺 The EMA’s CHMP has issued a positive opinion for perioperative pembrolizumab + enfortumab vedotin in cisplatin-ineligible muscle-invasive bladder cancer, following phase 3 KEYNOTE-905 data showing significant improvements in EFS, OS, and pCR rates. 🧬📊
In the trial, the
👁 309
❤ 3
🔁 2
May 26
#ASCO26: HRQoL data from KEYNOTE-905 support the addition of neoadj/adj EV + pembrolizumab in cisplatin-ineligible MIBC, showing no meaningful decline in patient-reported quality of life versus surgery alone despite improved efficacy outcomes
https://t.co/0BFVyeaSJR https://t.co/sdmS5IctDk
👁 279
❤ 4
🔁 2
May 27
MAIN-CAV / A032001 — Abs 4514
Maintenance Avelumab ± Cabozantinib · advanced Urothelial Carcinoma (Alliance, Phase 3)
▼
6-Abstract 4514: MAIN-CAV
Dr. @shilpaonc will present this phase 3 trial at #ASCO26, evaluating cabozantinib + avelumab vs avelumab alone as maintenance therapy in locally advanced/metastatic UC.
@DrRosenbergMSK @ASCO @OncoAlert https://t.co/v6SBe69iAm
👁 4.2K
❤ 18
🔁 6
Apr 27
Ab#4514 @ASCO #ASCO26 by @shilpaonc👉 https://t.co/jAbQr5NsmT👉Ph3 trial of cabozantinib+avelumab vs avelumab after 1L platinum in aUC #bladdercancer 👉addition of cabo to Av did not improve OS or PFS👇@DrRosenbergMSK @OncoAlert @urotoday @bladdercancerUS @bergsa83 https://t.co/OiY4DtLsvh
👁 2.3K
❤ 15
🔁 13
May 22
RAMPART
Adjuvant Durvalumab ± Tremelimumab · RCC
▼
Renal cancer highlights #ASCO26 1) RAMPART - adjuvant durva/tremi vs durva vs surveillance. How much does CTLA4 help? 2) Is ctDNA useful post surgery in RCC (KN565 data)? 3) Does radium-223 help in bone mets patients? (a RII study) 4) Data on 2 VEGF+PD1 combination single arm
👁 4.7K
❤ 77
🔁 32
May 26
RAMPART at #ASCO26: the first adjuvant RCC trial to show a DFS benefit for a PD-L1 plus CTLA-4 combination. Durva monotherapy similar signal but did not meet statistical bar.
Phase 3, N=790, resected intermediate/high-risk RCC. Median follow-up 3.5 years.
3-year DFS:
🎯 https://t.co/jqseIghWAd
👁 885
❤ 10
🔁 6
May 30
RAMPART: Adjuvant Durvalumab Does Not Improve DFS vs Active Monitoring in Intermediate- and High-Risk RCC https://t.co/R02Rv9UovN
#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence
👁 327
❤ 7
🔁 7
May 30
Durvalumab monotherapy vs active monitoring for resected primary #RCC in #RAMPART: An international, phase 3, randomized controlled trial. Presentation by James Larkin, MD @royalmarsdenNHS. #ASCO26 written coverage by @RKSayyid @UAUrology > https://t.co/4H53QXW7Gh @ASCO https://t.co/BhNblYUUZF
👁 324
❤ 8
🔁 8
May 30
The adjuvant RAMPART trial by James Larkin opens new areas of debate in the adjuvant renal cancer field. #ASCO26 https://t.co/IjcRiOrlNF
👁 289
❤ 3
🔁 1
May 30
NEXUS-01 — Abs 4508
LY4052031 (Nectin-4 ADC) · pretreated advanced Urothelial Carcinoma (Phase 1a/b)
▼
(1/3) NEXUS-01 adds to the growing story that Nectin-4 may remain a relevant target even after EV exposure. Data will be presented at #ASCO26 by @IyerGopa from @MSK_DeptOfMed
Although Nectin-4 expression may decrease in EV/P resistant tumors, this data support targeting the
👁 2.6K
❤ 22
🔁 6
May 22
🎯 #ASCO26 @ASCO NEXUS-01 @gopaiyer study in mUC with a new nectin4 ADC (camptho payload) MTD 3.6 mg/k?
ORR 42% (pretreated EV-Pembro)
👉 well tolerated (low diarrhea and > hematologic toxicity) @PGrivasMDPhD @OncoAlert @tompowles1 @DrChoueiri @GuardConsortium @UroTarget https://t.co/QopOVKvLtU
👁 1.2K
❤ 16
🔁 13
May 29
NEXUS-01: next-gen nectin-4 ADC LY4052031 in advanced/metastatic UC by @IyerGopa: ORR was 48% in evaluable mUC pts, including 40% after prior EV.
#ASCO26 #BladderCancer
@OncoAlert @asco @OncBrothers https://t.co/48PtsuGJdc
👁 1.2K
❤ 24
🔁 14
May 29
#ASCO26 GU Oncology Highlight 🚨
🔬 Abstract 4508 | NEXUS-01
LY4052031: a next-generation Nectin-4 ADC in advanced/metastatic urothelial carcinoma
Presented by Gopa Iyer, MD
@IyerGopa
@OncoAlert
@ASCO
One of the key questions in metastatic urothelial carcinoma today is no https://t.co/lM4Ad8ObMX
👁 301
❤ 10
🔁 8
May 29
AMBASSADOR / A031501 — Abs 4513
Adjuvant Pembrolizumab · high-risk MIBC & upper-tract UC (Alliance, Phase 3)
▼
Ab#4513 @ASCO #ASCO26 by @RonaldChenMD👉 https://t.co/URhd9X5Y58👉Ph3 AMBASSADOR 👉Adj pembro vs observation after surgery in high risk MIUC #bladdercancer👉Adj pembro⬆️DFS without negatively affecting HRQoL👇@apolo_andrea @OncoAlert @urotoday @bladdercancerUS @ALLIANCE_org https://t.co/Xzc5TxCxC0
👁 1.6K
❤ 22
🔁 17
May 22
Curing Early Bladder Cancer With Multidisciplinary Approaches, #DrMelissaReimers discusses 2 perioperative/adjuvant MIBC abstracts: SAKK 06/19 with intravesical rBCG + chemo-IO, and AMBASSADOR HRQOL with adjuvant pembrolizumab.
#ASCO26 #BladderCancer
@OncoAlert @ASCO https://t.co/GXj4wOZu4R
👁 1.2K
❤ 18
🔁 9
May 29
🔵 #ASCO26 GU — Bladder Cancer / Urothelial Cancer
Abstract 4513 | AMBASSADOR / Alliance A031501
“Health-related quality of life (HRQOL) with pembrolizumab or observation for high-risk muscle-invasive urothelial carcinoma after surgery”
Presenter: Ronald C. Chen, MD, MPH, https://t.co/BEp7VTKgAE
👁 648
❤ 13
🔁 9
May 29
#ASCO26 AMBASSADOR HRQOL: adjuvant pembrolizumab improved DFS in high-risk MIBC without meaningful HRQOL detriment.
In adjuvant therapy, preserved QoL is part of the value proposition.
@DrChoueiri @DrYukselUrun @OncoAlert #BladderCancer #oncology @OncoReporte @ONCOassist https://t.co/OJuEndhyPc
👁 490
❤ 12
🔁 9
May 29
@RonaldChenMD @KUcancercenter with full quality of life results from #AMBASSADOR trial adjuvant pembro vs placebo. More dyspnea long term but did not affect overall function. Will be monitoring for our patients on adj IO in clinic. @asco #ASCO26 @oncoalert @urotoday https://t.co/fAtPPMORaW
👁 401
❤ 10
🔁 10
May 29
update from AMBASSADOR: adjuvant pembrolizumab improved DFS after surgery for high-risk MIBC, with no negative impact on overall HRQOL. Important data to support shared decision-making in the adjuvant setting. #ASCO26 https://t.co/CDWUHObquj
👁 334
❤ 2
🔁 2
May 29
AMBASSADOR HRQoL data with adjuvant Pembro for MIBC #ASCO26 https://t.co/CbwcIOJAO3
👁 156
❤ 1
🔁 2
May 29
ENZAMET — Abs 5001
Enzalutamide + Testosterone Suppression · long-term OS · mHSPC (Phase 3)
▼
ENZAMET Decipher analysis (#ASCO26, Abstr 5001). A practical question we deal with constantly: who actually needs docetaxel added to ADT + enza in mHSPC? They ran the Decipher genomic classifier (>0.85 cutoff) on 634 pts from ENZAMET.
High-Decipher pts (>0.85) did clearly worse
👁 3.0K
❤ 18
🔁 8
May 24
@chrissweens1 presents level 1B evidence from ENZAMET suggesting Decipher GC >0.85 may identify pts deriving benefit from docetaxel intensification alongside ADT + enzalutamide, while no clear benefit signal was observed for GC ≤0.85.
#ASCO26 #ProstateCancer
@OncoAlert @ASCO https://t.co/QDiSHqMxbj
👁 1.4K
❤ 31
🔁 22
May 30
KEYNOTE-B15
Pembro · MIBC
▼
⚡️ Phase 3 KEYNOTE-B15/EV-304 at #ASCO26: perioperative EV + pembrolizumab vs gemcitabine/cisplatin in cisplatin-eligible MIBC.
EFS HR 0.53. pCR 55.8% vs 32.5%. OS HR 0.65.
First regimen in 25 years to surpass cisplatin-based neoadjuvant chemotherapy in MIBC.
@mattgalsky @ASCO https://t.co/q0cVPvks4m
👁 1.8K
❤ 51
🔁 22
May 28
KEYNOTE-B15 / EV-304 #ASCO2026
Perioperative EV + Pembrolizumab vs Gemcitabine + Cisplatin in cisplatin-eligible MIBC:
• 24-mo EFS: 79.4% vs 66.2% • HR for EFS: 0.53 • 24-mo OS: 86.9% vs 81.3% • pCR: 55.8% vs 32.5%
Key message: Strong perioperative efficacy signal with https://t.co/is5k6RE2uB
👁 1.2K
❤ 20
🔁 5
May 24
💥 @US_FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC based on data from the phase 3 KEYNOTE-B15/EV-304 trial.
Full details 📈: https://t.co/JENvanUfyo
#blcsm #oncology
👁 594
❤ 4
🔁 0
May 3
🚨 EV + Pembrolizumab is rapidly reshaping the perioperative bladder cancer landscape — and now raising real possibilities for bladder preservation in MIBC.
KEYNOTE-905/EV-303 and KEYNOTE-B15/EV-304 demonstrated unprecedented improvements in pCR, event-free survival, and https://t.co/GTmCJwJSEz
👁 476
❤ 10
🔁 3
May 16
Evaluating EV plus pembrolizumab in muscle-invasive #BladderCancer: #KEYNOTEB15 results. @MattGalsky @TischCancer joins @ERPlimackMD @FoxChaseCancer to discuss this phase III trial randomizing 808 #MIBC patients to neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab https://t.co/XgvxmG7b4o
👁 296
❤ 3
🔁 1
May 15
RADICAL / Alliance A031801
Radium-223 + Cabozantinib · RCC bone metastases (Alliance, Phase 2)
▼
#ASCO26 RADICAL: radium-223 + cabozantinib in RCC with bone metastases did not improve SSE-free survival.
Negative trials matter—they tell us what not to add.
@DrRanaMcKay @DrChoueiri @DrYukselUrun @OncoAlert @NazliDizman #ASCO26 #KidneyCancer #GUonc #oncology https://t.co/PptZPzPHLg
👁 808
❤ 16
🔁 13
May 29
Abstract 4500 | RADICAL / Alliance A031801
“A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients with RCC with bone metastases” #ASCO26
@ASCO @OncoAlert
@DrRanaMcKay @DrChoueiri
Bone metastases remain a major challenge in RCC:
🟠 Higher symptom https://t.co/4IsAjJP0bS
👁 715
❤ 19
🔁 13
May 29
🟠 #ASCO26 GU highlight RCC
Abstract 4500 | RADICAL / Alliance A031801
Radium-223 + cabozantinib vs cabozantinib in RCC with bone metastases
Presenter/first author: Rana R. McKay
@ASCO @OncoAlert @DrRanaMcKay
Clinical question:
In RCC patients with symptomatic bone metastases, https://t.co/Ajw91GJVdW
👁 547
❤ 13
🔁 7
May 30
🚨 Live at #ASCO26! 🎉 So proud to see @DrRanaMcKay present the RADICAL trial (Alliance A031801) — a phase 2 randomized study of radium-223 + cabozantinib vs. cabozantinib alone in patients with #RCC & bone metastases 🦴
A creative bone-targeted approach to a tough clinical https://t.co/0Yjof5aO2X
👁 335
❤ 5
🔁 4
May 29
Oral Abs: RADICAL: Ph 2 RCT of Ra-223 + Cabo vs Cabo in RCC w/ bone mets @DrRanaMcKay @urotoday #ASCO26
Ra-223 + Cabo vs Cabo:
🌟SSE-FS: HR 1.24, 95% CI 0.62-2.48
🌟PFS: HR 1.37, 95% CI 0.74-2.53
🌟OS: HR 1.40, 95% CI 0.70-2.79
🌟Trial closed for futility https://t.co/OS8qkdIbIx
👁 246
❤ 4
🔁 5
May 29
FUZUPRO
Prostate cancer
▼
Interesting phase III data from FUZUPRO in 1L mCRPC: fuzuloparib + AA-P prolonged rPFS over AA-P alone, with notable activity in DRD-positive pts (27.7 vs 13.9 mo; HR 0.51). Safety profile remained manageable without new signals.
#ASCO26 #ProstateCancer
@OncoAlert @ASCO https://t.co/nVLhS0AE3I
👁 1.2K
❤ 23
🔁 12
May 30
#ASCO26 FUZUPRO: fuzuloparib + abiraterone/prednisone improved rPFS in 1L mCRPC, especially DRD+ disease.
Another reminder: PARP + ARPI is strongest when biology guides selection.
@DrYukselUrun @OncoAlert @urotoday #ProstateCancer #oncology @nataliagandur @OncoReporte https://t.co/h1wV1R6CYz
👁 569
❤ 15
🔁 8
May 30
Dr. Ye PhIII FUZUPRO #RCT of #ADT + abi +/- novel #PARPi fuzuloparib in #1L #mCRPC (>75% w/o #HRR mutant) ➡️ sig rPFS benefit 24.8 vs 19.9 mos in favor of fuzu arm, OS immature, G>3 AE 40.2 vs 21.1% control (comparable safety to other PARPi despite newer gen)
#ASCO26 @OncoAlert https://t.co/Vg5VuO9lzm
👁 435
❤ 9
🔁 8
May 30
JAVELIN Bladder Medley
Avelumab maintenance combinations · Urothelial Carcinoma
▼
SAKK 06/19
Bladder-sparing chemoradiation · MIBC
▼
PEACE-3
Enzalutamide + Radium-223 · mCRPC
▼
Delayed survival benefit of enzalutamide + radium-223 in #mCRPC: a reconstructed individual patient data analysis of the PEACE-3 trial. Presentation by @YoshidaSoichiro. #AUA26 written coverage by @RKSayyid > https://t.co/1XrfwFdM5E @AmerUrological https://t.co/j9Fm91MtPG
👁 663
❤ 12
🔁 6
May 19
New data from PEACE-3 presented at #AUA26 highlight the time-dependent survival kinetics of enzalutamide plus radium-223 in patients with #mCRPC.
Although no early advantage was seen during active therapy, non-proportional hazards modeling revealed a delayed but profound
👁 362
❤ 3
🔁 0
May 18
miR-371
miRNA biomarker · Germ-cell / GU
▼
LITESPARK-011
Belzutifan · RCC
▼
🔬 Belzutifan + lenvatinib may reshape post–IO care in advanced RCC.
In phase III LITESPARK-011, the combo improved PFS (14.8 vs 10.7 months), ORR vs cabozantinib.
➡️ Trend toward OS benefit.
🗣️ Presented by @motzermd of @MSK_DeptOfMed at #GU26
https://t.co/PRDKdDovbo https://t.co/xtgExtwPc1
👁 636
❤ 6
🔁 1
May 4
Chris Labaki (@Chrislabaki1
) at #GU26 highlights belzutifan monotherapy & combinations in #KidneyCancer 🧬
LITESPARK-011 shows lenvatinib + belzutifan vs cabozantinib after ICI, shaping #TKI-based algorithms & combo strategies 📊
Watch: https://t.co/QXSF4pHzoB
#gusm
👁 98
❤ 0
🔁 0
May 9
Tian Zhang (@TiansterZhang) highlights key #GU26 data in #KidneyCancer, including LITESPARK-011 & LITESPARK-022 📊
See how these trials can impact clinical practice here: https://t.co/UoCwNAUcpG
#gusm #oncology
👁 67
❤ 0
🔁 0
Apr 29
ProstACT Global
177Lu-rosopatamab (TLX591) · mCRPC
▼
Breast Cancer296 tweets captured
The most important breast abstract from #ASCO26 is out. 4429 pts with ER+/HER2- BC randomized to SoC vs PAM50-directed adjuvant treatment. 19% had N2 dz (4-9 nodes), premenopausal pts received LHRHa. No benefit from chemo if ROR≤60. Looking forward to the full presentation. https://t.co/qX8HnKyBne https://t.co/rAnA0ULjic
👁 16.0K
❤ 124
🔁 44
May 21
Vepdegestrant (PROTAC ER degrader) @US_FDA ✅ for HR+ metastatic breast based off #Veritac2 Ph III vs. (Fulvestrant) after CDK4/6i + AI:
- mPFS 5.0 vs 2.1 mos in ESR1m (HR=0.57)
- OS is immature
- Well-tolerated, low discontinuation
#bcsm @OncUpdates @OncoAlert https://t.co/P4Af81jd9D
👁 15.8K
❤ 59
🔁 27
May 1
Major FDA news today for early-stage HER2+ breast cancer. T-DXd approved for two separate indications: neoadjuvant Stage II/III disease (T-DXd x4 followed by THP x4), and adjuvant treatment for residual invasive disease after neoadjuvant HER2-targeted therapy.
The data are https://t.co/1PGZlov2CK
👁 10.5K
❤ 64
🔁 21
May 15
My Top 10 Breast Cancer Abstracts at #ASCO26 👇 https://t.co/BCHikR7VLK
👁 10.0K
❤ 92
🔁 32
Apr 28
The American Society of Clinical Oncology (@ASCO) meeting is where data is presented.
Our friends at Pulse Health Sciences is where experts decide what to do with it.
Blueprint with convene nationally recognized faculty across GU & Breast Cancer to shape how emerging research https://t.co/aT8vXgUuGZ
👁 8.7K
❤ 61
🔁 19
May 24
🌸 THE 10 MOST IMPORTANT BREAST CANCER TRIALS OF #ASCO26
Chicago is loaded this year.
From ctDNA-guided endocrine switching to frontline ADCs and next-gen HER2 platforms, these are the studies most likely to shape breast oncology practice 👇
🩷 HR+ / HER2- DISEASE
1️⃣ https://t.co/nMoptMhbIO https://t.co/wsAdevStyx
👁 7.6K
❤ 89
🔁 39
May 19
Clinical Trials18 trials with discussion
SERENA-6 — LBA1007
Camizestrant for emergent ESR1 (ctDNA-guided) · HR+ MBC
▼
Why no #odac for $RHHBY Imvigor-011? Pdufa date May 2026, uses ctDNA to guide treatment decision in a similar way to $AZN Serena-6 study of camizestrant - which did get an odac. https://t.co/Wbva0ZJbOR
👁 9.6K
❤ 10
🔁 2
May 14
News from industry: SERENA6 Update in #BreastCancer
Source : AstraZeneca
https://t.co/MdNXkIue2L
EU CHMP has recommended approval of AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor for ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations https://t.co/qvK9sNBLsJ
👁 6.2K
❤ 16
🔁 14
May 22
$AZN #ASCO26 EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI®(durvalumab) and IMJUDO®(tremelimumab-actl) in early liver cancer
Phase III data from SERENA-6, DESTINY-Breast09 and TROPION-Breast02 span all three major subtypes of metastatic breast cancer
CARES https://t.co/8cCKHgXuGa
👁 5.0K
❤ 6
🔁 0
May 22
Today’s #ODAC vote was 6-3 against recommending camizestrant based on #SERENA6.
Not GI, but very relevant to all of us.
The trial asked a really important question:
Can we use ctDNA to detect ESR1 resistance before scans show PD, then switch endocrine therapy early? https://t.co/qeRysSs8Mj
👁 3.3K
❤ 40
🔁 10
Apr 30
Possible reason, on further thought: $AZN Serena-6 proposed giving treatment sooner than standard; $RHHBY Imvigor-011 proposes to eliminate it in patients who might not need it.
👁 2.4K
❤ 2
🔁 0
May 14
@AppleHelix Agreed, and I though Capitello-281 was on far shakier ground than Serena-6. FDA basically told $AZN: if you don't show a strong PFS benefit you need OS. Result: weak PSF, no OS benefit. And yet, Truqap gets the thumbs up. What do I know!
👁 1.9K
❤ 11
🔁 1
May 1
Will the FDA approve $AZN camizestrant despite the 6-3 vote adcom against Serena-6?
👁 1.9K
❤ 1
🔁 0
Apr 30
The Europeans have approved camizestrant upon emergence of an ESR1 mutation. In light of the 6-3 ODAC against this, I wonder if the EU vote will sway the FDA 🤔 #bcsm https://t.co/PbawgQe4HN
👁 1.7K
❤ 5
🔁 2
May 24
Additional data coming #ASCO26 re: #SERENA6 👀
#bcsm https://t.co/oxKWxpfZFn
👁 1.4K
❤ 22
🔁 5
May 27
SERENA-6 Surveillance Data: ESR1 mutations emerge in 42% of patients on AI + CDK4/6i.
One test is not enough — serial ctDNA monitoring is essential.
Early detection → timely switch to camizestrant before progression.
Bidard et al. • SERENA-6
#BreastCancer #ESR1 #ctDNA https://t.co/N3StLhdwXE
👁 1.1K
❤ 18
🔁 5
May 9
The @US_FDA extended the review period for camizestrant plus a CDK4/6 inhibitor in hormone receptor–positive breast cancer with an emergent ESR1 mutation. @jane_meisel @AlexisLeVee @drsarahsam @WinshipAtEmory @EmoryMedicine @UCLAHealth #bcsm #oncology
https://t.co/BpVoBHtqkq
👁 695
❤ 8
🔁 4
May 27
In this time of oral serd controversy (SERENA-6) FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer - The ASCO Post https://t.co/Kf11KqnnUB
👁 665
❤ 5
🔁 2
May 1
@myESMO Breast Cancer 2026: Pre-Conf Top Abstracts
DESTINY-Breast11 | TRAIN-4 | SATEEN | HER2CLIMB-02 | PREcoopERA | PHERGain-2 | PHERGain | MIRINAE | TRAK-ER | CAPItello-291 | TROPION-Breast02 | evERA BC | SERENA-6 | INAV0120 | Saci-IO
#ESMO #ESMOBC26 #ESMOBC2026 #Cancer https://t.co/i8bDLdUJH1
👁 658
❤ 4
🔁 1
May 6
The SERENA-6 trial is still a hot topic, with more updates coming at #ASCO26. Check out this #BreastCancerBreakthroughs video where Drs. Burstein (@DrHBurstein) and Mayer (@elmayermd) review recent #breastcancer results presented at #ESMObreast26.
https://t.co/shlSsNInqw
👁 454
❤ 7
🔁 2
May 28
🔎 FDA News: The #FDA delays camizestrant PDUFA action date as new ctDNA-driven SERENA-6 data aim to prove earlier switching benefits HR+/HER2– #BreastCancer with ESR1 mutations.
Read more: https://t.co/5JDsIApi8U
👁 280
❤ 2
🔁 1
May 27
🟢 $AZN — FDA Designation
EU CHMP Positive Opinion - Camizestrant + CDK4/6 inhibitor for 1L ER+/HER2- advanced breast cancer with ESR1 mutation
CHMP of the EMA recommended camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for approva…
👁 110
❤ 0
🔁 0
May 26
🚨 Latest #Phase 3 Update!
🔷 The CHMP has recommended approval of Camizestrant in combination with a CDK4/6 inhibitor for ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations detected during first-line endocrine therapy.
🔷 The recommendation is based https://t.co/pXxxWdiThH
👁 64
❤ 0
🔁 0
May 25
DESTINY-Breast11
T-DXd · HER2+ early Breast
▼
@allisonoconn @DrHBurstein @stolaney1 @PhilipPoorvu We now have the option of giving 4 cycles of neoadjuvant T-DXd (followed by THP, DB11 regimen) or give NACT, go to surgery, and only give adjuvant T-DXd (14 cycles, DB05 regimen) for patients with high-risk RD. Only the second trial war powered for iDFS, but both are very active! https://t.co/8gYQkpYzAj
👁 4.6K
❤ 48
🔁 14
May 16
#ESMOBreast26
DESTINY-Breast11: T-DXd→THP improved favorable RCB-0/I rates across all major HER2+ EBC subgroups 👀
🔹 HR+: 78.0% vs 64.7%
🔹 HR-: 90.4% vs 81.2%
🔹 Node-negative: 80.8% vs 68.6%
🔹 Node-positive: 81.5% vs 69.8%
📌 Benefit extended beyond pCR alone
📌 Residual https://t.co/zD3kxEp8aU https://t.co/K0CzX5q93i
👁 4.3K
❤ 18
🔁 11
May 6
🚨 FDA expands the role of Enhertu in curative-intent HER2+ early breast cancer.
AstraZeneca + Daiichi Sankyo’s trastuzumab deruxtecan is now approved in the US in BOTH:
🔹 Neoadjuvant setting (DESTINY-Breast11)
🔹 Adjuvant residual disease setting (DESTINY-Breast05)
Key data https://t.co/6901MjMVyP
👁 4.1K
❤ 74
🔁 26
May 16
🚨 DESTINY-Breast11 LBA1 at #ESMOBreast26
Can neoadjuvant T-DXd reshape cure-intent HER2+ breast cancer? 👀
T-DXd → THP achieved deeper responses vs standard ddAC-THP, with markedly higher favorable residual cancer burden (RCB-0/I) rates across ALL subgroups.
🔹 T-DXd → THP https://t.co/RDMSMz1PAu https://t.co/hwB5ljn3wY
👁 3.9K
❤ 30
🔁 12
May 6
DESTINY-Breast11 (DB-11) – RCB Analysis
T-DXd-THP significantly improves Residual Cancer Burden compared to standard ddAC-THP in high-risk HER2+ early breast cancer.
Key Highlights:
• RCB-0+I rate: 81.3% vs 69.1% (+12.2%)
• Consistent benefit across all subgroups (HR+, HR–, https://t.co/MR1PIF8nfl
👁 3.8K
❤ 36
🔁 7
May 5
With @myESMO Breast Cancer 2026 around the corner, we asked leading AI models to identify the most anticipated trials in breast cancer, here’s their combined ranking.
There's strong consensus around trials like DESTINY-Breast11, SATEEN, and TRAIN-4—highlighting continued https://t.co/chZm3F3kzf
👁 2.2K
❤ 21
🔁 8
Apr 27
1. DESTINY-Breast11 (Update): Ph III, NeoAdj, TDXd -> THP vs ddAC -> THP in high risk Her2+ early breast cancer
- Improved residual cancer burden (81.3% vs. 69.1%)
- ⬆️ pCR: 68.8% vs. 57.5%
- Awaiting OS
2/7 https://t.co/6INj42pZPL https://t.co/kbOFJ9dNnJ
👁 1.5K
❤ 6
🔁 0
May 9
Ahead of @ESMO BC 2026, we asked leading AI models to identify the most anticipated oncology trials. Now, comparing those predictions to engagement on 𝕏, here’s what stood out 👇
👉 Strong alignment at the top:
SATEEN and DESTINY-Breast11 were consistently identified across https://t.co/LDafFuhqwo
👁 1.1K
❤ 15
🔁 11
May 11
FDA Approval based on DESTINY-Breast11 and DESTINY-Breast05 in #BreastCancer
https://t.co/9N3IlAa0fX
The FDA approved fam-trastuzumab deruxtecan-nxki for two HER2-positive early-stage breast cancer indications: neoadjuvant therapy for Stage II/III disease followed by THP, and https://t.co/h5EYySZXRF
👁 1.1K
❤ 24
🔁 12
May 16
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and https://t.co/YQRtdZK629
👁 1.0K
❤ 17
🔁 3
May 16
DESTINY-Breast11:
T-DXd–Based Neoadjuvant Therapy Outperforms Anthracycline-Containing Regimens in High-Risk HER2+ EBC, Delivering Higher pCR and RCB 0/1 Rates and Supporting a Shift Toward an Anthracycline-Free Standard
@OncoAlert #ESMOBreast26 https://t.co/vuUL2XQInn
👁 924
❤ 24
🔁 8
May 6
Top Trials to Follow on Day 1 @myESMO Breast Cancer 2026.
DESTINY-Breast11 | PHERGAIN-2 | MIRINAE | TRAK-ER | PREcoopERA
#ESMO #ESMOBC26 #ESMOBC2026 #Cancer #Oncology #BreastCancer #TNBC #BCSM #trastuzumab #Tdxd #pertuzumab #TDM1 #atezolizumab #giredestrant #OncologyEvents https://t.co/BDZSXX8azz
👁 549
❤ 3
🔁 0
May 6
🚨 #FDA APPROVAL: The FDA has approved fam-trastuzumab deruxtecan (Enhertu) for 2 new indications in early-stage HER2+ #BreastCancer: one neoadjuvant (DESTINY-Breast11) and one adjuvant (DESTINY-Breast05) https://t.co/CqK5GUHTpg
👁 511
❤ 8
🔁 1
May 16
DESTINY-Breast11
Across all subgroups, residual disease is reduced with T-DXd-THP versus ddAC-THP
#esmobreast26
@OncoAlert https://t.co/kzPYxWJMST
👁 468
❤ 9
🔁 5
May 6
FDA has granted two new approvals for ENHERTU (trastuzumab deruxtecan) in HER2-positive early breast cancer.
🔹 Neoadjuvant setting (DESTINY-Breast11)
🔹 Adjuvant treatment for residual disease (DESTINY-Breast05)
Some remarkable findings:
* pCR rate:
67.3% vs 56.3%
* 53% https://t.co/3DJfmviGaY
👁 444
❤ 3
🔁 1
May 18
👀 Reduced RCB was shown for neoadjuvant T-DXd followed by THP compared with ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer, according to data from the phase 3 DESTINY-Breast11 trial.
Read more here ➡️: https://t.co/A3pZFtUxf2
#bcsm #oncology
👁 405
❤ 2
🔁 0
May 23
An analysis of DESTINY-Breast11 showed neoadjuvant T-DXd followed by THP improved residual cancer burden vs ddAC-THP in early-stage HER2+ breast cancer @myESMO #ESMOBreast26
Read more on the latest data here: https://t.co/wSQXtmjZSP https://t.co/AUeC9ze23b
👁 271
❤ 1
🔁 1
May 6
$AZN $DSNKY
Daiichi Sankyo and AstraZeneca’s Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
- Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3
👁 173
❤ 0
🔁 0
May 16
$AZN $DSNKY
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
- Approved for use before surgery based on DESTINY-Breast11 Phase III trial
- Approved for use
👁 156
❤ 0
🔁 0
May 16
@DrSGraff Impressive DESTINY-Breast11 results. T-DXd delivering 81% RCB-0/I rates could spare many HER2+ patients from aggressive surgery. Fewer complications, better quality of life. This is precision oncology transforming care. 🧬
👁 52
❤ 1
🔁 0
May 6
🟢 $AZN — FDA Approval
FDA Approval - Enhertu neoadjuvant for HER2-positive Stage II/III early breast cancer (DESTINY-Breast11)
FDA approved Enhertu (trastuzumab deruxtecan) followed by THP as neoadjuvant treatment for adult patients with HER2-positive Stage II or Stage III b…
👁 38
❤ 0
🔁 0
May 18
OPTIMA — Abs 500
Test-directed chemotherapy · High-risk ER+/HER2- Early Breast (Phase 3)
▼
🚨 The OncoAlert #BreastCancer faculty’s TOP 10 abstracts for #ASCO26 — selected by our leads and finalized through a Delphi voting process with senior breast cancer experts.
1️⃣ 500 — OPTIMA
Test-directed chemotherapy in high-risk ER+/HER2- early BC
2️⃣ LBA1006 — PERSEVERA BC https://t.co/FJSHDjv3Ln
👁 16.1K
❤ 65
🔁 39
May 25
#OPTIMA looked at Prosigna ability to predict chemo benefit in higher nodal burden ER+ #bcsm
🎙️pts with ROR ≤60 could avoid chemo, incl. premeno >40 receiving OFS AND higher N+ disease
***limitations: 63% of pts <5 yrs f/u, no one <40 yrs
#ASCO26 https://t.co/C4pi3T5WBO
👁 4.6K
❤ 29
🔁 13
May 30
💫🌟🚨 Top 10 #BreastCancer abstracts for #ASCO26 — selected by our leads and finalized via a Delphi voting process 🗳️🔬
1️⃣ 500 — OPTIMA
2️⃣ LBA1006 — PERSEVERA BC
3️⃣ 507 — KEYNOTE-522 final analysis
4️⃣ LBA1007 — SERENA-6
5️⃣ 502 — LIDERA BC
6️⃣ LBA1000 — ASCENT-04
7️⃣ 501 — NATALEE https://t.co/3BPHgMO1ct
👁 2.8K
❤ 23
🔁 14
May 25
First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
#ASCO26 Abstract Preview
https://t.co/vm2tCjbnd8
The OPTIMA trial evaluated Prosigna https://t.co/tLC2NO2dw9
👁 1.5K
❤ 18
🔁 8
May 25
#asco26. Stein presents data from optima. Using Prosigna to determine chemo benefit in early HR+ BC. Premenopausal women <40 where we stillneed info excluded. Shows Prosigna identifies N+ pts unlikely to benefit from chemo. IMP! 1500 older premen pts included. @OncoAlert https://t.co/MeAaes5bL9
👁 855
❤ 15
🔁 13
May 30
Dr Piccart reinforces that OPTIMA for the first time prospectively shows the chemo benefit for premenopausal low GEP women, is mostly due to chemotherapy induced ovarian suppression. https://t.co/QNSOtlyjqm
👁 638
❤ 12
🔁 8
May 30
@Dr_RShatsky @DrSGraff @hoperugo @ErikaHamilton9 @laura_huppert @stolaney1 @BCJoyceO @AnnPartridgeMD @JAMouabbi @KalinskyKevin If you are taking the Optima approach for premeno or N2 patients, use Prosigna….
👁 566
❤ 9
🔁 4
May 30
#ASCO26
Abstract #500
OPTIMA phase III trial - Test-directed chemotherapy in high clinical risk ER+/HER2- early breast cancer. https://t.co/D2JTC41yd7
👁 415
❤ 4
🔁 2
May 26
OPTIMA Redefines Adjuvant Therapy in HR+/HER2− Breast Cancer
Molecular risk not nodal burden alone, should guide chemotherapy decisions.
Prosigna-directed de-escalation maintained excellent outcomes while reducing overtreatment.
#ASCO26 #BreastCancer @OncoAlert #bcsm @ASCO https://t.co/E8yZHJRosE
👁 385
❤ 15
🔁 5
May 30
#ASCO26 oral eBC: OPTIMA trial supports chemo de-escalation in high-risk ER+/HER2− EBC.
A prosigna-directed tx was non-inferior to standard chemo for 5-yr IBCFS, allowing pts with ROR ≤60 to avoid CT, incl. premenopausal pts receiving OFS and N+ disease
@ASCO @OncoAlert https://t.co/h8A9wBqrRX
👁 324
❤ 9
🔁 5
May 30
OPTIMA study is the most practice changing for breast cancer at #ASCO26. No chemotherapy for low ROS score, 50 gene Prosigna by @Veracyte, for much more advanced early breast cancer compared to OncotypeDx indication by @ExactSciences. https://t.co/doMgW9boAP
👁 225
❤ 1
🔁 1
May 30
📌First results from the OPTIMA phase Ill randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
✨Robert C. Stein at #ASCO26
🔗 OPTIMA demonstrates that the 50-gene Prosigna test https://t.co/5QI1xj6u3k
👁 149
❤ 3
🔁 1
May 30
We are proud to announce results from the landmark independent #OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (@ucl).
The results, which will be presented at the #ASCO26 Annual Meeting, https://t.co/MZ83em7Flz
👁 137
❤ 0
🔁 2
May 29
#Asco26
OPTIMA trial: PROSIGNA identifies HR+HER2- BC not benefiting from adj chemo in pts aged 40 or above (including premenopausal receiving OFS)
Pts with pN2 included but numerically small subgroup
@OncoAlert https://t.co/il2PLruUUP
👁 16
❤ 1
🔁 0
May 30
lidERA BC — Abs 502
Adjuvant Giredestrant · Early ER+/HER2- Breast
▼
#ASCO26
Oral SERDs moving earlier in breast cancer?
The phase III lidERA trial shows adjuvant giredestrant improved outcomes vs standard endocrine therapy across BOTH premenopausal and postmenopausal HR+/HER2− early breast cancer.
🔹 Premenopausal:
• IDFS HR 0.65
• 42% https://t.co/5U53Qarltl https://t.co/cL8NHWlJqh
👁 3.5K
❤ 23
🔁 14
May 26
Benefit of adjuvant giredestrant over SoC endocrine treatment was observed irrespective of menopausal status, with a trend towards larger benefit in premenopausal patients. Comparable tox with giredestrant vs AI also seen irrespective of menopausal status (ie unrelated to OFS) https://t.co/0Ty9nFuL2e
👁 3.0K
❤ 26
🔁 14
May 30
#ASCO26 🌸 Could oral SERDs reshape adjuvant endocrine therapy in early breast cancer?
The phase III lidERA trial tested adjuvant giredestrant vs standard endocrine therapy in ER+, HER2-negative early breast cancer.
🧪 Study design
• Phase III, global, open-label
• N = 4170 https://t.co/UtSfqtCVf7 https://t.co/VNM289lCI0
👁 2.5K
❤ 17
🔁 9
May 30
#ASCO26
In lidERA, adjuvant giredestrant maintained its IDFS/DRFI benefit regardless of menopausal status.
Oral SERDs are entering the adjuvant HR+/HER2− space. However, the optimal strategy remains unclear: upfront oral SERD, a switch strategy after 2–3 years of AI, or https://t.co/BykiHBzzQz
👁 1.7K
❤ 22
🔁 8
May 30
ASCO 2026 Update — lidERA Trial
Menopausal Subgroup Analysis
• Giredestrant improved IDFS and DRFI across both menopausal groups
• Strongest signal seen in PRE-menopausal patients
• ~42% relative reduction in recurrence risk in PRE-menopausal subgroup
• Particularly notable https://t.co/S5kQm3SH7T
👁 1.6K
❤ 28
🔁 6
May 24
lidERA BC #ASCO26
Giredestrant (oral SERD) demonstrated consistent IDFS benefit over standard-of-care endocrine therapy in ER+/HER2− early breast cancer — regardless of menopausal status.
IDFS HR:
Pre-menopausal: 0.65 (3-yr rate: 94.0% vs 91.5%)
Post-menopausal: 0.74 (3-yr https://t.co/a68OFsxDKT
👁 929
❤ 16
🔁 7
May 30
🦴 😀 Giredestrant discont were < than AI...largely due to ⬇️ arthralgias (finally!!!)
We have CDK 4/6 also approved for ⬆️ risk ER+ adj #bcsm, lidERA did not account for this..are trials coming that did...but still may be a very reasonable option for many pts
#ASCO26 https://t.co/RtigzsBEv6
👁 901
❤ 16
🔁 5
May 30
Martine Piccart has crowned giredestrant the new queen 👑 of adjuvant ET! And the 👑 rules across menopausal status:
At #ASCO26, adjuvant giredestrant demonstrated consistent IDFS and DRFI benefit in both pre- and post-menopausal HR+ early breast cancer, with fewer https://t.co/mN06xTPr7k
👁 875
❤ 15
🔁 6
May 30
3. lidERA: PhIII, Adj giredestrant (SERD) vs. AI/Tamox in ER+, HER2– early breast cancer:
- 3yr IDFS (premenopausal): 94% vs. 91.5% (0.65)
- 3yr IDFS (postmenopausal): 91.3% vs. 88.3% (HR: 0.74)
- Less discontinuation rate with Girdestrant
- Awaiting approval
4/7 https://t.co/UsihAVIgiJ https://t.co/pibTsN6cti
👁 805
❤ 7
🔁 1
May 30
Interesting slide but are we ready to accept Giredestrant as new soc in adjuvant endocrine space ? @drsarahsam @dr_yakupergun @asco #asco26 https://t.co/98w23DDBnM
👁 778
❤ 6
🔁 3
May 30
Interesting tension from lidERA at #ASCO26
Where does adjuvant giredestrant actually fit in 2026?
🟡 Medium risk:
Could replace upfront ET in patients not meeting CDK4/6 criteria?
🟠 High risk:
After AI + CDK4/6… is there still incremental benefit?
Promising biology. https://t.co/UsOgPpofac https://t.co/nc2m8tS4FO
👁 770
❤ 6
🔁 3
May 30
One underrated lidERA signal at #ASCO26
Less musculoskeletal pain-related discontinuation with giredestrant vs standard ET.
If efficacy holds long term, tolerability may become the real differentiator in adjuvant ER+ therapy.
@OncoAlert @ASCO @myesmo @esmo_open @larvol https://t.co/4L1Bhuj4aM https://t.co/t68oaQeH5W
👁 680
❤ 10
🔁 6
May 30
📌 Efficacy and safety of giredestrant
in patients with estrogen receptor-positive, HER2-negative early breast cancer in the phase III lidERA
BC clinical trial: Results by menopausal status. presented by Peter Schmid✨#ASCO26 @OncoAlert #OncoAlertAF #BreastCancer https://t.co/baSbZioquz
👁 387
❤ 9
🔁 8
May 30
#ASCO26 oral eBC: LidERA analysis by menopausal status demonstrated consistent benefit of adj Giredestrant in both pre- and post-menopausal pts.
@ASCO @OncoAlert https://t.co/my5KChlpe5
👁 362
❤ 6
🔁 4
May 30
#ASCO26
Efficacy and safety of giredestrant (GIRE) in ER+/HER2− early breast cancer by menopausal status - lidERA BC trial https://t.co/fU6YOvj5mv
👁 332
❤ 5
🔁 2
May 26
LidERA results by menopausal status
Premenopausal pts (41%) show similar benefit to postmenopausal pts (HR 0.65 and HR 0.74, respectively)
Less discontinuations with giredestrant due to muscular skeletal events in premenopausal pets
@OncoAlert #Asco26 https://t.co/oLBMx6RjGc
👁 325
❤ 8
🔁 7
May 30
lidERA subgroup analysis by menopausal age:
Both pre and postmenopausal patients benefited with Giredestrant. https://t.co/OGv8JgIzUG
👁 321
❤ 8
🔁 3
May 30
LiDERA BC study showed that the giredestrant works for any menopause status. Also no difference in side effects profile. Safe and effective. This will be the next standard of care. How to balance with adjuvant CDK 4/6 inhibitor. https://t.co/mutGzibBCZ
👁 236
❤ 3
🔁 0
May 30
#ASCO26 lidERA data!!!!
Adjuvant giredestrant demonstrated meaningful IDFS benefit over SOC endocrine therapy in ER+/HER2- early breast cancer — regardless of menopausal status. Pre-menopausal: HR 0.65 / Post-menopausal: HR 0.74
Distant recurrence risk also reduced (HR 0.58 & https://t.co/lTSFKIEvR5
👁 209
❤ 6
🔁 2
May 30
Recurrence remains a challenge in HR+/HER2- early #breastcancer. Phase 3 lidERA trial previously showed improvement with giredestrant (oral SERD) vs standard hormone therapy 📈
Peter Schmid, MD, PhD presents results by menopausal status at #ASCO26 @ASCO https://t.co/Z7sH96ZZWU
👁 184
❤ 2
🔁 2
May 30
📣lidERA Update📣
🔸Pts with + eBC high/medium risk ➡️ giredestrant (w/ OFS premen) vs SOC ET x 5 yrs
🔸40.7% premen
🔸58% of premen pts on SOC ET tamoxifen received OFS
🔸3 yr iDFS premen 94% vs 91.4% (HR 0.65)
🔸3 yr iDFS postmen 91.3% vs 88% (HR 0.74) https://t.co/vXsD2FYZqL
👁 124
❤ 0
🔁 1
May 30
1/5 New Phase III data on giredestrant (lidERA & persevERA trials) at #ASCO26 shows potential as future standard of care in HR+ breast cancer.
https://t.co/KIGt8SdDBi
#breastcancer #OncoTwitter #cancerresearch
👁 18
❤ 0
🔁 0
May 19
DESTINY-Breast05
T-DXd · HER2+ Breast
▼
#ASCO26
DESTINY-Breast05 ILD analysis
ILD was more frequent with T-DXd.
Interesting signal:
ILD was more common in Japan.
Genetic susceptibility, imaging/diagnostic threshold, reporting practice, and RT techniques may all contribute.
RT timing does not seem to make a major https://t.co/VVzSea55fR
👁 7.8K
❤ 44
🔁 23
May 25
Adjuvant T-DXd is approved for pts with HER2+ BC and high-risk RD by DB05 criteria. What about pts with lower risk RD? We looked at ~10.000 pts in Flatiron, finding that 52% have low-risk RD, with 3yr DRFS 94%, suggesting that T-DM1 remains an adequate SoC for them. #ASCO26 Ab545 https://t.co/95xFq5O3Gq
👁 3.4K
❤ 60
🔁 19
May 28
T-DM1 or T-DXd after neoadjuvant therapy?
Residual HER2+ disease after NAC does not automatically mean adjuvant T-DXd.
🔹 KATHERINE → any residual invasive disease qualified for T-DM1
🔹 DESTINY-Breast05 → T-DXd studied in higher-risk residual disease
Key high-risk features https://t.co/t7EORh59x2
👁 2.4K
❤ 37
🔁 9
May 17
KATHERINE ≠ DESTINY-Breast05
Both addressed residual HER2+ disease after neoadjuvant therapy — but NOT the same baseline-risk population.
DESTINY-Breast05 enrolled a much more modern, treatment-exposed, higher-risk cohort: • ~81% ypN+
• ~52% initially inoperable disease
• https://t.co/RozmwjUBDN
👁 1.6K
❤ 30
🔁 10
May 17
DESTINY-Breast05 may redefine post-neoadjuvant HER2 escalation.
In ultra-high-risk residual HER2+ disease: • T-DXd significantly outperformed T-DM1
• 3-year IDFS: 92.4% vs 83.7%
• HR 0.47 → ~53% lower invasive recurrence/death
• Fewer distant + CNS recurrences
But: • https://t.co/AJwNs4cQhm
👁 1.3K
❤ 21
🔁 5
May 17
T-DXd + Radiation?
What DESTINY-Breast05 really showed:
• >50% received concurrent RT
• RT pneumonitis rates were similar with T-DXd and T-DM1
• Most events were low-grade RT-related findings
• Intensive CT surveillance likely increased detection
• True drug-related ILD https://t.co/jYZ9ayTpRA
👁 1.2K
❤ 16
🔁 6
May 17
TROPION-Breast02
Dato-DXd vs Chemotherapy · Metastatic TNBC
▼
#datoDXd FDA approved 1st line TNBC among pts who are not a candidate for immunotherapy
Not 1️⃣, not 2️⃣, but now 3️⃣ approvals in #bcsm this month!
#vepdegestrant
#TDxd neoadj/adj
#datodxD 1st L
https://t.co/FXeEAWVkqE
👁 9.5K
❤ 48
🔁 19
May 22
Dato-DXd now has FDA approval for first-line TNBC👇
TROPION-Breast02 https://t.co/AyfETdQNay
👁 4.8K
❤ 49
🔁 18
May 22
#ASCO26 🚨 Dato-DXd may be redefining frontline TNBC for patients ineligible for immunotherapy.
TROPION-Breast02 now shows benefit extending beyond initial progression:
📉 PFS2
📉 Time to first subsequent therapy
📉 Time to second subsequent therapy
🧵 Key results from Abstract https://t.co/K8SSiTMbWw
👁 1.8K
❤ 28
🔁 9
May 27
#ASCO26
Abstract #1002 - TROPION-Breast02: First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in metastatic TNBC unsuitable for immunotherapy. https://t.co/CDxpBP7K3c
👁 597
❤ 3
🔁 1
May 27
KEYNOTE-522
Pembro · TNBC neoadjuvant
▼
KEYNOTE-522 Final Analysis #ASCO26
8-year follow-up data confirms the enduring survival benefit of pembrolizumab in high-risk early-stage TNBC.
Overall Survival at ~84 months:
Pembro + Chemo/Pembro: 85.1%
Placebo + Chemo/Placebo: 77.2%
→ HR 0.64 (95% CI 0.49–0.85)
Event-Free https://t.co/IemEQL8sh1
👁 3.5K
❤ 24
🔁 4
May 30
#ASCO26 🚨 KEYNOTE-522 Final Analysis
Nearly 8 years later, the pembrolizumab story in early-stage TNBC keeps getting stronger.
Adding neoadjuvant + adjuvant pembrolizumab to chemotherapy delivered durable survival gains in high-risk early-stage TNBC:
🔹 EFS: HR 0.68
🔹 OS: HR https://t.co/LRVu67NZ6x https://t.co/Y1qhTMeSnK
👁 3.0K
❤ 9
🔁 4
May 30
8-year results from KEYNOTE-522 presented by @JavierCortesMD. Adding perioperative pembro to neoadjuvant chemo prevents ~10% recurrences and ~7% deaths from TNBC. A tough neoadjuvant regimen, but one that clearly saves lives. No TILs data presented yet, unfortunately. #ASCO26 https://t.co/Hmt376Lsu9
👁 2.7K
❤ 45
🔁 19
May 30
Final Subgroup analysis of Keynote 522 shows benefit irrespective of PDL1 status.
Age >65y appears to be a tricky population
But this was not powered for that and sample size is too small
Complete subgroup analysis ⬇️
#ASCO26
@ASCO @OncoAlert https://t.co/YvKnOY07Zm https://t.co/3uqXedoKlB
👁 1.4K
❤ 11
🔁 8
May 30
#ASCO26 to watch — #507 KEYNOTE-522
Final analysis (median FU ~7.8 years): 7-year EFS and OS for neoadj pembro + chemo in high-risk early TNBC.
The longest follow-up of an ICI in curative-intent BC.
Discussion points:
👁 1.1K
❤ 7
🔁 1
May 28
Final Analysis at 94 months for KEYNOTE-522 @JavierCortesMD @OncoAlert #ASCO26 https://t.co/ODKsmcyZjH
👁 1.0K
❤ 6
🔁 7
May 30
1. KEYNOTE-522 (final OS Update): current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk early TNBC.
- 7yr EFS: 78.3% vs. 69.8%
- 7yr OS: 85.1% vs. 77.2%
- OS benefit seen regardless of pCR status
- Reaffirms our current SoC
2/7 https://t.co/i0JKHADsTf https://t.co/lMgceXaDf7
👁 643
❤ 5
🔁 2
May 30
📌 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed
by adjuvant pembrolizumab or placebo for high-risk early-stage
TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.
Presented by @JavierCortesMD ✨
#ASCO26 @OncoAlert #OncoAlertAF
#BreastCancer https://t.co/CJ7z9n0Su0
👁 453
❤ 7
🔁 7
May 30
Why is the phase 3 KEYNOTE-522 study one to watch? @ErikaHamilton9 shares her perspective ahead of #ASCO26. Read more in the @OncLive article: https://t.co/LUJHPOWQhH
#CancerResearch #ASCO26
👁 331
❤ 4
🔁 2
May 14
🚨🎗️ ASCO26 | KEYNOTE-522 Confirms Long-Term Benefit of Pembrolizumab in High-Risk Early TNBC
Presenter: Sarah Sammons
With nearly 8 years of follow-up, KEYNOTE-522 continues to demonstrate durable benefit from the addition of pembrolizumab to neoadjuvant chemotherapy followed https://t.co/incGAI9VpO
👁 178
❤ 2
🔁 2
May 30
SAKK 96/12 REDUSE — Abs 1004
Denosumab q12w vs q4w · Skeletal events (Phase 3)
▼
REDUSE (SAKK 96/12) at #ASCO26 (Abstr 1004, oral): can denosumab be de-escalated in bone-metastatic cancer without losing skeletal protection?
In patients with breast cancer or CRPC and ≥3 bone metastases (n=1,380), denosumab every 12 weeks — after 4x monthly loading — was
👁 7.3K
❤ 30
🔁 12
May 22
#ASCO26
SAKK 96/12 REDUSE
Important data on denosumab dosing interval in patients with bone-metastatic breast cancer / CRPC.
After a 3-month loading phase, Q12W denosumab was found to be non-inferior to Q4W!
Toxicity also favored Q12W.
After the first 3 months, Q12W https://t.co/IGgPc4mGA6
👁 1.2K
❤ 25
🔁 15
May 26
REDUSE (SAKK 96/12) at #ASCO26 (Abstr 1004, oral): can denosumab be de-escalated in bone-metastatic cancer without losing skeletal protection?
In patients with breast cancer or CRPC and ≥3 bone metastases (n=1,380), denosumab every 12 weeks — after 4 months of monthly loading —
👁 9
❤ 0
🔁 0
May 22
REDUSE (SAKK 96/12) at #ASCO26 (Abstr 1004, oral): can denosumab be de-escalated in bone-metastatic cancer without losing skeletal protection?
In patients with breast cancer or CRPC and ≥3 bone metastases (n=1,380), denosumab every 12 weeks — after ~3 months of monthly loading
👁 4
❤ 0
🔁 0
May 22
NATALEE
Ribociclib + NSAI adjuvant · HR+/HER2- Early Breast (gene-expression analysis)
▼
#ASCO26 🧬 Not all HR+/HER2- early breast cancers behave the same.
New biomarker analysis from NATALEE suggests adjuvant ribociclib benefits were seen across ALL PAM50 subtypes, with a possible trend toward greater benefit in genomically higher-risk disease.
📌 3022 tumor https://t.co/xkes3EFLS6 https://t.co/cL8NHWlJqh
👁 3.2K
❤ 29
🔁 6
May 26
NATALEE Biomarker Analysis
#ASCO26
Ribociclib + NSAI demonstrated consistent iDFS benefit across all PAM50 intrinsic subtypes in HR+/HER2− early breast cancer — regardless of luminal A, luminal B, HER2-enriched, or basal-like classification (interaction P=.34).
iDFS HR: 0.71 https://t.co/JmH2S6nEJb
👁 1.4K
❤ 5
🔁 2
May 30
Benefit of #ribociclib in #NATALEE:
- persists across intrinsic subtypes
- is greater in pts with higher risk tumors
- may be variable based on certain gene expression ( ⬆️ benefit CEACAM6, ⬇️ CDK4, GATA3 etc)
#ASCO26 #bcsm https://t.co/7BlAYcA46M
👁 855
❤ 15
🔁 11
May 30
Exciting NATALEE update presented today at #ASCO26 (Abstract 501)!
New gene expression analysis from the largest biomarker dataset in any adjuvant CDK4/6i trial shows ribociclib + NSAI iDFS benefit is consistent across all PAM50 subtypes (66% LumA, 28% LumB, 3% HER2E, 3%
👁 477
❤ 12
🔁 5
May 30
#ASCO26
NATALEE trial: PAM50 subtypes
PAM50 subtypes were prognostic: compared with Luminal A, the risk was higher in Luminal B, HER2-enriched, and basal-like subtypes.
The HRs for ribociclib were 0.77 in Luminal A, 0.71 in Luminal B, 0.50 in HER2-enriched, and 0.42 in https://t.co/nl7snq5mPd
👁 451
❤ 7
🔁 4
May 30
Abstract 501 - NATALEE biomarker analysis #ASCO26
Prognostic and predictive impact of baseline gene expression in adjuvant ribociclib + NSAI for HR+/HER2- early breast cancer. https://t.co/GgwOHCYSHC
👁 424
❤ 3
🔁 1
May 26
#ASCO26 oral eBC: NATALEE biomarker data confirm broad RIB + ET benefit in HR+/HER2− eBC. Benefit was seen across PAM50 subtypes, with a trend for greater effect in high genomic-risk/proliferative tumors.
➡️ We are still missing predictive biomarker to better select pts that https://t.co/IZAkRu15ak
👁 297
❤ 10
🔁 3
May 30
NATALEE Trial:
Consistent iDFS Benefit with Ribociclib Across All PAM50 Intrinsic Subtypes in HR+/HER2− Early #BreastCancer
@OncoAlert @ASCO #ASCO26 #bcsm https://t.co/Xa11SvqEDs
👁 274
❤ 11
🔁 4
May 30
NATALEE gene-expression analysis presented #asco26
Ribociclib benefit seen across all PAM50 intrinsic subtypes
Trend toward greater benefit for higher genomic risk or proliferation signatures
Expression of several gene associated with increased ribociclib benefit
@OncoAlert https://t.co/mD6HunXsdF
👁 99
❤ 4
🔁 5
May 30
ASCENT-04 — LBA1000
Sacituzumab Govitecan + Pembro vs Chemo+Pembro · 1L PD-L1+ mTNBC
▼
#ASCO26 🔥
ASCENT-04 biomarker analysis strengthens the 1L mTNBC story:
SG + pembrolizumab beat chemo + pembrolizumab across biomarker groups.
Key signal:
🧬 Trop-2 benefit in all quartiles
Strongest in higher Trop-2:
Q3 HR 0.46
Q4 HR 0.57
BRCA:
WT HR 0.67
mut HR 0.88
HER2: https://t.co/uOKAY6i6zy https://t.co/cL8NHWlJqh
👁 6.5K
❤ 45
🔁 15
May 25
ASCENT-04 (Tolaney et al., ASCO 2026)
Trop-2 may enrich benefit magnitude—but no biomarker subgroup clearly lost benefit.
SG + pembrolizumab demonstrated consistent activity across evaluated Trop-2, BRCA, and HER2-defined subgroups in PD-L1+ metastatic TNBC.
#ASCO2026 #TNBC https://t.co/OUsr5JQX2r
👁 151
❤ 2
🔁 0
May 29
VIKTORIA-1
Gedatolisib + Fulvestrant ± Palbociclib · post-AI/CDK4-6i HR+/HER2- (Phase 3)
▼
Case in point for my prior statement on infographics for. AI. This infographic is straight up wrong. VIKTORIA 1 is gedatolisib + fulvestrant+ palbociclib. Not giredestrant +ribo. This stuff has to stop. @ASCO #ASCO2026 https://t.co/lAEJhnPzSb
👁 6.6K
❤ 20
🔁 3
May 26
Case in point fr my prior statement on infographics, this infographic is wrong. VIKTORIA 1 is gedatolisib + fulvestrant+ palbociclib. Not giredestrant +ribo. This stuff has to stop. @ASCO #ASCO2026 https://t.co/quuMVrlcpI
👁 76
❤ 0
🔁 0
May 26
ASCENT-03 — Abs 1001
Sacituzumab Govitecan vs Chemo · 1L untreated mTNBC (PFS2)
▼
#ASCO26 Abstracts 1001 and 1002.
Both follow up on trials that already changed frontline #mTNBC in 2025.
#ASCENT03 (Abstract 1001): #sacituzumab_govitecan established at ASCO 2025. Now, does the PFS benefit hold beyond first progression? PFS2 18.2 vs 14.0 months. HR 0.70.
>Yes!
👁 3.4K
❤ 21
🔁 10
May 25
#ASCO26
ASCENT-03 PFS2 analysis
PFS2 difference was 4.2 mo✅️
This is notable because 82% of patients in the chemo arm received SG as subsequent therapy.
Despite this crossover, earlier SG still maintained a PFS2 advantage.
This strengthens the argument for using SG in 1L https://t.co/OujxUZWxfR
👁 1.9K
❤ 27
🔁 13
May 26
#ASCO26 🚨 ASCENT-03 reinforces the durability of first-line sacituzumab govitecan in PD-L1–negative mTNBC.
Even after crossover and subsequent therapies, the PFS2 benefit persisted.
🔹 PFS2: 18.2 vs 14.0 mo
🔹 HR 0.70 (P=.0051)
🔹 18-mo PFS2: 52% vs 41%
This matters because https://t.co/PVDBYTeqon https://t.co/cL8NHWlJqh
👁 747
❤ 7
🔁 2
May 27
#ASCO26 Abstract 1001 - ASCENT-03: PFS2 and subsequent therapies with sacituzumab govitecan vs chemotherapy in previously untreated mTNBC. https://t.co/j45emY1iFo
👁 367
❤ 5
🔁 1
May 27
DESTINY-Breast09
T-DXd + Pertuzumab · 1L HER2+ MBC
▼
DESTINY-Breast09 exploratory analysis (#ASCO2026)
T-DXd + pertuzumab responses continued to deepen over time in HER2+ metastatic breast cancer.
PRs evolved into CRs. Median time to CR: 8.4 months. Maximum shrinkage: ~11 months.
Key message: Do not judge T-DXd response too https://t.co/BOgqABsE3x
👁 1.0K
❤ 24
🔁 8
May 26
Redefining 1L HER2+ Metastatic #BreastCancer:
From CLEOPATRA to ADC-Driven Precision Strategies 🧬
Emerging evidence from DESTINY-Breast09, HER2CLIMB-05, and PATINA highlights a major evolution toward biologically tailored frontline therapy integrating:
@OncoAlert #ESMOBreast26 https://t.co/j8jG0xAuNJ
👁 843
❤ 15
🔁 5
May 7
DESTINY-Breast09 #ASCO2026
Chemotherapy often gives an early hit.
T-DXd + pertuzumab appears different — responses continue maturing over time.
PR at the first scans may not be the final story.
“The first scan may not show the final benefit.”
Park et al
HER2+ metastatic https://t.co/mO55vgLUuy
👁 680
❤ 17
🔁 1
May 26
DESTINY-Breast09 exploratory analysis (#ASCO2026)
T-DXd + pertuzumab responses continued to deepen over time in HER2+ metastatic breast cancer.
PRs evolved into CRs. Median time to CR: 8.4 months. Maximum shrinkage: ~11 months.
Key message: Do not judge T-DXd response too https://t.co/ukAyETx3mC
👁 16
❤ 0
🔁 0
May 26
IRIS-A
Adjuvant Capecitabine + Trastuzumab · Stage I HER2+ Breast (Phase 2, ~98% 5-yr iDFS)
▼
I-SPY 2.2 — LBA514
Rilvegostomig + T-DXd · High-risk HER2-negative Breast (neoadjuvant)
▼
🟨Rilvegostomig + Gem-Cis in 1L of advanced BTC
#ASCO26
✅mOS: 16.8 mo
⏰Looking forward to results of phase III Artemide studies
#cancer #oncology #MedX #biliary #cholangiocarcinoma @curecc @PrecisionBTCnet @OncoAlert @AstraZeneca https://t.co/CZzK2aThCz
👁 1.4K
❤ 35
🔁 21
May 29
🟨Rilvegostomig + Gem-Cis in 1L of advanced BTC
#ASCO26
✅mOS: 16.8 mo
⏰Looking forward to results of phase III Artemide studies
#cancer #oncology #MedX #biliary #cholangiocarcinoma @curecc @PrecisionBTCnet @OncoAlert https://t.co/pUGSrLia0J
👁 10
❤ 0
🔁 0
May 29
KN026-004 — LBA660
Anbenitamab (biparatopic HER2) vs CLEOPATRA-style · HER2+ Breast
▼
Anbenitamab (HER2 bispecific) + albumin-bound docetaxel (HB1801) +/- carboplatin for preop HER2+ breast cancer vs THP +/- carboplatin increased pCR: 62.4% vs 51.2% in ITT, ER+ 51.7%vs 44.4%
74% N+, 80% T2, 56% ER+, 42% carbo
@OncoAlert #ASCO26
👁 403
❤ 12
🔁 8
May 30
Practice-Changing Signal 🚨
Neo-Healer establishes Anbenitamab + HB1801 as a highly promising new neoadjuvant backbone for high risk HER2+ #BreastCancer , delivering a significant tpCR advantage independent of carboplatin exposure.
#bcsm @OncoAlert #ASCO26 https://t.co/09fNU9fLZ5
👁 395
❤ 17
🔁 8
May 30
NEO-HEALER #ASCO2026
Anbenitamab-based neoadjuvant therapy improved tpCR versus THP in HER2-positive early/locally advanced breast cancer.
• tpCR: 62.4% vs 51.2%
• Absolute gain: +11.4%
• p = 0.0036
• Comparable safety
Key caveat: the experimental arm used nab-docetaxel, https://t.co/kEtK3wpFoU
👁 267
❤ 5
🔁 3
May 31
Updates from #ASCO2026: Results from a phase 3 trial demonstrated that #anbenitamab plus #chemo significantly improved total #pCR in #HER2-positive early or locally advanced breast cancer. Learn more: https://t.co/qWLjhzPHAn
#medtwitter #onctwitter https://t.co/AdScd7xblL
👁 58
❤ 0
🔁 0
May 30
evERA Breast
Giredestrant vs Physician's Choice endocrine · 2L+ ER+/HER2- MBC (Phase 3)
▼
persEVERA BC — LBA1006
Giredestrant + Palbociclib vs Letrozole + Palbociclib · 1L metastatic HR+ (missed PFS)
▼
GI Cancers255 tweets captured
1/n
Daraxonrasib (RMC-6236), the first-in-human oral 💊RAS(ON) multi-selective tri-complex inhibitor, in previously treated RAS-mutated pancreatic cancer phase I/II study is now published in the New England Journal of Medicine @NEJM
A novel💡 way to shut down ⚔️RAS, one of https://t.co/rmiHQTCFVS
👁 34.0K
❤ 263
🔁 94
May 7
We're seeing major advances vs pancreatic cancer. Today @NEJM data for daraxonrasib @RevMedicines https://t.co/IinceclK6w
Context for this first-in-class molecular glue https://t.co/IinceclK6w https://t.co/odhmXQqzMF
👁 31.9K
❤ 310
🔁 88
May 6
A few additional thoughts I've had reflecting upon lessons from daraxonrasib in addition to Wungki's excellent summary below https://t.co/kV0EWF816T
👁 19.6K
❤ 57
🔁 22
May 7
Expanded access - while very welcome - is a lot of paperwork. Daraxonrasib needs to be approved so it can be used without delay by patients with metastatic #PancreaticCancer who have progressed on prior therapy.
There is a national priority voucher - what are we waiting for? https://t.co/yAAD4OgRCo
👁 17.9K
❤ 85
🔁 10
May 1
FDA just granted expanded access for daraxonrasib by Revolution Medicines. This allows patients who cannot enroll in a clinical trial to access the drug through their physician.
The FDA processed this in just 2 days. That is unusually fast and reflects the urgency around https://t.co/rZFzI5nurC
👁 11.3K
❤ 83
🔁 22
May 2
Daraxonrasib in PDAC now published in NEJM.
We have had press releases and presentations, but now a publication.
And yes, the data still look very real. 🧬
Pancreatic cancer is a RAS disease.
90% have activating RAS mutations.
G12D, G12V, G12R dominate.
And historically we have
👁 10.8K
❤ 170
🔁 60
May 7
Clinical Trials9 trials with discussion
RASolute 302
Daraxonrasib · 2L mPDAC (Phase III)
▼
🩺 THE 10 MOST IMPORTANT GI CANCER TRIALS OF #ASCO26
🌟 PLENARY & PRACTICE-CHANGERS
1️⃣ RASolute 302 (LBA5)
Daraxonrasib (RMC-6236) vs chemotherapy in metastatic pancreatic cancer
Can RAS finally become druggable in pancreatic cancer?
2️⃣ CIRCULATE (LBA3500)
ctDNA-guided https://t.co/waiLddBHrv https://t.co/wsAdevStyx
👁 16.7K
❤ 126
🔁 51
May 23
🚨 New edition of The OncoAlert Newsletter is live — and this one is packed.
REGISTER TO GET IT👉 https://t.co/gspVIddsef or https://t.co/d9YuqYt6MU
Here's what's inside 👇
🧬 NEJM SPOTLIGHT — Daraxonrasib in RAS-mutant pancreatic cancer: 35% ORR, 8.5-mo PFS in 2L PDAC. RAS https://t.co/14HNKsNNyd
👁 7.0K
❤ 31
🔁 13
May 7
ASCO 2026 may be one of the more consequential meetings in recent years — especially if the full data from RASolute 302 confirm the promise seen in the topline results.
For me, the headline question is whether we are finally seeing a meaningful RAS-targeted advance in metastatic https://t.co/krAquvD4jw
👁 5.9K
❤ 0
🔁 0
May 27
Daraxonrasib phase 3 (RASolute 302) data to be presented at #ASCO26 plenary session on May 31st. https://t.co/H7XyO8quIV
👁 5.5K
❤ 93
🔁 19
Apr 21
#ASCO26 is <4 weeks away! @ASCO
Here are the #GI oncology oral abstracts I’m most excited about 👇
➡️Notable phase 3s:
PDAC: RASolute302 ⭐️
HCC: EMERALD-3 & IMBRAVE251
EGC: ATTRACTION 6 & BL-B01D1-305
CC: FIGHT-302
CRC: PUMP (HAI), EPISODE-III (ASA)
- HER2+: Tras rezetecan https://t.co/JVuYKa9SHf
👁 5.3K
❤ 70
🔁 36
May 4
For years, GI oncology meetings felt defined by incremental progress & cautious optimism.
#ASCO26 feels different.
The phase 3 RASolute 302 data with @RevMedicines daraxonrasib in 2L #pancreaticcancer is a true milestone moment for RAS-targeted therapy.
And this is just the
👁 1.8K
❤ 27
🔁 7
May 22
➕Plenary: Rasolute 302, daraxonrasib phase III https://t.co/ebhNTu7DtU
👁 1.8K
❤ 12
🔁 5
May 23
@oncodaily @OncoDailyGI @OncBrothers @brunolarvol @MSK_DeptOfMed @MSKCancerCenter @lustgartenfdn @NatureMedicine @CD_AACR @CpcrMsk @GiOncNow 7/n
This is not the finish line🏁
RASolute 302, 303, 304 and more.
Deeply grateful to the patients 💜, families👨👩👧👦, investigators👨⚕️🩺, research teams🏥 and collaborators who made this work possible.
The final result of RASolute 302, registrational randomized phase 3 trial https://t.co/nVyORkUHek
👁 1.4K
❤ 22
🔁 5
May 7
Phase 1/2 data for our RAS(ON) multi-selective inhibitor published in @NEJM.
Findings contributed to the scientific and clinical rationale for Phase 3 RASolute 302 trial in metastatic RAS mutant pancreatic cancer.
More: https://t.co/hkM1z0skXl https://t.co/AqFc4ZcAfu
👁 1.4K
❤ 20
🔁 7
May 6
Phase 1/2 data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/qjRucVNcCs
👁 1.1K
❤ 20
🔁 12
Apr 21
Daraxonrasib (RASolute 302 trial) just posted a .40 HR and was hailed a miracle.
What happens when the $SLS REGAL trial produces even better results, with a first of its kind peptide therapy that can be applied to many other WT1 cancer targets?
Billions. Lots of billions!!! https://t.co/Jwl0cTIOXm
👁 963
❤ 7
🔁 1
May 20
#ASCO26
This one is special.
This is the hottest paper of 2026 and potentially in the history of pancreatic cancer.
Let’s dive in.
RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer
Abstract LBA5 (soon!) https://t.co/Lq7PEjOWAo
👁 704
❤ 29
🔁 21
May 31
RASolute 302 (ASCO 2026) — ongoing global phase 3 study evaluating daraxonrasib (RMC-6236) in previously treated metastatic PDAC.
Key points:
• Broad RAS(ON) inhibition strategy
• >90% of PDAC linked to RAS signaling
• Encouraging early phase 1 signals
• Phase 3 trial now https://t.co/srMHNeQ71n
👁 626
❤ 5
🔁 2
May 24
13.2 months vs 6.7. That's the median OS Revolution Medicines ($RVMD) is taking to the ASCO plenary Sunday — daraxonrasib, the first pan-RAS inhibitor to double survival in previously-treated metastatic pancreatic cancer (RASolute 302, HR 0.40, p<0.0001).
Read the venue, not
👁 513
❤ 1
🔁 0
May 25
🚨@ASCO GI Abstracts to Watch 👀
⭐️RASolute 302: daraxonrasib vs chemo in mPDAC
⭐️HERIZON-GEA-01:PD-L1 subgroup data
⭐️BREAKWATER +SWOG S2107 : IO + chemo backbone in BRAF V600E mCRC
⭐️CIRCULATE: ctDNA-guided adjuvant in stage II colon cancer #OncTwitter
https://t.co/oRM2ert8E9
👁 438
❤ 1
🔁 3
May 20
🧬 Which upper GI abstracts should clinicians watch at #ASCO2026?
Dr. @Erman_Akkus @AnkaraUni previews major studies including RASolute-302, DESTINY-Gastric, and HERIZON across pancreatic, gastric, biliary, and HCC care.
🎥 Watch on #Vumedi: https://t.co/HgsZB3O8lN https://t.co/WnIlYAxmgs
👁 382
❤ 6
🔁 3
May 19
🚨ASCO 2026 Scouting Report 🚨
👀 VIDEO: 5-minute breakdown on key watch points + clinical context 👇
👉https://t.co/Gpy5GbxUiW
The 3 Plenary trials that might change your practice:
✅RASolute 302 – daraxonrasib nearly doubles OS (13.2 vs 6.7 mo, HR 0.40) in 2L pancreatic https://t.co/JkQhchtSTb
👁 380
❤ 2
🔁 2
May 20
@UGrewalMD @TheGutOncLab @NEJM Efficacy data interestingly seem very similar to what’s been released from RASolute 302
👁 339
❤ 2
🔁 1
May 7
3 things Dr. Kate Baker is watching closely at #ASCO26 this year 👀
• RASolute 302 evaluating daraxonrasib in KRAS-mutated pancreatic cancer
• HARMONi-6 and the continued development of ivonescimab in lung cancer
• New ADC sequencing and combination data across solid tumors https://t.co/3CdmLHWuLa
👁 302
❤ 1
🔁 2
May 26
#ASCO26 LBA5 - Wolpin - Daraxonrasib RAS(ON) multi-selective inhibitor vs chemo in prior Tx metastatic pancreatic adenocarcinoma (mPDAC) - Ph3 RASolute 302 [May 31, 2026] https://t.co/oWEeVo2oyq #NCT06625320 #pancsm #caxtx #PrecisionMedicine
👁 230
❤ 2
🔁 1
May 26
‼️ RASolute 302 is THE gastrointestinal cancer abstract of #ASCO26
🎙️ @GIMedOnc visited our home studio and sat down with us to discuss GI cancer and what to expect at the largest cancer conference of the year!
Stay tuned for the full podcast this Thursday!
#pancsm #oncology https://t.co/X1GqeifpRv
👁 222
❤ 2
🔁 2
May 26
$RVMD isn’t just leading the RAS race; it’s building a fortress. 🏰
With shares holding steady at the $150 level, the market is finally pricing in the gravity of the RASolute 302 data. A Hazard Ratio of 0.40 (60% reduction in risk of death) in pancreatic cancer is nothing short
👁 216
❤ 0
🔁 0
May 14
Revolution Medicines to discuss data from Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma $RVMD, #RevolutionMedicines, #RevMed https://t.co/rKwXoNTqHs
👁 212
❤ 0
🔁 0
May 21
🔎 FDA News: The #FDA has authorized expanded access to daraxonrasib for metastatic #PancreaticCancer, after phase 3 results show major survival gains over chemotherapy and manageable safety.
Read more: https://t.co/wG31FzGum2
#GICancers #PDAC #FDANews
👁 204
❤ 0
🔁 1
May 1
Pancreatic cancer may be entering a new era.
Daraxonrasib receives rapid FDA expanded access in metastatic PDAC (approved in 2 days).
RASolute 302:
* OS: 13.2 vs 6.7 months
* 60% reduction in risk of death
Key questions:
Will RASolute 303 reproduce this in the first-line
👁 202
❤ 2
🔁 0
May 5
Celebrating RASolute302 Results of Daraxonrasib in Pancreatic Cancer - Shubham Pant
@DrShubhamPant @MDAndersonNews
https://t.co/vsZNKBYb90 https://t.co/g2OMtbFrYI
👁 196
❤ 4
🔁 2
May 17
Daraxonrasib Phase 3 Data Marks a Momentous Occasion for the Field - Anirban Maitra
@Aiims1742
https://t.co/eTqdZpCkcX https://t.co/WXD1ERbAn2
👁 160
❤ 5
🔁 0
May 22
📝 The phase 1/2 data of daraxonrasib in #PancreaticCancer have been published in @NEJM.
These data led to the phase 3 RASolute 302 trial which supported the FDA's recent allowance of early access to the RAS inhibitor.
Read more: https://t.co/hdwXMVxr5s
#PDAC #GICancers
👁 153
❤ 1
🔁 1
May 8
@DrRishabhOnco RASolute-302… all day erryday
👁 132
❤ 0
🔁 0
May 15
Daraxonrasib vs. chemo in previously treated mPDAC — Phase 3 RASolute 302 primary analysis.
Plenary · Abstract LBA 5
📍 Hall B1, Chicago
🗓 May 31 · 20:21 CT
Topline: positive. Full OS data: embargoed until presentation.
2nd-line PDAC has had no meaningful survival advance in
👁 91
❤ 0
🔁 0
May 28
Daraxonrasib (RASolute 302) — RAS-targeting in pretreated metastatic pancreatic cancer. The "undruggable" target, now in a phase 3 plenary.
Buzz Score: 100% (2/9)
#ASCO26 #PancreaticCancer
👁 90
❤ 0
🔁 0
May 27
RASolute 302 Phase 3 results:
Median OS: 13.2 months vs 6.7 months for chemo.
Hazard ratio: 0.40
p < 0.0001
Nearly double the survival.
All primary and key secondary endpoints met.
Published simultaneously in the New England Journal of Medicine.
👁 85
❤ 1
🔁 0
May 28
4/4 Take-home message.
Daraxonrasib showed meaningful activity across common KRAS variants including G12D, G12V and G12R.
The key lesson:
High efficacy comes at the cost of frequent dose optimisation rather than discontinuation.
Now all eyes on RASolute-302. 🔬
👁 84
❤ 1
🔁 0
May 19
Standard of care in 2nd line metastatic pancreatic cancer may have just been rewritten. May 6th NEJM published Phase 1/2 daraxonrasib data. The Phase 3 RASolute 302 reported HR 0.40 for OS, 13.2 vs 6.7 months, p<0.0001. One of the largest OS hazard ratios for mutant KRAS PDAC. https://t.co/9SG1DHjf7o
👁 50
❤ 0
🔁 0
May 14
Phase 3 RASolute 302 results — already toplined:
Daraxonrasib vs standard chemotherapy (2nd line PDAC):
→ Median OS: 13.2 months vs 6.7 months
→ Hazard ratio: 0.40
→ p < 0.0001
That's nearly DOUBLE the survival.
An HR of 0.40 in pancreatic cancer is almost unheard of.
👁 47
❤ 0
🔁 0
May 15
@OncUpdates @ASCO RASolute 302 is the readout that could actually change PDAC frontline if the OS hazard holds up across G12D and G12V subgroups. HERIZON-GEA PD-L1 subgroup will tell us whether HER2-low gastric is sequencable.
👁 39
❤ 0
🔁 0
May 21
Phase I data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/15HOeWlm0Q
👁 37
❤ 0
🔁 0
Apr 21
@ChandrakanthMv RASolute 302 highlights something important in PDAC:
We still evaluate highly dynamic RAS biology mostly with snapshots:
• MRI
• PET
• PFS
• OS
But RAS signaling is temporal, adaptive, and immune-linked. Two patients can show similar scans while having completely different:
👁 35
❤ 0
🔁 0
May 24
‼️ RASolute 302 is THE gastrointestinal cancer abstract of #ASCO26
🎙️ @GIMedOnc visited our home studio and sat down with us to discuss GI cancer and what to expect at the largest cancer conference of the year!
Stay tuned for the full podcast this Thursday! https://t.co/rJ7tW57IEg
👁 32
❤ 1
🔁 0
May 26
Phase I data re: @AACR #AACR2026 Daraxonrasib + Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch https://t.co/uwUuuER8Ak
👁 19
❤ 0
🔁 0
Apr 21
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
👁 16
❤ 0
🔁 0
May 21
🔵 RASolute 302 in @NEJM: daraxonrasib (RAS(ON) inhibitor) vs chemo in pretreated mPDAC
What all 👀 have been looking this #ASCO26
• mOS 13.2 vs 6.6 mo, HR 0.40
• mPFS 7.3 vs 3.5 mo, HR 0.45
• Discontinuation 1.2% vs 11.2%
mOS still modest, but the first real signal in https://t.co/Xerda5JtDQ
👁 14
❤ 0
🔁 0
May 31
3 macro indicators from a single week for oncology capital allocation over the next decade.
1. Daraxonrasib, Phase 3 RASolute 302
2. Vepdegestrant, FDA Approved , May 1
3. BioNTech 22% of workforce cut
a structural shift in biopharma strategy rather than a standard news cycle.
👁 —
❤ 0
🔁 0
May 18
HERIZON-GEA-01
Zanidatamab · 1L HER2+ GEA
▼
In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy. Full phase 3 HERIZON-GEA-01 trial results: https://t.co/EoAKVty6RC https://t.co/BP5cVjuquX
👁 16.3K
❤ 47
🔁 17
May 27
Abstract Titles #ASCO26
Rapid oral, upper GI
◾️Ph2 savolitinib in MET-amp GEA
◾️PD-L1 subgroup analysis from HERIZON-GEA-01
◾️Ph3 neoadjuvant/adjuvant serplulimab vs placebo combined with chemo for PD-L1 positive GC
@ASCO @OncoAlert
👁 1.5K
❤ 15
🔁 4
Apr 25
New phase 3 in @NEJM* for HER2+ gastroesophageal cancer (HERIZON-GEA-01). 914 patients, first-line.
Zanidatamab (dual HER2 antibody) plus chemo, with or without tislelizumab (immunotherapy), vs. trastuzumab plus chemo (current standard).
Progression-free survival: 12.4 months https://t.co/H78BSwZbMj
👁 1.4K
❤ 14
🔁 5
May 27
Updated HERIZON-GEA-01 data from @ASCO 2026 in 1L HER2+ Unresc/LA/m GC/GEJA landscape from Dr. Daniel Lin (@DanielLinMD) 👉 https://t.co/tkxM8TEPjz
Updated Landscape 👉 https://t.co/sqzIKL502n
Explore more insights and conference data from #ASCO26 👉 https://t.co/8KejbHRmAP https://t.co/k5VCSjbFqB
👁 1.3K
❤ 9
🔁 7
May 27
HERIZON-GEA-01 was first signaled at #ASCOGI26.
Now, with the full @NEJM publication on May 27, 2026, the message is clearer:
In 1L HER2-positive gastroesophageal adenocarcinoma, zanidatamab-based therapy significantly extended PFS vs trastuzumab-based standard treatment.
Not https://t.co/1VCalhZUsx
👁 1.0K
❤ 12
🔁 10
May 28
As GI oncology discussions accelerate ahead of @ASCO 2026, we asked leading AI models to identify the trials most likely to drive attention at this year’s meeting.
There was particularly strong consensus around ATTRACTION-6, CIRCULATE, EMERALD-3, HERIZON-GEA-01, and RASolute https://t.co/UwoQM24Lyb
👁 975
❤ 11
🔁 6
May 27
HERIZON-GEA-01 #ASCO2026
Zanidatamab + tislelizumab + chemotherapy demonstrated meaningful improvement in PFS and OS in HER2+ metastatic GEA — irrespective of PD-L1 status.
An important clinical signal:
PD-L1 negativity did NOT eliminate benefit.
Also notable:
Longer OS in the https://t.co/pBOkdwnB0K
👁 934
❤ 16
🔁 3
May 25
#ASCO26
Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma:
PD-L1 subgroup analysis from HERIZON-GEA-01
$ZYME $JAZZ $RHHBY https://t.co/Q5tkPBskD6
👁 821
❤ 4
🔁 0
May 21
#ASCO26 abstr 4010
PD-L1 subgroup from Ph3 HERIZON-GEA-01
@ASCO @OncoAlert https://t.co/1RdjgYQmhr
👁 749
❤ 18
🔁 5
May 22
🧠📊 HERIZON-GEA-01
✔️ Zani+tisle+CT ↑ PFS & OS vs trastu+CT
📈 PFS: 12.4 vs 8.1 m (HR 0.63)
📈 OS: 26.4 vs 19.2 m (HR 0.72)
✔️ Zani+CT also ↑ PFS
📈 12.4 vs 8.1 m (HR 0.65)
⚠️ 24.8% grade 3-4 diarrhea
💡 Dual HER2 blockade: new 1L benchmark in HER2+ GEA
🔗 https://t.co/xjxCtpQNsA
👁 651
❤ 8
🔁 6
May 28
#ASCO26
Characterization and management of gastrointestinal adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: Analysis from HERIZON-GEA-01
$ZYME $JAZZ $RHHBY https://t.co/cydoHSnnT4
👁 614
❤ 0
🔁 0
May 21
🚨 Newly published in @NEJM: HERIZON-GEA-01 data show #zanidatamab plus chemotherapy ± tislelizumab significantly improved survival in HER2-positive GEA. 📊
Our latest coverage features exclusive insights from Geoffrey Ku, MD, of @MSKCancerCenter on the implications of this
👁 420
❤ 4
🔁 1
May 27
💥 @US_FDA has granted priority review to zanidatamab-based regimens in first-line HER2+ GEA based on data from the phase 3 HERIZON-GEA-01 trial.
Full details 📈: https://t.co/41mtHbzq6a
#esocsm #oncology
👁 369
❤ 5
🔁 0
May 12
The @US_FDA has granted priority review to zanidatamab-based regimens in first-line HER2+ gastric cancer, GEJ cancer, and GEA. #esocsm #oncology
https://t.co/ZM3jcGOKOe
👁 348
❤ 3
🔁 1
Apr 27
📰 News based on results from the phase 3 HERIZON-GEA-01 trial:
Tislelizumab, zanidatamab, and chemo received priority review for first-line unresectable advanced or metastatic HER2+ gastric, GEJ, or esophageal adenocarcinoma.
➡️ https://t.co/k34LknkaxQ
#GIcancer https://t.co/HCZmhvh3Kg
👁 267
❤ 3
🔁 1
May 1
$JAZZ
Jazz Pharmaceuticals' Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
- Expanded safety,
👁 201
❤ 0
🔁 1
May 27
ICYMI: The #FDA granted priority review to #zanidatamab regimens for 1L HER2+ gastric/GEJ/GEA.
PDUFA action date: August 25, 2026
Read more: https://t.co/v7a2Mtj4wI
👁 175
❤ 0
🔁 0
Apr 28
Does Tislelizumab Actually Make a Difference in HERIZON-GEA-01? - Nikhil Vasudeva to Kohei Shitara
@DrNikhilvasudev @KoheiShitara
https://t.co/61uNzE9BIm https://t.co/redDIHfWJN
👁 84
❤ 1
🔁 0
May 29
HERIZON-GEA-01 was first signaled at #ASCOGI26.
Now, with the full @NEJM publication on May 27, 2026, the message is clearer:
In 1L HER2-positive gastroesophageal adenocarcinoma, zanidatamab-based therapy significantly extended PFS vs trastuzumab-based standard treatment.
Not https://t.co/uuFHzWtYvq
👁 14
❤ 0
🔁 0
May 28
FIGHT-302
Pemigatinib · 1L FGFR2-rearranged Cholangiocarcinoma (Phase 3)
▼
🔥Hot off the press! #ASCO26 abstract release: Phase 3 data from FIGHT-302 to highlight the clinical utility of first-line oral pemigatinib vs gemcitabine/cisplatin in biomarker-selected, FGFR2+ metastatic #CCA.
Unpack the newly published details below! ⬇️
@ASCO @GIcancerDoc
👁 3.7K
❤ 8
🔁 4
May 21
🟦FIGHT-302 #ASCO26 @ASCO
1L pemigatinib vs gem-cis in advanced BTC with FGFR2 rearrangement
✅1.5mo median PFS benefit
🚨Similar OS, 24.4mo (50% crossover)
⚠️Closed early due to slow accural
✅My takeaway:
Patients with FGFR+ should access the drug either in 1 or 2 L https://t.co/a6alSfgAMX
👁 1.5K
❤ 21
🔁 9
May 25
Camrelizumab + Rivoceranib + TACE
vs TACE · unresectable HCC (Phase 3)
▼
#ASCO26
https://t.co/eHgtQitZKI
Camrelizumab + rivoceranib + TACE vs TACE alone in uHCC
Abstract #: 4001
Presentation: June 1, Upper GI Orals
In HCC, the question is increasingly not local vs systemic, but how best to combine the two.
This China-based randomized phase 3 trial
👁 2.1K
❤ 25
🔁 10
May 22
#ASCO26
Can immunotherapy + anti-VEGFR finally redefine TACE for intermediate-stage HCC?
Phase III data from Abstract 4001 shows that adding camrelizumab + rivoceranib to TACE significantly improved PFS in unresectable HCC.
🧪 Trial:
423 pts with TACE-eligible uHCC
• https://t.co/lkoCYFrRgp https://t.co/aJxcIHzkTR
👁 2.0K
❤ 21
🔁 13
May 27
ASCO 2026 • Abstract 4001
“TACE alone may no longer be enough” for selected intermediate-stage HCC.
Earlier integration of immunotherapy + anti-VEGF therapy with TACE improved PFS:
11.1 vs 8.3 months (HR 0.73)
Trial:
Camrelizumab + Rivoceranib + TACE vs TACE alone
A https://t.co/u9vELns5JI
👁 509
❤ 1
🔁 0
May 28
#ASCO26
Abstract 4001 - Camrelizumab + Rivoceranib + TACE vs TACE Alone in Unresectable HCC https://t.co/UFcQfiZ2bO
👁 392
❤ 5
🔁 3
May 27
ATTRACTION-6
Nivolumab + Ipilimumab + Chemo · 1L HER2- advanced EGA
▼
#ASCO26
https://t.co/vN5XTT9RAP
ATTRACTION-6: Nivolumab + ipilimumab + chemo vs chemo in 1L HER2-negative G/GEJ cancer
Abstract #4006
Presentation: June 1, 2026
Womp.
Dual-checkpoint has a home in multiple diseases: melanoma, PD-L1 negative NSCLC, MSI-H cancers, and HCC among
👁 2.3K
❤ 32
🔁 9
May 22
#ASCO26 abstr 4006
Ph3 Nivo + Ipi + chemo vs chemo in 1L HER2-neg GEA (ATTRACTION-6)
◾️OS: 15.7 vs 15.8 mo, HR 0.90, p=0.267
◾️PFS: 8.9 vs 7.7 mo, HR 0.83
◾️ORR: 57.9% vs 38.5%
◾️≥G3 TRAEs: 64.8% vs 42.9%
👉Nivo + Ipi + chemo did not improve OS over chemo alone.
@ASCO @OncoAlert
👁 882
❤ 17
🔁 3
May 22
ATTRACTION-6
First-line HER2-negative advanced gastric/GEJ cancer
• Nivo + Ipi + Chemo improved response rates
• Small PFS improvement observed
• No overall survival benefit vs chemo alone
• Higher toxicity with dual checkpoint blockade
Oh et al • ASCO 2026
#ASCO2026 https://t.co/kvtCUcjWWZ
👁 578
❤ 14
🔁 2
May 26
Izalontamab Brengitecan (iza-bren)
EGFR/HER3 bispecific ADC vs Chemo · Esophageal SCC (Phase 3)
▼
#ASCO26 abstr 4008
Ph3 Iza-bren vs chemo in 2L ESCC
◾️OS: 9.8 vs 7.2 mo, HR 0.64, p=0.0004
◾️PFS: 4.2 vs 2.0 mo, HR 0.50, p<0.0001
◾️ORR: 35.3% vs 13.1%
👉Met both dual primary endpoint OS & PFS!!
@ASCO @OncoAlert
👁 1.5K
❤ 19
🔁 4
May 22
Bispecific agents are moving rapidly toward translation in the breast cancer space! @nerealiamd, and @MinhTriMD, highlight upcoming phase 3 data for iza-bren in metastatic TNBC and novel immunotherapy/ADC combinations.
Read the exclusive expert analysis ahead of #ASCO26: https://t.co/V8E5ph0TAc
👁 187
❤ 3
🔁 1
May 27
Trastuzumab Rezetecan
vs SOC · chemo-refractory HER2+ CRC (Phase 3)
▼
BREAKWATER
Encorafenib + Cetuximab · BRAF mCRC
▼
Abstract Titles #ASCO26
Oral, CRC
◾️Ph3 Trastuzumab rezetecan vs chemo in HER2-pos CRC
◾️DFS & TTR with ctDNA-based decision for adj Tx in stage II colon cancer
◾️BREAKWATER: PFS & OS of EC + FOLFIRI in 1L BRAF V600E mCRC
◾️SWOG S2107: rPh2 EC w/ or w/o Nivo in MSS, BRAF V600E
👁 992
❤ 11
🔁 4
Apr 25
BREAKWATER: PFS and OS analyses of 1L encorafenib + cetuximab + FOLFIRI in BRAF V600E-mCRC
#ASCO26
👉mPFS 8.3 vs 15.2 mo
👉mOS NE vs 20 mo
🧐significant benefit, valid alternative, approved by FDA...
@myesmo @ASCO https://t.co/ZqN7xxrx6A
👁 31
❤ 0
🔁 0
May 31
EMERALD-3
Tremelimumab + Durvalumab ± Lenvatinib + TACE · unresectable HCC (Phase 3)
▼
A thrill to be at #ASCO26 where the best in #GIonc will be presented. To have an earth shattering #plenary with #RASOLUTE will be a dream come true but many other highlights #Fight302 🥊 #Emerald3 💎 #PUMP ⛽️ #BREAKWATER 🌊. So much to love!
#OncoAlertAF
@FadiHaddad_MD https://t.co/2cUfQV9Pmm
👁 514
❤ 9
🔁 5
May 29
$AZN
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
- EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) in early liver
👁 178
❤ 0
🔁 0
May 22
Multiple Myeloma164 tweets captured
Honestly I want to hear from myeloma experts. If you had “high risk” smoldering myeloma per 20-2-20 would want daratumumab?
Or if you were like me you would want close monitoring and real therapy god forbid you progress.
👁 7.8K
❤ 43
🔁 4
May 23
Pleasure working with @ASCO on this! Living guidelines in myeloma #MMsm reflect how rapidly the field is changing... this update ≤6 months after our last one!
CAR-T and bsAbs (tec-dara) now on equal footing for relapsed myeloma at first relapse - shared decision-making is 🔑 https://t.co/ZEHiMDeCH4 https://t.co/rczQDJDJAH
👁 6.3K
❤ 50
🔁 17
May 21
HIGH MRD NEGATIVITY RATES AND PROLONGED PFS WITH BELANTAMAB MAFODOTIN PLUS DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE NEWLY-DIAGNOSED MYELOMA... by Prof. Evangelos Terpos #mmsm EHA Library; Jun 14 2026; 4206758
https://t.co/4F8ZHKWB59 https://t.co/1BBxMtpQ6s
👁 5.2K
❤ 17
🔁 5
May 19
BCMA targeting continues to evolve. ⚔️🧬
We recently reviewed the MajesTEC universe.
TODAY let’s focus on the DREAMM program and the long, unusual journey of Blenrep (belantamab mafodotin).
From:
🧪 DREAMM-1 proof of concept
➡️ DREAMM-2 accelerated approval
➡️ DREAMM-3 https://t.co/jXjTRLLdrL https://t.co/q9RBfoy9JE
👁 5.1K
❤ 25
🔁 6
May 28
With #ASCO26 approaching, here are the potentially practice-changing abstracts in plasma cell disorders that caught my attention. I will update my thoughts as simultaneous publications are released for some of them🧵#MultipleMyeloma #Amyloidosis
👁 4.9K
❤ 42
🔁 13
May 25
The main change for this cycle: "Ciltacabtagene autoleucel or the combination of teclistamab and daratumumab are preferred options at first relapse in eligible patients who have not previously received B-cell maturation antigen (BCMA) directed therapy. Teclistimatab plus
👁 3.7K
❤ 38
🔁 11
May 20
Clinical Trials4 trials with discussion
MajesTEC-9
Teclistamab vs PVd/Kd · RRMM (Phase III)
▼
Just out: Majestic Majestec-9 results.
#ASCO26 @NEJM
Single agent teclistamab beats standard triplet in relapsed myeloma.
https://t.co/2TeFjBuZSv
@DrOlaLandgren @thanosdimop https://t.co/YzL3USaptY
👁 15.1K
❤ 163
🔁 48
May 29
We now have release of SUCCESSOR-2 data!
Mezi + weekly Kd vs twice weekly Kd
- 85% anti cd38 refractory
- mPFS 18 vs 8 months (control arm did the same as MajesTEC-9)
My take: 18 months is nothing to scoff at, and compares favorably with KPd data. It still leaves something to be https://t.co/3ZcLf3f0Pa https://t.co/wQiEOcDK6z
👁 13.2K
❤ 28
🔁 5
May 29
Most important #ASCO26 myeloma abstract. Practice changing. Majestec-9 trial.
PFS significantly better with Teclistmaab vs PVd/Kd (HR, 0.29; 95% CI, 0.23–0.38; P<0.0001); 18-mo PFS rate: 69.8% vs 26.9%.
OS significantly better with Tec vs PVd/Kd (HR, 0.60; 95% CI, 0.43–0.83;
👁 12.3K
❤ 87
🔁 26
May 23
#mmsm #ASCO26 MajesTEC-9
➡️Tec vs. PVd/Kd (1-3 prior lines of therapy)
➡️Len refractory: 80%; anti-CD38 refractory: 85%
➡️median F/U ~1.5 yrs
➡️18-mo PFS rate: 70% vs 27%
➡️improved OS with Tec vs PVd/Kd (HR: 0.60), even with >2/3 of pts getting BsAb or CAR-T as subsequent https://t.co/WzdX5QhBg3
👁 12.1K
❤ 31
🔁 18
May 21
1. MajesTEC-9 [Tec vs PVd/Kd]: Single-agent Tec decimated PVd/Kd in a population that was 80% anti-CD38-refrcatory and 85% Len-refractory, with a PFS HR of 0.29 and OS HR of 0.6.
While the trial should have ideally allowed crossover to Tec in the control arm, ~70% ended up
👁 7.1K
❤ 29
🔁 7
May 25
< 3 wks to #ASCO26, here is a📝 of 🔑abstracts for general onc that could guide our SoC!
- #RASolute302
- #EPISODE3
- #LIBRETTO432
- #HARMONi6
- #PROTEUS
- #EV302
- #SARC041
- #persevERA
- #origAMI5
- #MajesTEC9 & #SUCCESOR2
#OncTwitter @ASCO @OncoAlert @OncUpdates https://t.co/trnsHuvxhh
👁 7.0K
❤ 99
🔁 36
May 10
MajesTEC-9 is now out in @NEJM! 18-month PFS ~70% and DoR~80% with Tec! Infection risk mostly front-loaded (1st 6 months) but doesn't plateau [G3+ infections remains at ~10% in each time window beyond 12 months]. The slope of PFS curve in Tec arms progressively flattens with https://t.co/AnDlG0vEjw https://t.co/cAHsfF2a2a
👁 6.3K
❤ 53
🔁 13
May 29
MagnetisMM-5 press release - elra outperformed DPd in myeloma with 1+ prior line!
Obviously all eyes will be on this vs MajesTEC-3 (and more pertinently, MajesTEC-9)…
… but this confirms that the heyday of Dara-Pd and Isa-Pd at first relapse is rapidly coming to an end 👏 https://t.co/alzQ0578XK
👁 6.2K
❤ 59
🔁 14
Apr 29
1) MajesTEC-9 (Mina, 7507) - Teclistamab vs. (VPd or Kd). Full summary below. Tec clearly beats out some inferior and less-than-standard comparators.
I want to make 4 points about this study
1 - VPd and Kd are not strong comparators, but outside of CAR T/BsAb, there are not https://t.co/ELu6cD9khQ
👁 4.9K
❤ 54
🔁 21
May 29
MajesTec - 9 & MajecTec - 3 & Cartitude - 4 - My interpretations.
IMO: the real question is no longer Tec vs CAR-T.
The real question is: which patient should receive which immunotherapy, and when?
MajesTEC-9, CARTITUDE-4, and CARTITUDE-1 may be teaching us that sequencing https://t.co/EwWQNtwkJa https://t.co/YskpM9nwYM
👁 4.8K
❤ 45
🔁 13
May 29
MAJESTEC-9 trial at #ASCO26 : the message was strikingly simple: a couple of curves summarized it all. At the end, curves speak louder than words. @TheIACH @COMyCongress https://t.co/qRLn964Rsu
👁 4.4K
❤ 64
🔁 25
May 29
Original Article: Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy (phase 3 MajesTEC-9 trial) https://t.co/pNQbui4Dfk
Editorial: Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules https://t.co/xS3G7IpyKF
#ASCO26 | @ASCO https://t.co/2M5M7QM68L
👁 4.4K
❤ 16
🔁 6
May 30
Hi friends, it's #Myeloma Monday! #ASCO26 edition 🎉🎉🎉
Here are Top Posts of the Week 🧵
1/ @VincentRK on the practice changing MajesTEC-9 #ASCO26:
https://t.co/CKemyRWotb
👁 4.1K
❤ 24
🔁 9
May 25
#ASCO26 @ASCO abstracts are out, looking for a great meeting #mmsm @utswcancer
Here are my top 5 plasma cell disorders to watch for
🧵
1⃣MajesTEC-9: RCT of teclistamab monotherapy vs PVd/Kd in RRMM: press release with PFS and OS benefit. Will allow for earlier use of single https://t.co/BiaHZKDmbs
👁 4.0K
❤ 33
🔁 12
Apr 21
Concomitant publication in @NEJM
#ASCO26
BCMA bispecific moves earlier in myeloma.
MajesTEC-9 | NEJM 2026
Teclistamab monotherapy vs PVd/Kd in RRMM after 1-3 prior lines, all exposed to anti-CD38 + lenalidomide.
🧬 18-mo PFS
69.8% vs 26.9%
HR 0.29
🫀 18-mo OS
79.2% vs 68.6% https://t.co/OVXJK44Nvf https://t.co/9qRwXkLUDS
👁 3.7K
❤ 13
🔁 5
May 29
#ASCO26 #mmsm Oral sessions myeloma
MajesTEC-9
KD was given in 69% of patients in control arm (~205 patients)
Steroids were dropped early in the treatment course
Patients characteristics below https://t.co/j0HQbyOoP8
👁 3.1K
❤ 17
🔁 4
May 29
majesTEC-9 results posted: Tec crushed PVd/Kd for #myeloma after 1-3 prior LOT. Results relevant for US practice, as 85% of pts were anti-CD38 refractory. 18m PFS: 70% (vs 30% for pVd/Kd), w OS benefit too (HR 0.60). https://t.co/mRnJmrkoDk
👁 2.7K
❤ 23
🔁 9
May 22
#ASCO26
Teclistamab moves earlier in RRMM.
MajesTEC-9 shows a major PFS & OS benefit for teclistamab monotherapy vs PVd/Kd in anti-CD38/LEN-exposed relapsed refractory multiple myeloma.
🔬 MajesTEC-9 | Phase 3
👥 RRMM after 1-3 prior lines
⚖️ Tec vs investigator’s choice https://t.co/SRRE9woHnH https://t.co/9qRwXkLUDS
👁 2.5K
❤ 16
🔁 3
May 28
1/ Here’s my annual @ASCO #ASC026 list of 10 interesting #myeloma #mmsm @mtmdphd
- MAJESTEC-9
https://t.co/CENCQnEvPf
- SUCESSOR-2 MeziKd vs Kd
https://t.co/ABtc1yY9Pu
- InMyCAR updated results
https://t.co/eTeMqxjpnG
- LINKER-AL2 in AL amyl.
https://t.co/QmyeF2yQLh
👁 2.3K
❤ 31
🔁 11
May 24
5. MajesTEC-9: PhIII, Teclistamab vs. PVd (Pom + Bortezomib + Dex) or Kd (Carfilzomib + Dex) in refractory/relapse myeloma
- At 18mos, PFS: 70% vs. 27%
- OS ⬆️ w/ Tec (HR: 0.60)
- Gr 3/4 AEs: 85% vs. 76% 😲
- Tec based Rx in 2L now SoC
6/7 https://t.co/r1VsLNggoF https://t.co/n6a72HFfSZ
👁 2.2K
❤ 12
🔁 4
May 29
MajesTEC-9 is one of the most important myeloma studies of the year.
But after reviewing the eligibility criteria and baseline characteristics, I think several myths are emerging.
❌ It was not a triple-class refractory study.
❌ It was not a CAR-T comparison study.
❌ It https://t.co/O6rGHKPkHK
👁 1.9K
❤ 45
🔁 9
May 30
#ASCO26 @ASCO MajesTEC-9 @NEJM #mmsm
Teclistamab monotherapy vs PVd/Kd in RRMM with 1-3 prior lines (all lenalidomide + anti-CD38 exposed)
➡️Median follow-up: 17 months
➡️sCR 54% vs 9%
➡️18-mo PFS 70% vs 27% (HR 0.29)
➡️18-mo OS 79% vs 69% (HR 0.60)
➡️190/291 (~2/3) still on https://t.co/Xty2ufVU3m
👁 1.8K
❤ 22
🔁 8
May 29
#ASCO26 @ASCO MajesTEC-9 @NEJM #mmsm
Excellent results for use of BCMA BsAb in early relapse
2 main take aways:
➡️If you are not comfortable with BsAb in myeloma, you need to be. Those provide superior outcomes
➡️Infections are serious complication, occurs in all relapsed
👁 1.8K
❤ 8
🔁 2
May 29
Incidentally, the exact same arguments can be made about Kd/PVd in control of MajesTEC-9. @JJ_IMMedAffairs https://t.co/syzVrdo1ZU
👁 1.7K
❤ 5
🔁 0
May 30
MajesTEC-9 just landed in NEJM — the first phase 3 to run a BCMA bispecific as a SINGLE agent at first-or-later relapse, in patients already exposed to anti-CD38 + lenalidomide.
The topline: a 71% cut in progression or death. But the full read rewards a closer look. 🧵
👁 1.2K
❤ 13
🔁 5
May 29
Teclistamab changes the relapse conversation in myeloma.
MajesTEC-9 | NEJM 2026
In RRMM after 1-3 prior lines:
🧬 18-mo PFS
69.8% vs 26.9%
HR 0.29
🫀 18-mo OS
79.2% vs 68.6%
HR 0.60
🎯 CR+
65.9% vs 16.8%
The message is getting harder to ignore:
BCMA bispecifics are moving https://t.co/8nzDQAIQUG https://t.co/Grj4tYI4vg
👁 1.2K
❤ 13
🔁 3
May 30
#ASCO26
Abstract #7507
MajesTEC-9: Teclistamab vs PVd/Kd in RRMM https://t.co/pC8Zhdt3lZ
👁 980
❤ 2
🔁 2
May 28
#ASCO26 @ASCO MajesTEC-9 @NEJM #mmsm
➡️Any grade infection: 83% (tec) vs 68% (PVd/Kd)
🛑Grade 3/4: 42% vs 29%
🛑Opportunistic infections any grade: 14% vs 6%
🛑Grade 3/4 opportunistic: 6% vs 1%
Highest in first 6 months, then decreased in both arms.🛑 Fatal infections: https://t.co/qbjdhTBBZC
👁 932
❤ 3
🔁 2
May 29
#ASCO26 @ASCO MajesTEC-9 @NEJM #mmsm
Characteristics of patients
➡️Median age : 70 years (range 34-86 years)
➡️≥75 yrs: 29%
➡️Median time from diagnosis: 3.7 years (range 0.2-22.1)
➡️Prior transplant: ~ 50%
➡️Refractory to any IMID (~ 85%), refractory to any anti-CD38 (~ 85%) https://t.co/fMOLRIxfZO
👁 899
❤ 1
🔁 2
May 29
MajesTEC-9 phase 3 trial evaluates teclistamab monotherapy vs investigator’s choice of PVd or Kd in relapsed/refractory multiple myeloma, aiming to redefine treatment standards in RRMM. #mmsm #ASCO26
Congratulations to @RobertoMinaMD et all, patients and their families
- 74% https://t.co/Aoost9RjSo
👁 880
❤ 12
🔁 6
May 30
1/ Here’s my annual @ASCO #ASC026 list of 10 interesting #myeloma #mmsm @mtmdphd
- MajesTEC-9 Tec
https://t.co/CENCQnEvPf
- SUCCESSOR-2 MeziKd vs Kd
https://t.co/ABtc1yY9Pu
- inMMyCAR
https://t.co/eTeMqxjpnG
- LINKER-AL2 elra in AL amyl.
https://t.co/QmyeF2yQLh
👁 838
❤ 10
🔁 10
May 24
3/ @HadidiSamer with more on MajesTEC-9:
https://t.co/anup63FS8p
👁 830
❤ 9
🔁 3
May 25
#ASCO26 @ASCO MajesTEC-9 @NEJM #mmsm
➡️Median PFS not reached vs 8 mo
➡️ Median DOR not reached vs 13 mo
➡️18-mo OS 79% vs 69% (HR 0.60)
➡️MRD-negative CR (10⁻⁵) ITT: 39% vs 7% https://t.co/SaN6ZEVOZF
👁 758
❤ 5
🔁 3
May 29
MajesTEC-9 just landed in NEJM, and it's worth more than the headline. Teclistamab — a BCMA bispecific — was tested as a SINGLE agent at first-or-later relapse, in myeloma already exposed to anti-CD38 + lenalidomide, against investigator's choice of PVd or Kd. The topline is a
👁 735
❤ 16
🔁 5
May 30
#ASCO26 @ASCO MajesTEC-9 @NEJM #mmsm
Other side effectS
➡️CRS: 66% (G1 49%, G2 17%, G3 1%). All resolved. ➡️ICANS: 4%, mostly G1/2. ( 1 G3 did not resolve)
🛑Neutropenia G3/4: 54% vs 22% (highest in first 6 mo, decreased after) - correlates with infection risk https://t.co/Mfj1QCVZqe
👁 650
❤ 4
🔁 4
May 29
#ASCO26 #mmsm Oral sessions myeloma
MajesTEC-9
Still ~21% released on Tec but much lower than comparator arm
Improved PFS and responses including MRD negativity https://t.co/yMK4FSL9fB
👁 593
❤ 9
🔁 4
May 29
ASCO 2026 Update — MajesTEC-9
• Teclistamab significantly improved PFS vs PVd/Kd in early RRMM
• Deep responses: ≥CR 65.9% vs 16.8%
• Benefit seen in a heavily refractory population
• OS improvement observed despite later BCMA-directed therapy crossover in the control arm https://t.co/beCRXd98Y1
👁 557
❤ 2
🔁 2
May 24
🔥Hot off the press! #ASCO26 abstract release: Phase 3 MajesTEC-9 trial data with teclistamab monotherapy in patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy.
@RobertoMinaMD @MassGeneralNews @harvardmed @WinshipAtEmory
👁 446
❤ 2
🔁 0
May 22
#ASCO26 #mmsm Oral sessions myeloma
MajesTEC-9
Infections occurred, mainly at the first 6 months (IVIG is very imp)
Infections continue to occur even 1-2 years after (need to do time limited therapy) https://t.co/Dmnp4wpEoE
👁 374
❤ 4
🔁 2
May 29
#ASCO26 #mmsm
Some easy summary data for MajesTEC-9, really nice results and summary of adverse events https://t.co/S9nYxJ9RM6
👁 341
❤ 10
🔁 5
May 30
#ASCO26 #mmsm Oral sessions myeloma
MajesTEC-9
Improved OS with HR: 0.60
Subsequent line of therapy used BsAb or CAR-T https://t.co/G6mahFVCRD
👁 299
❤ 2
🔁 2
May 29
@Abdallah81MD @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @oncodaily With 85% CD38 refractory in MajesTEC-9, they are very different patient population
👁 246
❤ 3
🔁 0
May 5
📢 #ASCO26: “MajesTEC-9 is the second phase 3 study to show a significant PFS and OS benefit in the second-line setting and beyond with teclistamab-based therapy for R/R #MultipleMyeloma,” said @RobertoMinaMD. @WinshipAtEmory https://t.co/H49dbogKJr
👁 213
❤ 2
🔁 2
May 30
🚨 What 3 multiple myeloma abstracts should you be on the lookout for at #ASCO26?
1️⃣ The phase 3 MajesTEC-9 trial
2️⃣ The phase 2 Optec/Optal trial
3️⃣ The phase 3 SUCCESSOR-2 trial
https://t.co/3SdWanQSzZ
#mmsm #oncology #cancer https://t.co/YwV6MtSR2g
👁 155
❤ 0
🔁 0
May 29
One framing point: don't line MajesTEC-9 up against MajesTEC-3. Different experiment — monotherapy vs a tec+DARA doublet, CD38-exposed vs CD38-refractory-EXCLUDED, 17 vs 34 mo follow-up.
The matched comparator is MonumenTAL-6 (talquetamab, same CD38-exposed population, PVd arm).
👁 149
❤ 0
🔁 0
May 29
@RayWangonc Yes, I agree. Tec is a very solid 2L option.
The unanswered questions are:
• Fixed-duration therapy for favorable-risk patients?
• CAR-T vs Tec-based platforms for high-risk first relapse?
• Who still benefits from conventional salvage?
MajesTEC-9 tells us Tec belongs
👁 60
❤ 2
🔁 0
May 30
@b_2boysmom1310 @DrRishabhOnco Good question.
For the ~35% of patients who were triple-class refractory, Kd is not an unreasonable comparator in my view, particularly in patients already refractory to daratumumab.
However, MajesTEC-9 enrolled a heterogeneous population. Not all patients were
👁 20
❤ 1
🔁 0
May 30
For years, BCMA-directed therapies have delivered remarkable results in heavily pretreated multiple myeloma. The question has been: what happens if we move them earlier?
The phase 3 MajesTEC-9 trial provides a compelling answer.
Patients with relapsed or refractory multiple
👁 9
❤ 0
🔁 1
May 30
SUCCESSOR-2
Myeloma · Phase III
▼
3) SUCCESSOR-2. Mezi-Kd vs. Kd. It's a late breaker so stay tuned for the data.
This will be an important study as it will serve as the FIRST randomized study of carfilzomib with an IMiD/CELMoD.
This could help to establish an effective regimen for anti-CD38 refractory patients
👁 7.0K
❤ 13
🔁 2
May 29
Why SUCCESSOR-2 is a valid, practice-informing trial and should support approval of Mezigdomide in combination with Carfilzomib and Dexamethasone. I hear some grievance about Kd as control, would argue they are ill informed. 1/x #mmsm
👁 5.0K
❤ 22
🔁 8
May 30
CELMoDs - that much closer to clinic 👏
SUCCESSOR-2 press release: Mezi-Kd beat Kd in registrational Ph3 trial. Data no doubt coming soon!
I love KPd and will love this 100x more as pre-CAR holding/bridging or post-CAR/bsAb failure. T cells ❤️ mezi!
https://t.co/umLNroSwxP https://t.co/TxSZ4RL1p1
👁 2.9K
❤ 32
🔁 9
Mar 10
#ASCO26 LBA
🚨 Mezigdomide may become a major new option in early relapsed/refractory multiple myeloma.
Phase 3 SUCCESSOR-2 showed that adding the oral CELMoD mezigdomide to carfilzomib/dexamethasone nearly doubled PFS in heavily pretreated RRMM.
🩸 SUCCESSOR-2 | RRMM https://t.co/4jZkF5h4aG https://t.co/9qRwXkLUDS
👁 1.7K
❤ 12
🔁 7
May 29
5. SUCCESSOR-2 RCT [Mezi-Kd vs Kd] in R/R #MultipleMyeloma: Abstract not released yet, but will likely be a potential non-CAR/BsAb option for CD38-refractory patients.
👁 1.5K
❤ 11
🔁 1
May 25
Phase 3 SUCCESSOR-2: Mezigdomide + carfilzomib + dexamethasone (MeziKd) demonstrated improved outcomes vs Kd alone in relapsed/refractory multiple myeloma, highlighting a promising new option for RRMM treatment. #mmsm #ASCO26
Congratulations to Paul Richardson et al. We badly https://t.co/xVW7KySerI
👁 1.1K
❤ 17
🔁 10
May 29
SUCCESSOR-2: where success met Mezigdomide and when success becomes Meziurable.! #ASCO26 @TheIACH @COMyCongress https://t.co/VNB6OVhj1F
👁 942
❤ 19
🔁 6
May 30
#ASCO26 @ASCO abstracts are out, looking for a great meeting #mmsm @utswcancer
Here are my top 5 plasma cell disorders to watch for
🧵
2⃣SUCCESSOR-2 trial: RCT of MeziKd vs Kd in RRMM: Mezi activity post BCMA failure is encouraging and hope this will allow for access to this https://t.co/HoLQPALBx4
👁 893
❤ 6
🔁 2
Apr 21
.@RahulBanerjeeMD previews the phase 3 SUCCESSOR-2 trial evaluating mezigdomide in combination with carfilzomib and dexamethasone, which will be presented at #ASCO26 #mmsm
Read more on the most anticipated @ASCO myeloma abstracts here https://t.co/uus32HJvuI https://t.co/54RkngNT8K
👁 790
❤ 10
🔁 7
May 26
#ASCO26 #mmsm Oral sessions myeloma
SUCCESSOR-2 : Mezi-KD
Patients characteristics summarized below https://t.co/NiiXdLE7C2
👁 746
❤ 8
🔁 3
May 29
Cartitude 4, Tec-3, Tec-9, Tal-3, Tal-6, successor-2, MagnetisMM-5, MagnetisMM-32 are all valid practice-informing trial. Their controls were appropriate given the evidence at time of design and accrual. But they set a new benchmark against which future Rx must be compared.
👁 708
❤ 17
🔁 2
May 29
6. SUCCESSOR-2: PhIII, Mezigdomide (CELMoD) + Carfilzomib + Dex (MeziKd) vs. Kd in refractory/relapse myeloma
- At 18mos, PFS: 70% vs. 27%
- OS ⬆️ w/ Tec (HR: 0.60)
- Gr 3/4 AEs: 85% vs. 76% 😲
- Non CART or BsAb in 2L
7/7 https://t.co/JsVao6j9Hy https://t.co/zL9yK18PD6
👁 614
❤ 3
🔁 2
May 29
#ASCO26 LBA7506
SUCCESSOR-2: Mezigdomide + carfilzomib + dexamethasone vs Kd in relapsed/refractory multiple myeloma https://t.co/0e62kkS7ta
👁 591
❤ 1
🔁 1
May 29
#ASCO26 #mmsm Oral sessions myeloma
SUCCESSOR-2 : Mezi-KD
PFS improved with deeper responses. Better PFS2
No difference in OS https://t.co/LDUSPyZhrF
👁 552
❤ 4
🔁 1
May 29
#ASCO26 #mmsm Oral sessions myeloma
SUCCESSOR-2 : Mezi-KD
G5 AEs were higher in Mezi-KD
Higher risk of G3/4 infections also noted
Higher grade 3/4 Neutropenia in Mezi-KD https://t.co/2wO4U4MuqR
👁 437
❤ 3
🔁 1
May 29
.@DanaFarber’s Dr. Paul Richardson presents results from the SUCCESSOR-2 study showing the oral drug mezigdomide markedly improved PFS in patients w/relapsed or refractory multiple myeloma. Results support this potent & novel therapy as a possible new standard of care for RRMM. https://t.co/ThmlvLsW9I
👁 412
❤ 8
🔁 3
May 29
SUCCESSOR-2 (LBA7506) | ASCO 2026
🔑 The problem:
Most modern myeloma patients now relapse after lenalidomide and anti-CD38 therapy.
🧬 The innovation:
Mezigdomide is a CELMoD (Cereblon E3 Ligase Modulator)—a next-generation cereblon-targeting agent designed to overcome https://t.co/jh7M0aAYjh
👁 293
❤ 0
🔁 0
May 29
📢 #ASCO26: SUCCESSOR-2 shows oral mezigdomide plus carfilzomib/dexamethasone extends PFS to 18 months in high-risk relapsed #myeloma, according to data presented by Dr. Paul G. Richardson (@DanaFarber).
Read more: https://t.co/wtbc9eEOCs
#Oncology #Hematology #ClinicalTrials
👁 224
❤ 2
🔁 0
May 30
Updates from #ASCO26: Results from the phase 3 #SUCCESSOR2 trial demonstrated that #mezigdomide plus #carfilzomib and #dexamethasone significantly improved #PFS in previously treated R/R multiple #myeloma. Learn more: https://t.co/yuxh49XqKY
#medtwitter #onctwitter https://t.co/dY53G5yxTr
👁 117
❤ 0
🔁 0
May 29
Bristol Myers Squibb myeloma drug doubles progression-free survival in pivotal SUCCESSOR-2 trial https://t.co/IhqTzWNRC0 $BMY #BMY #BristolMyersSquibb #MultipleMyeloma #Mezigdomide #CELMoD #Oncology #ASCO26 #Pharma #NYSE #USStocks
👁 82
❤ 0
🔁 0
May 30
🚨 Latest #Oncology Update!
🔷 The Phase III SUCCESSOR-2 trial showed that Mezigdomide + Carfilzomib + Dexamethasone (MeziKd) significantly improved outcomes in relapsed/refractory multiple myeloma, reducing the risk of disease progression or death by 52% versus Carfilzomib + https://t.co/RIjwYRoYS9
👁 75
❤ 0
🔁 0
May 30
MajesTEC-3
Teclistamab + Daratumumab · RRMM (Phase III)
▼
With 85% CD38-refractory, we are seeing at least a similar (if not better) PFS with single-agent Teclistamab when compared to Cilta-cel arm of CARTITUDE-4, which had just ~25% CD38-refractory. These results, along with MajesTEC-3, challenge the dogma of “CAR T before BsAbs” in https://t.co/D5kF3Igr8X
👁 8.2K
❤ 54
🔁 18
May 22
For relapsed myeloma not refractory to dara (including dara exposed but not refractory), Teclistamab plus Dara or ciltacel remain first choice. Based on Majestec-3 trial.
Tec and Tec Dara and Ciltacel are all contingent on access, and whether the treatment can be administered
👁 2.7K
❤ 20
🔁 1
May 23
@kansagraMD Great to see Talq become q4 week after C4-6 and pom 2mg only. Tal-DP vs Tal-D should be looked at in HRCG, EMD, and Functionally high-risk myeloma subgroups. 2yr PFS looks similar to MajesTEC-3. This could be a great option for post 2L CAR T relapse. Will wait for https://t.co/jSHlySQ8Bn
👁 1.8K
❤ 15
🔁 4
May 12
@HadidiSamer It would be interesting to see if pts who were CD38 non refractory (15%) had similar outcomes to those in MajesTEC-3. In other words, do we need CD38+Tec ot TEC alone is sufficient.
👁 214
❤ 4
🔁 0
May 22
@Phhersh @NEJM @TheLancet Ok, I see your point. Yes, agree with that. With just 18 months median follow-up, I wouldn’t put much weight on the tail here (it’s a “fairy tail” as @VPrasadMDMPH would say haha). The median follow-up up is almost double in MajesTEC-3 and CARTITUDE-4, for example. Will have to
👁 107
❤ 1
🔁 0
May 30
@OpenMedicineHQ @VincentRK MajesTEC-3 is reshaping my approach to first relapse. Tec-dara offers strong PFS without the complexity of CAR-T. 🧬
👁 98
❤ 2
🔁 0
May 19
inMMyCAR
In vivo CAR-T · Multiple Myeloma
▼
#mmsm #ASCO26 inMMyCAR, in vivo CAR-T
➡️N=6 pts, age: 61-72 yrs
➡️CRS 4/6, all G2 (relatively higher than approved CAR-T), required tocilizumab and corticosteroids
➡️no ICANS or delayed toxicity (though very limited follow up)
🛑Follow up short overall, all responded 👇
This https://t.co/0FiktoYI6q
👁 1.5K
❤ 17
🔁 6
May 22
#ASCO26 @ASCO abstracts are out, looking for a great meeting #mmsm @utswcancer
Here are my top 5 plasma cell disorders to watch for
🧵
5⃣ inMMyCAR: KLN-1010 CAR-T, phase I, initially presented in #ASH25 with short follow up and low n. Updated results. https://t.co/0NrgliNoLx
👁 695
❤ 5
🔁 1
Apr 21
Sarcoma79 tweets captured
🚨Delighted to deliver a lecture at the #ASCO26 Clinical Science Symposium Session on one of the most exciting frontiers in sarcoma therapeutics @ASCO
🖖"To Boldly Deliver Where No Drug Has Gone Before: Antibody-Drug Conjugates in Sarcoma"
👉ADCs have transformed the treatment https://t.co/ed5iWtCxoY
👁 5.2K
❤ 62
🔁 19
May 20
Alright! @FLLFlyer to @MDW
Officially on my way to #asco26 @asco who’s in Chicago already? @OncoAlert @OncBrothers @OpenMedicineHQ @SylvesterCancer @SCCCSarcoma @HemOncMiami @COlazagasti @Latinamd how much luggage do you have? https://t.co/ExsAglRnLF
👁 3.9K
❤ 71
🔁 8
May 28
@ASCO Plenaries:
➡️ seeing #sarcoma + #pancreas take main stage for practice changing trials = amazing!
➡️ Two #lungcancer studies featuring areas of need: #squamous + #earlystage
➡️ Look forward to learning with colleagues from around the 🌎!
#ASCO26 @OncoAlert https://t.co/bUDQTVDv05
👁 2.1K
❤ 25
🔁 7
Apr 26
#Signature #AirportExpress ✈️ 🚝 📸before long trek (14hrs 50mins! 😭) across the 🌎 from 🇭🇰 to #Chicago for @ASCO #ASCO26. Looking forward to insightful discussions and meetings with #LCSM 🫁, #sarcoma 🦴🥩😝, #drugdevelopment 💊, #healthpolicy 🏥 colleagues and friends from https://t.co/6o0mBwugtP
👁 2.1K
❤ 55
🔁 6
May 28
Reviewing the #ASCO26 program announcement & spotted a photo of @realbowtiedoc and me from our @PallOncCoP meeting. Such a great memory
Looking forward to being back in Chicago and hopefully seeing many of you there! @ASCO
https://t.co/wFEDuB4oNO https://t.co/yPp1zk1LnH
👁 1.6K
❤ 23
🔁 8
Apr 25
🧵1/ Continuing the series on major sarcoma presentations at #ASCO2026:
Conventional chondrosarcoma (CS) remains one of the most challenging diseases in sarcoma oncology.
Surgery is the cornerstone for localized disease, but for unresectable/metastatic CS, systemic options have
👁 1.0K
❤ 12
🔁 6
May 19
Clinical Trials8 trials with discussion
SARC041
Sarcoma · Phase 3
▼
In preparation for the 2026 @ASCO Annual Meeting, I'll post tweetorials for the most expected data in #sarcoma. Starting with the plenary, of course - SARC041! @SARCtrials
🧵1/ Well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS) remains one of the most common,
👁 3.6K
❤ 20
🔁 8
May 18
@asco #asco26 is four weeks away. Looking forward to seeing everyone in Chicago.
Eagerly awaited: Plenary Session trials
PROTEUS - Perioperative apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized / locally advanced prostate cancer
SARC041 - https://t.co/A33pOdQV7K
👁 3.2K
❤ 36
🔁 16
May 1
The loudest plenary trial at ASCO may be one pharma did not fund.
This year’s list tells a very clear story.
⭐ Daraxonrasib
13.2 vs 6.7 mo in pancreatic cancer.
But then there is SARC041.
A breast-cancer drug working in sarcoma.
Pharma did not fund the Phase 3.
NCI CTEP https://t.co/HzLK6lZB1v
👁 1.6K
❤ 14
🔁 5
May 21
@Dr_RShatsky @ASCO Similarly I am glad people are highlighting SARC 041 but have seen several AI-generated graphics w/ errors (not just this one).
It's a huge triumph!
But:
- SARC is not an NCI coop group, though it is an awesome nonprofit
- Study was funded by Lilly.
- Not first Ph3 in ddLPS
👁 811
❤ 2
🔁 0
May 27
#ASCO26 LBA2 - Dickson -SARC041: Ph3 DBRCT abemaciclib vs placebo in Pts w/ adv dedifferentiated liposarcoma [May 31, 2026] https://t.co/oWEeVo2oyq #NCT04967521 #scmsm
👁 163
❤ 2
🔁 0
May 26
@mukundiyngr Daraxonrasib is the obvious talk of the town, but wow in the SARC041 story
👁 116
❤ 2
🔁 0
May 21
5/ Then came abemaciclib.
Key differences versus palbociclib: • more continuous CDK4 inhibition • continuous dosing schedule • potentially greater activity in CDK4-dependent tumors
This led to the phase II study to be reported by Dickson et al (SARC041)
👁 89
❤ 3
🔁 0
May 18
Abemaciclib vs. placebo in advanced dedifferentiated liposarcoma — Phase 3 SARC041.
Plenary · Abstract LBA 2
📍 Hall B1, Chicago
🗓 May 31 · 18:39 CT
First sarcoma trial in the ASCO Plenary in 7 years. No approved targeted therapy exists for DDLS. Embargoed until presentation.
👁 84
❤ 0
🔁 0
May 28
6. Abemaciclib (SARC041) — CDK4/6 inhibition in advanced dedifferentiated liposarcoma. A rare tumor, a targeted bet.
Buzz Score: 89% (7/9)
#ASCO26 #Sarcoma
👁 75
❤ 0
🔁 0
May 27
RINGSIDE — Abs 11506
Varegacestat · Progressing Desmoid Tumors (Phase 3)
▼
So anything actually new in $IMNM's Ringside presentation that we didn't already know in December? Apparently it's good enough for #Asco26 https://t.co/xo4KB4HMvL
👁 4.3K
❤ 9
🔁 1
May 30
Desmoid tumors are “benign” histologically — but clinically aggressive, painful, and difficult to control.
At #ASCO2026, the Phase 3 RINGSIDE trial showed major activity with the oral γ-secretase inhibitor (GSI) varegacestat:
• HR 0.16 for progression
• ORR 56% vs 9%
• Deep https://t.co/pcGFvua8cy
👁 1.7K
❤ 35
🔁 15
May 23
#ASCO26
Desmoid tumors may finally have a true targeted standard. 🎯
RINGSIDE phase III shows varegacestat dramatically improved outcomes in progressing desmoid tumors.
🧵 Key findings from Abstract 11506:
🔹 Trial
Varegacestat vs placebo
156 patients with progressing desmoid https://t.co/K6dEiqn2G1 https://t.co/wsAdevStyx
👁 1.3K
❤ 15
🔁 11
May 27
🧠📊 #ASCO26 #Sarcoma | RINGSIDE (Phase III)
✔️ Varegacestat vs PBO in progressing desmoid tumors
📈 ORR: 55.7% vs 9.1%
📈 PFS: HR 0.16
📈 2-y PFS: 88.9% vs 56.7%
💬 Pain improvement: −2.24 vs +0.18
📉 tumor volume change: −83.4% vs +11.3%
⚠️ Diarrhea 82%, fatigue 44%, rash 43 https://t.co/CnYqvh4xKd
👁 536
❤ 13
🔁 11
May 30
#ASCO26
Abstract 11506
RINGSIDE: Phase III varegacestat in progressing desmoid tumors https://t.co/yMxTHPtuUm
👁 271
❤ 3
🔁 1
May 27
PEAK — Abs 11500
Bezuclastinib + Sunitinib vs Sunitinib · GIST (Phase 3)
▼
$COGT Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting https://t.co/VMxPpUANix
👁 5.4K
❤ 9
🔁 3
May 30
Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (#GIST) #ASCO26 @SylvesterCancer 46 vs 26% ORR
PFS 16.5 vs 9.6 months https://t.co/EWfHSqjqAA
👁 330
❤ 9
🔁 8
May 30
afami-cel — Abs 11505
Afamitresgene autoleucel · Metastatic Synovial Sarcoma
▼
#ASCO26 🧬
Afami-cel may be the clearest proof yet that engineered TCR therapy can work in solid tumors.
In advanced synovial sarcoma:
🧪 MAGE-A4 targeted TCR therapy
👥 Pooled phase 1/2 dataset (N=153)
🎯 ORR: 43.8%
✅ CR: 4.6%
📉 Median PFS: 4.0 mo overall
📈 Median PFS in https://t.co/jIejf8D5nA https://t.co/wsAdevStyx
👁 1.3K
❤ 14
🔁 5
May 30
🧠📊 #ASCO26 #Sarcoma | Afami-cel in advanced synovial sarcoma (n=153)
📈 ORR 43.8% | mDoR 7.1 mo | mPFS 4.0 mo | mOS 20.2 mo
🎯 mOS 37.5 mo in responders vs 10.9 mo in non-responders
⚠️ CRS 73% (Grade ≥3: 3.3%)
🧬 Afami-cel demonstrate meaningful and durable activity https://t.co/50yaOfKOgj
👁 552
❤ 10
🔁 9
May 30
🚨 Afami-cel in metastatic synovial sarcoma: pooled analysis of 153 patients from phase 1/2 #ASCO26
🎯 ORR: 43.8% (CR 4.6%) || Median DoR: 7.1 months
💥 Median OS: 20.2 months
▪️ Responders achieved a median OS of 37.5 months
🛑 CRS 73%
The largest afami-cel dataset to date https://t.co/19gSL2Wpy6
👁 543
❤ 11
🔁 9
May 30
🚨 Afami-cel in metastatic synovial sarcoma: pooled analysis of 153 patients from phase 1/2 #ASCO26
🎯 ORR: 43.8% (CR 4.6%) || Median DoR: 7.1 months
💥 Median OS: 20.2 months
▪️ Responders achieved a median OS of 37.5 months
The largest afami-cel dataset to date confirms https://t.co/jwjFg2c2fC
👁 6
❤ 0
🔁 0
May 30
2ND-STEP (JCOG1802) — Abs 11508
Trabectedin vs Eribulin vs Pazopanib · 2L Soft-Tissue Sarcoma
▼
ChonDRAgon — Abs 11504
Ozekibart (INBRX-109, DR5 agonist) · Chondrosarcoma (Phase 2)
▼
🐉 ChonDRAgon (Phase II, n=206): Ozekibart in advanced cnventional chondrosarcoma #ASCO26
▪️ mPFS: 5.5 vs 2.7 mo by central review (HR 0.48; p<0.0001)
💥 DCR: 54.0% vs 27.5%
❔ ORR: 5.8% vs 0%…
🎯 Delayed pain deterioration: 2.76 vs 1.41 mo
For a disease with virtually no https://t.co/yzsDJhSgfi
👁 723
❤ 12
🔁 7
May 30
🧠📊 #ASCO26 | ChonDRAGon
✔️ Ozekibart (DR5 agonist) in advanced conventional chondrosarcoma
📈 mPFS: 5.52 vs 2.66 months
📉 Risk of progression/death reduced 52% (HR 0.48; P<0.0001)
📈 DCR: 54.0% vs 27.5%
📈 ORR: 5.8% vs 0%
💪 Delayed deterioration
🎯 Potential new SoC https://t.co/Cm0LnuRWil
👁 555
❤ 6
🔁 6
May 30
Trabectedin + RT — Abs 11507
Concomitant RT · Resectable Retroperitoneal L-sarcoma (GEIS/ISG/FSG)
▼
VEBrant — Abs 11503
Vebreltinib · Advanced Clear Cell Sarcoma (Phase 2)
▼
🚨 VEBrant (Phase II): Vebreltinib + PD-1 rechallenge in advanced Clear Cell Sarcoma (pts with EWSR1-fusion CCS progressing after prior PD-1 therapy) #ASCO26!
💥 ORR 36.8% (7/19 evaluable pts) || DCR 68.4%
🤚🏼 mPFS: 4.2 mo (6.8 mo in prior VEGF-TKI non-responders) || OS not https://t.co/t6pkBNtjeQ
👁 603
❤ 9
🔁 11
May 30
Continuing to prepare for #ASCO2026: VEBrant presents a novel, meaningful targeted therapy signal in clear cell sarcoma — and it arrives for a disease that has had no established standard of care, in patients with a median age of 29.
Clear cell sarcoma (CCS) is an ultra-rare
👁 406
❤ 6
🔁 2
May 26
Melanoma24 tweets captured
Somehow I'm one of @ASCO's Featured Voices for social this year — genuinely pleased about it, and in stellar company!! Headed to #ASCO26 next week: GU, melanoma/skin, and whatever else catches my eye. Come hang out in the timeline!! https://t.co/ka3DebuauS
👁 3.4K
❤ 29
🔁 8
May 20
💥My Top 10 @ASCO 2026 Skin Cancer picks are here! @OncoAlert
A skin cancer track that’s ready to STAMP its mark, PIVOT the field, and give melanoma a Neo-antigen glow-up 😉
#ASCO2026 #Melanoma #SkinCancer #Immunotherapy #OncoAlert
@OncoReporte @myESMO @_SEOM https://t.co/soZxIRJM6j
👁 1.4K
❤ 22
🔁 2
May 26
🔥Precision immunotherapy: revolutionizing Ca Tx with targeted innovations
🆙 @ASCO Ed Book 2026
☑TCEs & ADCs offer strategies beyond ICI
🎯Tebentafusp & tarlatamab establish POC; EV+pembro reshapes urothelial Ca
🎙Dr. Myung-Ju Ahn
@OncoAlert @Larvol
https://t.co/afu3WTfoDh
👁 1.3K
❤ 9
🔁 1
May 12
#ASCO26 🖤 #Melanoma edition.
6 abstracts.
-Cell therapy with no high-dose IL-2 💉
-Neoadjuvant toxicity that changes the benefit/risk calculus ⚖️
-KEYNOTE-942 at 5 years 📊
Uveal unmet need still open 👁️
My personal read & full guide on LinkedIn 👇👇
👁 791
❤ 6
🔁 4
May 25
⭐ Beyond tumor silos: #ASCO26 data with real-world impact ⭐
This OncoAlert Top 10 across #Melanoma, Head & Neck, and #PallOnc highlights how broad the oncology conversation at #ASCO26 will be. 🚨🌍
From cellular therapy and neoantigen vaccines, to immunotherapy combinations, https://t.co/NHrxRBxqfg
👁 650
❤ 8
🔁 5
May 29
“Immunotherapy in #Melanoma: Real-World Applications of Recent Data for Community Practice” with Drs. Tawbi (@HTawbi_MD), Gibney and McKean (@MeredithMcKean) on 5/30 at 6:30 PM CDT ➡️ https://t.co/8HwEy8CdsQ #ASCO26 #Oncology https://t.co/O7BGNCWlNP
👁 326
❤ 9
🔁 5
May 15
Clinical Trials1 trial with discussion
IMCgp100-202
Tebentafusp · 5-yr OS · Metastatic Uveal Melanoma
▼
🆕 Article in press: Five-year survival with tebentafusp in metastatic uveal melanoma
👉 https://t.co/1Pqi1595e1 https://t.co/9OGQDXwEEG
👁 3.1K
❤ 31
🔁 11
May 21
Tebentafusp doubles 5-year survival in previously untreated metastatic uveal melanoma. Paul D. Nathan, MBBS, PhD, FRCP breaks down the phase 3 CT029 data and what ctDNA response means for predicting patient benefit.
Watch now: https://t.co/1TTCgHI06E
#UvealMelanoma #Oncology https://t.co/7bZrnZZ9zr
👁 247
❤ 1
🔁 2
May 18
Leukemia & Lymphoma18 tweets captured
Thanks for allowing me to speak about my favorite topic- menin inhibitors in AML. Such exciting data on the horizon! https://t.co/Qnp7veEdUB
👁 1.0K
❤ 13
🔁 1
May 22
#ASCO26 ZZFIRST: enzalutamide + talazoparib met the PSA <0.2 endpoint in high-volume mHSPC, but anemia and 2 AML cases matter.
The key issue: efficacy vs long-term toxicity.
@DrYukselUrun @OncoAlert #ProstateCancer @urotoday #oncology @nataliagandur https://t.co/lZURnj3KFg
👁 469
❤ 11
🔁 7
May 30
#ASCO26
Can lower-intensity therapy outperform “7+3” in the real world for AML patients at high risk of induction mortality?
A prospective Indian study from Tata Memorial Hospital compared AZA+VEN vs intensive 3+7 induction in de novo AML patients.
🧪 Study population
• 154 https://t.co/QIHWVdq8gr https://t.co/9qRwXkLUDS
👁 324
❤ 2
🔁 4
May 31
@quimmateo PhII rand ZZFIRST trial of #ADT + enza +/- talazoparib in #1L high-volume #mHSPC (>75% w/o #HRR mut) ➡️ 73% 12-mo #PSA response rate w/tala arm meeting primary endpoint but no significant difference in #rPFS, 2 cases of MDS/AML in tala arm
#ASCO26 @OncoAlert https://t.co/sSQJoCqqR6
👁 305
❤ 9
🔁 7
May 30
Older adults w AML discuss multiple priorities during treatment decisions, but many values are not explored in depth
The #URGOAL communication intervention showed greater patient engagement & improved value alignment #ASCO26 @melissa_loh
https://t.co/XGv2I5NXl3 https://t.co/ERH0B8rJLk
👁 266
❤ 4
🔁 5
May 23
Great start to @ASCO #ASCO26 today at the @lymphoma honoring Dr. Winter of @LurieCancer and many survivors.
Great cause and purpose. https://t.co/iB7GDKHyqD
👁 260
❤ 0
🔁 1
May 29
Other Solid Tumors64 tweets captured
Why crown trial should have all the FUN ?
The love affair between MSI high and IO drugs continues. This time in advanced Endometrial cancer . Dostarlimab in RUBY trial. Long term follow up . @ASCO #asco26 https://t.co/phPqKNdph3
👁 3.5K
❤ 21
🔁 5
May 30
𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: @YaleCancer's @DrRoyHerbst, recognized as one of the foremost leaders in lung and head & neck cancer research, shares his take on what's in focus at this year's ASCO Annual Meeting. #ASCO26
Full video: https://t.co/L7jHGzwsSr https://t.co/uTw68vnXX8
👁 2.6K
❤ 8
🔁 2
May 29
Attending #ASCO26? Make sure not to miss the educational session on novel ADCs on Saturday afternoon! I’ll cover some recent hot topics in the field: combinations, sequencing, and strategies to get the most out of ADC treatment for solid tumors. Chaired by @curijoey 🎯 https://t.co/XvJeMkKpWN
👁 2.5K
❤ 50
🔁 14
May 21
🚨 #ASCO26 CHRONO Trial
Can surgery safely be delayed after neoadjuvant chemotherapy in advanced ovarian cancer?
The phase II CHRONO trial says:
👉 Delaying interval debulking surgery after 6 cycles of NAC did NOT worsen outcomes.
🧪 Stage IIIB-IVA high-grade epithelial https://t.co/PUzcjEOuJg https://t.co/PxugrpSRGF
👁 2.1K
❤ 13
🔁 4
May 28
🆙 #ASCO26 #LCSM Poster Session
🔥DM005 (Anti-EGFR/c-MET Bispecific ADC): First-in-Human Study in Advanced Solid Tumors
🎙️Dr. Jin-Ji Yang
🔢8530
☑️NCT06515990
🔗 https://t.co/uyGCcj0JfL
@OncoAlert @Larvol @ASCO @EGFRResisters @metcrusaders https://t.co/qb7eJTRKAK
👁 1.1K
❤ 13
🔁 4
May 10
Short-term fasting around chemo administration linked to better outcomes among women with advanced ovarian cancer #asco26 @asco @ASCOPres https://t.co/QT3VxCHZ2j
👁 958
❤ 15
🔁 9
May 27
Clinical Trials1 trial with discussion
OPTIMUM-02
ctDNA-guided · Adjuvant
▼
$IDYA to Initiate NDA Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program.
Completion Expected in 2H'26
👁 5.3K
❤ 16
🔁 3
Apr 30
$IDYA full results from the OptimUM-02 trial will be presented in a late-breaking presentation at #ASCO26
👁 3.0K
❤ 5
🔁 0
Apr 30
$IDYA As expected,late-breaking abstract for OptimUM-02 of
darovasertib in 1L metastatic uveal melanoma (HLA-A2(-) patients) was not
available (until Monday, 6/1). continue to see the totality of known data
from the top-line (~6.9 month PFS benefit for darovasertib + crizotinib
👁 3.0K
❤ 6
🔁 0
May 22
$IDYA to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program https://t.co/9SBOWnKWQ2
👁 782
❤ 4
🔁 0
Apr 30
$IDYA
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
👁 245
❤ 0
🔁 0
Apr 21
$IDYA
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
More Info: https://t.co/GHGrqamvxP
👁 222
❤ 0
🔁 0
Apr 21
News & Publications
Major Media Coverage Heading Into ASCO 2026
Key stories, publications, and press coverage from the AACR Annual Meeting — curated from major oncology media and ASCO previews.
Media Coverage
Merck/Kelun sac-TMT 'Potentially Better' Than Summit/Akeso's Ivonescimab in Lung Cancer
Adam Feuerstein: the Kelun/$MRK TROP2 ADC sac-TMT "looks very good in lung cancer, potentially better than Akeso / $SMMT's ivonescimab" — and the data are "very competitive," raising the prospect that a TROP2-targeted ADC could "steal the show from the PD1/VEGFs" ahead of Summit's HARMONi-6 readout.
Press ReleaseOptiTROP-Lung05 (Abs 8506): Merck/Kelun sac-TMT + Pembro Posts First Global Phase 3 Win — Progression Risk Cut 65%
Merck-Kelun's sacituzumab tirumotecan (sac-TMT) plus pembrolizumab beat pembrolizumab in 1L PD-L1+ NSCLC (OptiTROP-Lung05, Abstract 8506) — the first ADC+immunotherapy combination to win a global Phase 3 in untreated lung cancer. Matthew Herper reports it "cut tumor progression risk by 65%" (HR 0.35; ORR 70% vs 42%) — intensifying competitive pressure on Summit/Akeso's ivonescimab (HARMONi-6). (Separately, OptiTROP-Lung04 showed sac-TMT monotherapy beats chemo in 2L+ EGFR-mutant NSCLC.)
Media CoverageDaraxonrasib Shows 'Unprecedented' Survival in Pretreated Pancreatic Cancer (RASolute 302)
Phase 3 RASolute 302: the multiselective RAS(ON) inhibitor daraxonrasib nearly doubled median OS vs chemotherapy in previously treated metastatic PDAC — 13.2 vs 6.7 months (HR 0.40, P<0.0001), a 60% reduction in risk of death. Plenary, LBA5, May 31 — PI Brian Wolpin and KOLs call it practice-changing for RAS-mutant pancreatic cancer.
FDAFDA Approves Datopotamab Deruxtecan (Dato-DXd) for Unresectable / Metastatic TNBC
The FDA approved the TROP2 antibody-drug conjugate Dato-DXd (Datroway) for unresectable or metastatic triple-negative breast cancer — a fresh ADC approval landing right ahead of ASCO 2026.
Media CoverageSeven Years Strong: CROWN Confirms Lorlatinib's Durability in 1L ALK+ NSCLC (Abs 8502)
Updated 7-year CROWN data: median PFS with first-line lorlatinib STILL not reached — a 7-year PFS rate of 55% vs 3% for crizotinib in ALK+ NSCLC, described as the longest PFS ever reported in advanced NSCLC.
Media CoverageFull KEYNOTE-522 Survival Data Set to Redefine Early-Stage TNBC Standards
Confirmed overall-survival gains from the full KEYNOTE-522 dataset position neoadjuvant/adjuvant pembrolizumab to definitively set the standard of care in early-stage triple-negative breast cancer.
Media CoverageASCO 2026 Preview: Late-Breaking Abstracts Poised to Reshape the Treatment Landscape
Expert preview of the late-breakers most likely to change practice across lung, breast, GI, and GU — framed by tumor-type session and discussant.
Media CoverageASCO26: 5 Data Snapshots Ahead of the Year's Biggest Cancer Drug Meeting
The most consequential readouts to watch — Merck, BioNTech, Lilly, and Moderna among the names with highly anticipated immunotherapy and ADC datasets.
Press ReleaseMerck/Kelun sac-TMT ADC Combo Beats Keytruda by 65% on Progression in 1L Lung Cancer
In-depth analysis of OptiTROP-Lung05 — a potential new first-line lung-cancer standard as the TROP2 ADC + pembrolizumab combination tops Keytruda monotherapy on PFS.
Press ReleaseCelcuity's Phase 3 VIKTORIA-1 Achieves Primary Endpoint in PIK3CA-wt HR+/HER2- Breast Cancer
Gedatolisib combinations significantly reduced progression risk — 76% with palbociclib + fulvestrant (mPFS 9.3 vs 2.0 mo) and 67% with fulvestrant alone (mPFS 7.4 vs 2.0 mo) in PIK3CA wild-type advanced breast cancer.
Media CoverageEnzalutamide + Radium-223 (PEACE-3) Extends Survival in mCRPC
Coverage of the PEACE-3 survival benefit for Xtandi plus Xofigo in metastatic castration-resistant prostate cancer — a key GU readout at ASCO 2026.
Press ReleaseLilly to Showcase Oncology Portfolio at ASCO 2026 — Selpercatinib & Abemaciclib Plenary
Pivotal LIBRETTO-432 (adjuvant selpercatinib, RET+ NSCLC) and abemaciclib data featured in Plenary/oral sessions across multiple tumor types and modalities.
Press ReleasePfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
Updates for LORBRENA (ALK+ NSCLC), a BRAFTOVI regimen in BRAF-mutant CRC, TALZENNA + XTANDI in mCSPC, and TUKYSA first-line maintenance in HER2+ breast.
Media CoverageOncLive Polls Reveal Top GI Cancer Abstracts & Areas of Interest at ASCO 2026
Specialist-led poll on the most-anticipated GI late-breakers — colorectal, pancreatic, gastroesophageal, and hepatobiliary readouts to watch.
Media CoverageBreast Cancer Hub — May 2026 ADC FDA Approvals & ASCO Coverage
Running archive of May 2026 antibody-drug-conjugate FDA approvals (incl. Dato-DXd 1L TNBC, T-DXd HER2+ early breast) and ASCO 2026 breast highlights.
Media CoverageMerck's Biggest Looming Rival in Cancer Just Took a Gut Punch — Summit (SMMT) Crashes
Summit Therapeutics stock crashed after ivonescimab + chemo failed to impress at an interim lung-cancer analysis — reframing $SMMT as a damaged Keytruda challenger going into ASCO; trial continues to final analysis in Q2.
Media CoverageRevolution Medicines (RVMD): Merck M&A Talks Reported, Then Pulled Back
$RVMD jumped on reports Merck was in talks to acquire the RAS-platform company, then reset when later reporting said Merck was no longer pursuing a deal — leaving a 'stand-alone RAS platform with strategic optionality' narrative into ASCO.
Media CoverageThe Week Ahead in Biotech: ASCO Presentations in the Spotlight
Investor preview of the biotech names with ASCO 2026 catalysts — $SMMT, $RVMD, $MRK, $CELC, $IDYA — and the winners/losers framing analysts are watching around the meeting.
Press ReleaseBioNTech/BMS Bring Pumitamig (BNT327) to ASCO 2026 — the Lead 'Ivonescimab Rival' Bispecific
Interim Phase 2 dose-optimization data for pumitamig (PD-L1xVEGF-A bispecific, partnered with BMS) plus chemo in 1L NSCLC (ROSETTA Lung-02). Finance accounts ($BNTX $BMY $PFE) read it as the PD-(L)1/VEGF class answering Summit/Akeso's ivonescimab stumble — 'pumitamig looks similar to ivonescimab again.' Phase 3 efficacy still pending.
Press ReleaseImmunityBio (IBRX): Median OS Not Reached With Chemo-Free ANKTIVA + CAR-NK in Recurrent Glioblastoma
QUILT 3.078 Phase 2: in 2L recurrent/progressive GBM, the chemo-free ANKTIVA (N-803) + CAR-NK (t-haNK) regimen reported median OS not yet reached, a near-complete response beyond 12 months, and lymphocyte recovery without chemo (Jan 22, 2026 cut; 23 pts, 19 alive). Early-stage, small-N — among the most-shared finance-account posts of the pre-ASCO run.
Press ReleaseReplimune ($REPL): FDA Aligns on RP1 BLA Resubmission — Priority Review After Two Prior CRLs
After two CRLs (July 2025 and April 2026) and a leadership shakeup at FDA (Commissioner Marty Makary stepped down earlier this month), Replimune and the FDA aligned on a path forward for resubmission and reconsideration of the RP1 (vusolimogene oderparepvec) + nivolumab BLA in advanced post-PD-1 melanoma. The FDA indicated it will treat the resubmission as an urgent matter and prioritize review. $REPL closed +80% Friday — the biggest single-day gain in seven months.
Media CoverageIGNYTE 3-Year OS at ASCO26: RP1 + Nivolumab Delivers 32.9-mo mOS in Post-PD-1 Melanoma
Mature 3-year landmark analysis from IGNYTE (RP1 + nivolumab, anti-PD-1-failed advanced melanoma) at ASCO26: median OS 32.9 months · 3-year OS 47.8% all treated / 83.5% of responders · ORR 33.6% · mDOR 24.8 months · 44.8% of responders durable at 3 years · no Grade 5 events. The clinical anchor underpinning the resubmission narrative — original IGNYTE PI Michael Wong (MD Anderson) and melanoma KOLs Omid Hamid, Katy Beasley/Beto, and Mohammed Milhem have been vocal champions through both CRL cycles.
Market & Investor Signal
Finance Buzz by Tumor Type
Tweets carrying stock cashtags ($TICKER) — investor, IR, and analyst commentary — segregated from the physician feed and grouped by cancer type.
ASCO 2026 Catalysts 10 confirmed
Confirmed ASCO 2026 disclosures for tickers in the buzz feed below — abstract slots and toplines per company press releases & meeting previews. Not investment advice.
$AZN▲ Positive readout
🔵 EMERALD-3 AstraZeneca
Durvalumab + Tremelimumab + Lenvatinib + TACE
Unresectable HCC · LBA4000
Statistically significant PFS improvement vs TACE alone; OS trend, no new safety signals.
Source ↗$CELC▲ Positive readout
🎗️ VIKTORIA-1 Celcuity
Gedatolisib + Fulvestrant ± Palbociclib
PIK3CA-wt HR+/HER2- mBC · Late-breaking oral
Phase 3 hit: gedatolisib cut progression risk 76% with palbociclib + fulvestrant (mPFS 9.3 vs 2.0 mo) and 67% with fulvestrant alone (mPFS 7.4 vs 2.0 mo) in PIK3CA wild-type advanced breast. Winner setup if full data + tolerability hold.
Source ↗$IBRX▲ Positive readout
⬜ QUILT 3.078 (Ph 2) ImmunityBio
ANKTIVA (N-803) + CAR-NK (t-haNK) · chemo-free
2L recurrent / progressive glioblastoma · ASCO 2026 · 4 abstracts
Early Phase 2 / compassionate-use signal in recurrent GBM: median OS not yet reached, a near-complete response beyond 12 months, and lymphocyte recovery without chemo (data cut Jan 22, 2026; 23 pts, 19 alive). Highest-impression finance-account tweet of the run (~26K imp) — but small-N, early-stage; enthusiasm runs ahead of mature data.
Source ↗$IDYA▲ Positive readout
🌑 OptimUM-02 IDEAYA Biosciences
Darovasertib + Crizotinib
1L HLA-A2-neg metastatic uveal melanoma · LBA9503 · Jun 1
Phase 2/3 registrational late-breaker — darovasertib + Xalkori PFS curves already shown topping IO regimens. Winner, but 'a lot in the price'; incremental upside needs mature PFS/OS + clean safety (classic 'sell-the-news' risk if merely in-line).
Source ↗$MRK▲ Positive readout
🫁 OptiTROP-Lung05 (Abs 8506) Merck / Kelun
sac-TMT + Pembro · TROP2 ADC + IO
1L PD-L1+ NSCLC — first global Phase 3 win · ASCO 2026 · ahead of schedule
TROP2 ADC posted its first global Phase 3 lung win — progression risk cut 65% (Herper). Feuerstein: 'potentially better' than ivonescimab — a competitive threat to Summit/Akeso's HARMONi-6 and the PD-1/VEGF class. (Merck also brings 5-yr KEYTRUDA combo data across the broader portfolio.)
Source ↗$PFE▲ Positive readout
🔷 TALAPRO-3 Pfizer
Talazoparib + Enzalutamide
mCSPC with DDR alterations · LBA5007
Met primary endpoint — clinically meaningful rPFS benefit vs placebo + enzalutamide.
Source ↗$RVMD▲ Positive readout
🔵 RASolute-302 Revolution Medicines
Daraxonrasib
2L metastatic PDAC · Plenary · LBA5 · May 31
Hit PFS + OS vs IV chemo; comprehensive Phase 3 results at plenary. Sentiment trade: $RVMD spiked on reported Merck M&A talks, then reset when reporting said Merck pulled back — now a 'stand-alone RAS platform with strategic optionality' story.
Source ↗$VSTM▲ Positive readout
🔵 GFH375 / VS-7375 (Ph 1/2) Verastem / GenFleet
Oral KRAS G12D (ON/OFF) inhibitor
KRAS G12D-mutant solid tumors (PDAC, NSCLC) · ASCO 2026 · GenFleet readout
Partner GenFleet's China Phase 1/2 of the oral KRAS G12D inhibitor reported ORR ~52% in PDAC (23 pts) and ~42% in NSCLC (12 pts) at a prior cut, with new preliminary efficacy featured at ASCO 2026; US Phase 1/2a interim update due 1H 2026. Emerging KRAS G12D contender behind RVMD's pan-RAS daraxonrasib.
Source ↗$BNTX● Update
🫁 ROSETTA Lung-02 (Ph 2/3) BioNTech / BMS
Pumitamig (BNT327 / BMS-986545) · PD-L1xVEGF-A bispecific + chemo
1L NSCLC (squamous & non-squamous, all PD-L1) · ASCO 2026 · interim dose-optimization
Interim Phase 2 dose-optimization data showed encouraging anti-tumor activity in 1L NSCLC + chemo across PD-L1 levels. Investor frame across the finance feed = the lead 'ivonescimab rival' bispecific: 'pumitamig looks similar to ivonescimab again' and 'after the ivonescimab stumble, rivals unveil their own bispecific data ($BNTX $BMY $PFE).' Phase 3 efficacy still pending.
Source ↗$SMMT▼ Miss
🫁 HARMONi-6 Summit / Akeso
Ivonescimab + Tevimbra + chemo
1L squamous NSCLC · Plenary · LBA4 · May 31
Investor read = LOSER into ASCO: ivonescimab + chemo failed to impress at an interim analysis and $SMMT crashed; reframed as a 'damaged contender vs Keytruda' (trial continues to final analysis in Q2). Overhang: Merck/Kelun sac-TMT (OptiTROP-Lung05) just beat Keytruda mono ~65% on PFS. Watch for 'salvage thesis' / PD-L1-subset language in notes.
Source ↗⬜ Other / Multi-Tumor 154 buzz
$SMMT ivo HARMONi-3 update on squamous subgroup interim PFS analysis:
"At this early interim PFS analysis reviewed exclusively by the Independent Data Monitoring Committee (iDMC), the iDMC recommended that the study continue as planned."
👁 46.9K
❤ 48
🔁 2
Apr 30
$REGN acting like a penny stock biotech shitco. Shamefull.
Lag3 fail.
https://t.co/AUdzIsVmgW
👁 44.3K
❤ 101
🔁 4
May 16
I want $ABVX to be acquired bc a BioX-mass casualty event awaits if a deal doesn’t happen. And @seedy19tron will have to sell his cricket team. https://t.co/YObkkNToQG
👁 43.1K
❤ 90
🔁 2
May 19
The $IBRX hysteria boost on this site in recent days/weeks is a solid indicator of panic. The Anktiva “story” and its related components are falling apart.
👁 35.9K
❤ 26
🔁 2
May 29
An important update to the $ATRA / Pierre Fabre Ebvallo story just breaking:
FDA to reconsider treatment for rare cancer after its surprise rejection https://t.co/8zQSb7q5jU
👁 33.9K
❤ 48
🔁 11
May 7
Whether or not you believe $REPL RP1 deserves to be approved or not, let's please be truthful about what has transpired so far:
Richard Pazdur and others in the FDA's cancer office were responsible for RP1's initial rejection. They objected late in the review process. CBER ie
👁 33.2K
❤ 119
🔁 6
May 29
🔵 GI Cancers 21 buzz
13.2 months vs 6.7. That's the number Revolution Medicines ($RVMD) takes to the ASCO plenary this Sunday — and it's the number that broke every drug that tried before it.
Daraxonrasib is the first pan-RAS(ON) inhibitor to roughly DOUBLE overall survival in previously-treated
👁 35.5K
❤ 13
🔁 0
May 27
Revolution Medicines $RVMD starts shipping experimental pancreatic cancer drug, daraxonrasib.
“We don’t have a set number where we are going to cap it. We want to make sure everybody who needs daraxonrasib for pancreatic cancer will receive it. That’s just very, very important
👁 19.3K
❤ 120
🔁 13
May 30
Some $RVMD news from our STAT @ #ASCO26 event: CEO Mark Goldsmith said the company has begun shipping daraxonrasib to physicians and pancreatic cancer patients under the FDA Expanded Access Program.
Good news for patients.
When will RevMed file for FDA approval? “ASAP,”
👁 16.2K
❤ 119
🔁 10
May 30
$XBI
Again, potential variations on that theme of $XBI valuation escaping M&A orbit to reach Go-It-Alone velocity:
$RVMD — daraxonrasib, just the beginning of Revolutions’ pan-RAS revolution. They’re the buyers now…
$INSM — recent earning’s dip notwithstanding, are they https://t.co/FDN9ariEC7
👁 12.8K
❤ 29
🔁 2
May 17
$ERAS $RVMD ( $BBIO)
Reminds me of $ERAS recent fireside, talking about their IP composition of matter for 0015:
“Two distinct modifications”
“Two key mechanistic changes”
… changes from what?
A $RVMD daraxonrasib structure that wasn’t, at that time, publicly available? https://t.co/CwrgS89pYq https://t.co/5EJOe0U696
👁 8.7K
❤ 17
🔁 0
May 21
🎗️ AACR Highlights 🔬
This weekly shoutout: highlights from X on #AACR26!
AACR26 ended, but KRAS/RAS momentum, ADC expansion, PD-1×VEGF combos, daraxonrasib data, RLT rise and trial design debates keep driving oncology discussions.
@FierceBiotech
$MRK PD-1xVEGF shows 55% uORR https://t.co/vXGAWU8yU5 https://t.co/jtEawdOUG5
👁 6.3K
❤ 18
🔁 4
Apr 25
🫁 Lung Cancer 15 buzz
The #ASCO26 abstracts are live. I wrote a story about the Kelun $MRK ADC sac-TMT, which looks very good in lung cancer, potentially better than Akeso / $SMMT 's ivonescimab
https://t.co/exfmgabTLa
👁 40.9K
❤ 52
🔁 9
May 21
$KURA BofA #ASCO26 will be first opportunity to evaluate
potential of a darli + KRASi combo in KRAS G12C tumors (NSCLC, CRC,&PDAC;
3078)—offering a key test of Kura’s thesis its FTI can broadly enhance targeted therapy
efficacy experts suggested ORRs >40% and PFSs
>6 months
👁 12.1K
❤ 15
🔁 1
May 20
This week's Biotech Scorecard: An #ASCO26 mystery: What does Akeso’s primo plenary spot say about its ivonescimab lung cancer survival data? $SMMT
If the news was good, we'd have heard by now, right? Or, is Akeso just being ultra conservative?
https://t.co/onSduihfrl
👁 10.5K
❤ 22
🔁 1
Apr 30
#ASCO26 Day 1. We're ASCOmaxxing.
Positive data for Bristol $BMY in multiple myeloma and Pfizer $PFE in lung cancer. The FDA will surely convene an adcomm for $REPL, right? And Dizal's good day/bad day.
https://t.co/NiENYMHswv via @statnews
👁 9.6K
❤ 56
🔁 4
May 29
$IDYA-related (SCLC): ABBV/Zelgen's trispecific DLL3 TCE avelutamig ph.II in 3L+ SCLC showed
12mo-OS landmark of ~66% w/ 10mg pivotal dose (53% ORR w/ 7mos mPFS) consistent w/
AMGN's tarlatamab ~60% which reinforces the OS bar for IDYA/Hengrui's 2L+
SCLC update at med conf 2H26.
👁 8.2K
❤ 11
🔁 0
May 23
@janiesaysyay @bullishbruk @ImmunityBio @LoriMills4CA42 @alc2022 @MartyMakary @DrMakaryFDA I'm very sorry about your mom getting lung cancer, but her Covid booster didn't cause it. And no one at the FDA is slow walking Anktiva. If you want to be mad, be mad at $IBRX and @DrPatrick for not conducting or completing the clinical trials necessary to determine if the drug
👁 2.6K
❤ 4
🔁 0
May 6
🔷 GU Cancers 7 buzz
A lot of words but no clarity on whether the FDA accepted $IBRX sBLA for Anktiva in NMIBC papillary disease.
PDUFA date?
Also, if cis and papillary are the same disease, then all currently approved treatments for cis should receive approval for papillary. This is not the https://t.co/zaJo0kxVIZ
👁 26.4K
❤ 27
🔁 2
May 19
Nevertheless the two most promising abstracts imo were from US-originated ADCs:
$ABBV's STEAP1/PSMA - 67% PSA50 and 45% confirmed ORR in heavily pretreated prostate cancer
$LLY's NECTIN4 - 48% ORR in bladder cancer including 40% ORR in Padcev failures
https://t.co/w7Inaf4599 https://t.co/DsnbfmBauF
👁 15.3K
❤ 59
🔁 11
May 21
$IBRX #ASCO26 Update: In bladder cancer patients whose disease returned after BCG, Anktiva + BCG achieved nearly 3x higher complete response rates at 12 months compared to Keytruda (pembrolizumab) — 47% vs 19% - in a matched analysis. Responses also lasted about 10 months longer https://t.co/1ogNR09Si6
👁 10.9K
❤ 176
🔁 31
May 21
$IBRX Breaking at #ASCO26: Anktiva + BCG shows 47% complete response at 12 months vs 19% for Keytruda in BCG-unresponsive bladder cancer (nearly 3x better) in matched analysis.
Responses lasted ~10 months longer with a favorable safety trend.
Big win for Anktiva+BCG. Big hope https://t.co/qk7dYLlyw8
👁 9.1K
❤ 131
🔁 28
May 21
$AZN to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026. #ASCO26 https://t.co/S5kij03Sm1
👁 5.9K
❤ 7
🔁 0
May 22
A lot of words but no clarity on whether the FDA accepted $IBRX sBLA for Anktiva in NMIBC papillary disease.
PDUFA date?
Also, if cis and papillary are the same disease, then all curreny approved treatments for cis should receive approval for papillary. This is not the https://t.co/zaJo0kxVIZ
👁 845
❤ 1
🔁 0
May 19
🌑 Melanoma 4 buzz
ASCO abstract for $MRK $MRNA Ph2b personalized cancer vaccine for melanoma patients. RFS HR=0.51, OS HR=0.47
With INTerpath-001 Ph3 trial 7x the size of this Ph2b, this is highly likely to readout positive later this year ($MRK management guided ~Sep 2026)
$PSNL is the https://t.co/gNdS9nobl7
👁 10.7K
❤ 66
🔁 10
May 21
$MDNAF We are proud to partner with Fondazione Melanoma Onlus @FondMelanoma to present the NEO-CYT Trial at #ASCO26! Join Dr. Paolo Ascierto @PAscierto in Chicago as we share Phase 1b updates on #MDNA11 for high-risk Stage III Cutaneous #Melanoma.
Sunday, May 31, 2026
Poster https://t.co/rQ2sFVRwJJ
👁 3.5K
❤ 18
🔁 1
May 1
$MDNA.to $MDNAF Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at #ASCO26
https://t.co/QAn7vAYz1f
👁 3.1K
❤ 13
🔁 5
Apr 30
$REPL 3 year overall survival data with RP1+nivolumab in anti-PD1 failed melanoma at #ASCO26 https://t.co/EW3oyUHITM
👁 1.5K
❤ 6
🔁 1
May 30
🩸 Leukemia & Lymphoma 2 buzz
Seedy is not long enough $ABVX, however I’m old enough to remember when $ABBV spent $21B to buy half of ibrutinib. https://t.co/7YG7sk0TQe
👁 39.5K
❤ 74
🔁 1
May 5
$KURA BofA #ASCO26 $KURA: GIST, early but progress on another growth leg
Kura has framed the menin inhibitor class as a ~$7B opportunity,reflecting not only questions around 1L use
but especially in indications beyond AML like GIST. The company’s “Trial in Progress”
poster for https://t.co/2SxOkbZm7A
👁 4.3K
❤ 7
🔁 1
May 20
🦴 Sarcoma 2 buzz
$COGT PDUFA 12/30/26
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST)
- Pivotal data from Phase 3 PEAK trial in GIST patients at #ASCO26
$866M cash - runway into 2028
https://t.co/J536q9PvMA
👁 3.6K
❤ 14
🔁 3
May 5
$GSK gets an early GIST at #ASCO26
https://t.co/86ZSHMxkF8
👁 506
❤ 0
🔁 0
May 22
🎗️ Breast Cancer 2 buzz
Great News! Arvinas received FDA approval for VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after prior endocrine therapy. $ARVN $PFE #ASCO26 https://t.co/g9n5cceCM6
👁 1.1K
❤ 5
🔁 1
May 1
$ATOS
ASCO 2026: Atossa Therapeutics Announces Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
- Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at
👁 121
❤ 1
🔁 0
May 27
Stay in the loop
Get Daily ASCO 2026 Updates
A quick daily digest — top KOL voices, plenary highlights, and trial signals from Chicago, delivered to your inbox throughout the meeting.